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This publication presents the data and findings of the risk assessment on the new psychoactive 
substance carfentanil (methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate), 
carried out by the extended Scientific Committee of the EMCDDA on 7 and 8 November 2017.  
The Risk Assessment Report, which was submitted to the European Commission and the Council of 
the European Union on 14 November 2017, examines the health and social risks of the substance, 
information on international trafficking and the involvement of organised crime, as well as a 
consideration of the potential implications of subjecting the substance to control measures. 
Carfentanil is the twenty-first new psychoactive substance to be risk assessed under the terms of 
Council Decision 2005/387/JHA. 
On the basis of the Risk Assessment Report on a new psychoactive substance, and, on the initiative 
of the European Commission, the Council may decide that the substance should be subject to control 
measures across the Member States. This decision is adopted in the final stage of the three-step 
process — early warning, risk assessment and control of new psychoactive substances — 
established by the Council Decision 2005/387/JHA. This legal framework allows the EU institutions 
and Member States to act on all new and potentially threatening narcotic and psychotropic drugs 
which appear on the European drug scene, with the EMCDDA and Europol, in collaboration with their 
respective networks, playing a central role in the early detection of such substances as well as the 
harms caused by their use — information that underpins risk assessment, and, ultimately, decision-
making.  
In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place 
carfentanil in Schedule I and Schedule IV of the Single Convention on Narcotic Drugs of 1961 based 
on a recommendation by the World Health Organization. This recommendation was substantially 
supported by European data provided by the EMCDDA. 
Finally, we would like to thank all the participants in the risk assessment process for the high quality of 
work carried out. The resulting report is a valuable contribution at European level, which gives clear 
support to political decision-making.  
Dr Anne Line Bretteville-Jensen 
Chair, Scientific Committee of the EMCDDA 
Alexis Goosdeel 
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The EMCDDA has been assigned a key role in the detection and assessment of new drugs in the 
European Union under the terms of a Council Decision 2005/387/JHA on the information exchange, 
risk-assessment and control of new psychoactive substances. 
It establishes a mechanism for the rapid exchange of information on new psychoactive substances 
and provides for an assessment of the risks associated with them in order to permit the measures 
applicable in the Member States for the control of narcotic and psychotropic substances to be applied 
also to new psychoactive substances. 
The three-step process involves information exchange/early warning, risk assessment and decision-
making (see below). More detailed information can be found in the section ‘Action on new drugs’ of 
the EMCDDA’s website: www.emcdda.europa.eu/activities/action-on-new-drugs  
 
  
EMCDDA actions on monitoring and responding to 
new drugs  
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Europol–EMCDDA Joint Report on a new psychoactive substance: methyl 1-(2-phenylethyl)-4-
[phenyl(propanoyl)amino]piperidine-4-carboxylate — in accordance with Article 5 of Council 
Decision 2005/387/JHA on the information exchange, risk assessment and control of new 
psychoactive substances 
In May 2017, the EMCDDA and Europol examined the available information on a new psychoactive 
substance methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate, commonly 
known by the abbreviation carfentanil, through a joint assessment based upon the following criteria: 
(1) the amount of the material seized; (2) evidence of organised crime involvement; (3) evidence of 
international trafficking; (4) analogy with better-studied compounds; (5) evidence of the potential for 
further (rapid) spread; and (6) evidence of cases of serious intoxication or fatalities. 
The EMCDDA and Europol agreed that the information available on carfentanil satisfied criteria 1, 4, 5 
and 6. The two organisations therefore concluded that sufficient information has been accumulated to 
merit the production of a Joint Report on carfentanil as stipulated by Article 5.1 of the Decision. 
Accordingly, the NFPs, the Europol national units (ENUs), the EMA and the World Health 
Organization (WHO) were formally asked to provide the relevant information within six weeks from the 
date of the request, i.e. by 29 June 2017. 
The resulting Joint Report on carfentanil was submitted to the Council, the Commission and the EMA 
on 27 July 2017. The report concluded that the health and social risks, caused by the use of, the 
manufacture of, and traffic in carfentanil, as well as the involvement of organised crime and possible 
consequences of control measures, could be thoroughly assessed through a risk assessment 
procedure as foreseen by Article 6 of Council Decision 2005/387/JHA. 
The full text of the Joint Report can be found at: 
www.emcdda.europa.eu/publications/joint-reports/carfentanil 
  
Europol–EMCDDA Joint Report on carfentanil 
(methyl 1-(2-phenylethyl)-4-
[phenyl(propanoyl)amino]piperidine-4-carboxylate) 
— a summary 
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Introduction  
This Risk Assessment Report presents the summary findings and the conclusion of the risk 
assessment carried out by the extended Scientific Committee of the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) on the new psychoactive substance methyl 1-(2-phenylethyl)-4-
[phenyl(propanoyl)amino]piperidine-4-carboxylate (commonly known as carfentanil). The report is 
intended for policy makers and decision makers in the institutions of the European Union. 
The report has been prepared and drafted in accordance with the conceptual framework and the 
procedure set out in the risk assessment operating guidelines (1). It is written as a stand-alone 
document, which presents a summary of the information considered during the detailed analysis of 
the scientific and law enforcement data available at this time. The conclusion section of the report 
summarises the main issues addressed and reflects the opinions held by the members of the 
Scientific Committee. A list of the information resources considered by the Scientific Committee, 
including a detailed technical report on carfentanil, is provided below.  
The risk assessment has been undertaken in compliance with Article 6 of Council Decision 
2005/387/JHA of 10 May 2005 on the information exchange, risk assessment and control of new 
psychoactive substances (2) (hereafter ‘Council Decision’). The Council Decision establishes a 
mechanism for the rapid exchange of information on new psychoactive substances (hereafter ‘EU 
Early Warning System’ (3)) that may pose public health and social threats, including those related to 
the involvement of organised crime. Thus, it allows the institutions of the European Union and the 
Member States to act on all new narcotic and psychotropic substances (4) that appear on the 
European Union drug market. The Council Decision also provides for an assessment of the risks 
                                                          
(1)  EMCDDA (2010), Risk assessment of new psychoactive substances: Operating guidelines, Publications Office of the 
European Union, Luxembourg. Available at: http://www.emcdda.europa.eu/html.cfm/index100978EN.html 
(2) OJ L 127, 20.5.2005, p. 32. 
(3) The information exchange mechanism laid down by the Council Decision is operationalized as the European Union 
Early Warning System on New Psychoactive Substances (‘EU Early Warning System’). It is operated by the 
EMCDDA and Europol in partnership with the Reitox national focal points and Europol national units in the Member 
States, the European Commission, and the European Medicines Agency. 
(4) According to the definition provided by the Council Decision, a ‘new psychoactive substance’ means a new narcotic 
drug or a new psychotropic drug in pure form or in a preparation; ‘new narcotic drug’ means a substance in pure form 
or in a preparation that has not been scheduled under the 1961 United Nations Single Convention on Narcotic Drugs, 
and that may pose a threat to public health comparable to the substances listed in Schedule I, II or IV; ‘new 
psychotropic drug’ means a substance in pure form or in a preparation that has not been scheduled under the 1971 
United Nations Convention on Psychotropic Substances, and that may pose a threat to public health comparable to 
the substances listed in Schedule I, II, III or IV. 
Risk Assessment Report on a new psychoactive 
substance: methyl 1-(2-phenylethyl)-4-
[phenyl(propanoyl)amino]piperidine-4-carboxylate 
(carfentanil) 
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associated with these new psychoactive substances so that, if necessary, control measures can be 
applied in the Member States for narcotic and psychotropic substances (5). 
Carfentanil was formally notified on 12 February 2013 by the EMCDDA on behalf of the Latvian 
national focal point, in accordance with Article 4 of the Council Decision. The notification related to the 
seizure of 70.139 grams of light yellow powder seized on 8 December 2012 by police. Following an 
assessment of the available information on carfentanil, and, in accordance with Article 5 of the 
Council Decision, on 27 July 2017 the EMCDDA and Europol submitted a Joint Report on carfentanil 
(6) to the Council of the European Union, the European Commission, and the European Medicines 
Agency (EMA). Taking into account the conclusion of the Joint Report, and, in accordance with Article 
6 of the Council Decision, on 14 September 2017 the Council formally requested that ‘the risk 
assessment should be carried out by the extended Scientific Committee of the EMCDDA and be 
submitted to the Commission and the Council within twelve weeks from the date of this notification’. 
In accordance with Article 6.2, the meeting to assess the risks of carfentanil was convened under the 
auspices of the Scientific Committee of the EMCDDA with the participation of four additional experts 
designated by the Director of the EMCDDA, acting on the advice of the Chairperson of the Scientific 
Committee, chosen from a panel proposed by Member States and approved by the Management 
Board of the EMCDDA. The additional experts were from scientific fields that were either not 
represented, or not sufficiently represented on the Scientific Committee, and whose contribution was 
necessary for a balanced and adequate assessment of the possible risks of carfentanil, including 
health and social risks. A further four experts participated in the risk assessment: two experts from the 
Commission, one expert from Europol, and one expert from the European Medicines Agency (EMA). 
The meeting took place on 08 November 2017 at the EMCDDA in Lisbon. The risk assessment was 
carried out on the basis of information provided to the Scientific Committee by the Member States, the 
EMCDDA, Europol, and the EMA. A list of the extended Scientific Committee, as well as the list of 
other participants attending the risk assessment meeting, is annexed to this report (page 103). 
For the risk assessment, the extended Scientific Committee considered the following information 
resources: 
 Technical report on methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-
carboxylate (carfentanil) (Annex 1); 
 EMCDDA–Europol Joint Report on a new psychoactive substance: methyl 1-(2-phenylethyl)-
4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil) (6); 
 Open source information including scientific articles, official reports, grey literature, internet 
drug discussion forums and related websites (hereafter ‘user websites’); 
 Additional information provided during the course of the risk assessment meeting by the 
participants; 
 The EMCDDA operating guidelines for the risk assessment of new psychoactive substances 
(1); and, 
 Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk 
assessment and control of new psychoactive substances (2). 
                                                          
(5) In compliance with the provisions of the United Nations Single Convention on Narcotic Drugs, 1961, and the United 
Nations Convention on Psychotropic Substances, 1971. 
(6) EMCDDA (2017), EMCDDA–Europol Joint Report on a new psychoactive substance methyl 1-(2-phenylethyl)-4-
[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), EMCDDA, Lisbon.  
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Finally, it is important to note that this risk assessment report contains a discussion of the available 
information on serious adverse events such as acute intoxications (typically presenting to hospital 
emergency departments) and deaths associated with carfentanil. Such information is critical to the 
identification of emerging toxicological problems associated with new psychoactive substances within 
the European Union. In this context, it is important to recognise that the capacity to detect, identify, 
and report these events differ both within and between Member States. In the past few years, 
programmes have been introduced in some Member States to strengthen these capacities. The 
EMCDDA’s toxicovigilance system, which is a central component of the EU Early Warning System, 
has also been strengthened resulting in more information being available regarding serious adverse 
events associated with new psychoactive substances. Nonetheless, it is likely that these events 
remain under-detected and under-reported.  
Physical, chemical and pharmacological description 
Methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil) is a 4-
carboxylic acid methyl ester derivative of fentanyl. Carfentanil contains one basic nitrogen atom in the 
piperidine ring readily forming salts with organic or inorganic acids. Fentanyl analogues (fentanils) 
have in common an aralkyl group attached to a 4-N-acylanilinopiperidine. 
Carfentanil is known from the scientific literature.  
Pharmacologically, carfentanil is an opioid receptor agonist. 
Synthetic opioids like fentanyl and related 4-anilinopiperidine derivatives are potent analgesics. 
Initially developed in the 1960’s as part of research efforts to develop safer and better opioid 
analgesics, a small number of this family of compounds—alfentanil, fentanyl, sufentanil and 
remifentanil—have become widely used in human medicine as adjuncts to general anaesthesia 
during surgery and for pain management. They are available in a wide variety of formulations, such as 
liquids for injection, tablets, transdermal patches, lozenges, and nasal sprays. Some are also used in 
veterinary medicine as general anaesthetics, for pain management, and, in the case of carfentanil and 
thiafentanil, to immobilise large animals.  
Fentanyl analogues first emerged on the illicit drug market in the United States of America in 1979. At 
the time they were not controlled under drug legislation. They were manufactured in clandestine 
laboratories and sold on the heroin market as heroin or ‘synthetic heroin’.  
A total of fifteen fentanils are controlled under the United Nations Single Convention on Narcotic 
Drugs, 1961, as amended by the 1972 Protocol. 
The major pharmacological effects of the fentanils, including their analgesic activity, are due to their 
activation of opioid receptors, and, in particular, the µ-opioid receptor. Besides their analgesic 
properties, a notable feature associated with µ-opioid receptor agonists is that they cause dose-
dependent respiratory depression, in which overdose can be life-threatening. Other additional 
pharmacological effects include miosis, sedation, bradycardia, hypothermia, constipation, physical 
dependence, and changes in mood such as euphoria. 
Carfentanil as free base may occur as solids. No data on the physical properties of the hydrochloride 
salt are available. A carfentanil formulation for veterinary use was commercially available as its citrate 
salt under the trade name Wildnil®. Available data states that carfentanil is soluble in chloroform, 
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dichloromethane, ethyl acetate, and, to some extent, in methanol. The high LogP (octanol-water 
distribution) indicates that carfentanil is a lipophilic compound. 
In Europe, carfentanil has been seized as powder (ranging from white and pale yellow to brown); to a 
lesser extent it has also been seized as a liquid. In some cases it has been identified along with other 
substances, including other opioids. For example, carfentanil was detected in mixtures with heroin in 
over 30% of law enforcement seizures; in a small number of cases cocaine was present in addition to 
heroin and carfentanil. 
The analytical identification of carfentanil in physical and biological samples is possible using several 
analytical techniques. These include chromatographic and mass-spectrometric techniques, and 
specific immunoassays. 
Analytical reference materials are important for the correct identification and for facilitating the 
quantification of carfentanil in physical and biological samples. Such reference materials are 
commercially available. It should be noted that concentrations in blood samples can be in the sub-
nanogram per millilitre range.  
Carfentanil may not be part of most routine drug screenings and therefore may be under-detected and 
under-reported. 
Route of administration and dosage 
In Europe, carfentanil is currently typically administered by intravenous injection. This is because it is 
sold as or mixed with heroin or other opioids without users being aware. Carfentanil can also be 
administered orally as a powder, as tablets, or as a solution; it can also be administered intranasally 
or sublingually via spray or snorted (insufflated); inhaled by vaporising e-liquid type solutions 
(‘vaping’); inhaled by smoking or vaporising the ‘free base’; and administered transdermally. In view of 
its high potency, users may prepare diluted solutions for intranasal application using nasal sprays. 
Limited information is available regarding the dose and the dose regimens of carfentanil. It is not 
possible to currently discern the ‘typical’ dosages administered by users. In addition, doses appear to 
differ depending on factors such as the route of administration, the tolerance of the users, the use of 
other drugs, and the desired effects. 
Pharmacology 
Studies investigating the binding and functional activity at opioid receptors in vitro for carfentanil show 
that it is a highly selective μ-opioid receptor agonist. Carfentanil has been extensively tested in 
animals, showing extremely high analgesic potency. Carfentanil is used to immobilise wildlife and zoo 
animals usually in combination with a α2-adrenoreceptor agonist.  
When the agonist activity of the carfentanil is compared with that of morphine, its potency is much 
higher in tests in vivo (e.g., analgesia), than in tests in vitro (e.g., binding affinity for μ receptors). For 
example the analgesic potency of carfentanil has been reported to be up to 10,000 times that of 
morphine, while its affinity for μ receptors is only 14 to 135 times higher.  
The pharmacokinetic properties of carfentanil are consistent with its high lipophilicity that results in 
rapid absorption and tissue distribution, including diffusion across the blood-brain barrier. 
RISK ASSESSMENT I CARFENTANIL 
 
10 
 
According to animal data and limited human data, carfentanil is readily absorbed following injection, 
transmucosal administration, or inhalation. It is widely distributed throughout the body and crosses the 
blood brain barrier. In regions of the brain with higher binding potential, carfentanil disappears 
gradually with the majority still remaining after 90 minutes. Systemically available carfentanil is rapidly 
metabolised showing similarities to fentanyl metabolism. Consequently drug-drug interactions 
observed with fentanyl might equally apply. Both, carfentanil and its metabolites, are excreted in 
urine.  
The concomitant use of other central nervous system (CNS) depressants, including other opioids, 
sedatives/hypnotics, ethanol, pregabalin, gabapentin, tranquillisers, and sedating anti-histamines, 
may produce additive depressant effects. 
Psychological and behavioural effects 
From the available data, the psychological and behavioural effects of carfentanil share similarities with 
fentanyl and other opioid analgesics. Dizziness, drowsiness, and incoordination have been reported. 
Other effects common to opioids, such as relaxation and euphoria, can be expected; at higher doses, 
sedation and profound intoxication occur. 
Legitimate uses 
There is no marketing authorisation (existing, on-going, or suspended) for carfentanil in the European 
Union or in the Member States that responded to the request for information, which was undertaken 
as part of the Joint Report process. However, the data collection is incomplete and some countries 
indicated that this information is not known. 
It is possible that the substance may have limited use in veterinary medicine in Europe based on a 
medicinal product that is prepared extemporaneously in accordance with national legislation. 
Carfentanil is used in veterinary medicine as a tranquilising agent in zoological parks and wildlife 
environments to rapidly incapacitate large animals in order to facilitate veterinary procedures. 
Carfentanil was first introduced to the market for veterinary use in 1986. Carfentanil was marketed in 
the United States under the proprietary name Wildnil® and is approved by the United States Food and 
Drug Administration for use as an immobilising agent in certain animal species. Commercial 
production of Wildnil® ceased in 2003, and it appears that the substance is available only as a 
compounded dosage form. 
There is no information to suggest that carfentanil is currently used in the manufacture of a medicinal 
product in the European Union. However, in the absence of a database on the synthetic routes of all 
medicinal products it is not possible to confirm whether or not carfentanil is currently used in the 
manufacture of a medicinal product.  
[11C]Carfentanil is widely used as a selective radiotracer in animal and human positron emission 
tomography (PET) imaging studies of the μ-opioid system.  
Carfentanil is also used as an analytical reference material in clinical and forensic case 
work/investigations as well as scientific research.  
There is currently no information that suggests carfentanil is used for any other legitimate purposes. 
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There are no reported uses of carfentanil as a component in industrial, cosmetic or agricultural 
products. In addition, a search of the Registration, Evaluation, Authorisation and Restriction of 
Chemicals (REACH) registered substances database hosted by the European Chemicals Agency 
(ECHA) using the available CAS Registry Numbers returned no hits. 
Chemical precursors that are used for the manufacture 
Information on the chemical precursors and the synthetic methods employed for carfentanil detected 
on the drug market within the European Union is limited.  
Carfentanil was first synthesised by a group of chemists at Janssen Pharmaceutica in 1974, using a 
method which was subsequently patented. A number of additional methods have been reported in the 
literature. The manufacture of carfentanil most likely relies on precursors and synthetic methods 
similar to those used for the manufacture of pharmaceutical fentanyl. Accordingly, methods developed 
for the synthesis of fentanyl are applicable to carfentanil. Most of these are straightforward, make use 
of common laboratory equipment and precursors, and require only basic knowledge of chemistry. The 
substance N-phenethyl-4-piperidone (NPP) and methyl 4-[phenyl(propanoyl)amino]piperidine-4-
carboxylate could be used for the manufacture of carfentanil.  
A pre-precursor of carfentanil and other fentanils, NPP, has been recently scheduled (7). 
Due to the high potency of carfentanil there is a serious risk of severe poisoning following accidental 
exposure during its manufacture. Extreme care must be taken when carrying out the final synthetic 
step as well as when purifying and handling the substance. 
Health risks 
Individual health risks 
The assessment of individual health risks includes consideration of the acute and chronic toxicity of 
carfentanil, as well as its dependence potential, and its similarities to and differences from other 
chemically or pharmacologically related substances. 
It is important to note that when interpreting the information from deaths reported to the EMCDDA as 
well as information from user websites, that individuals may have used other substances in addition to 
carfentanil. The presence of and/or interaction with other substances or pre-existing health conditions 
may account for some of the reported effects. 
Carfentanil may be used in combination with other drugs (intentionally or unintentionally).  
Information from law enforcement seizures and deaths reported to the EMCDDA show that carfentanil 
is being mixed with heroin, fentanyl, and other fentanils, sold on the illicit opioid market, and injected 
by opioid users (including heroin injectors). Many of the users will be unaware that they are using 
carfentanil. Drug injection is associated with health risks which include transmission of blood borne 
diseases.  
                                                          
(7) Table I of the United Nations Convention against Traffic in Narcotic Drugs and Psychotropic Substances, 1988.  
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While specific information for carfentanil is limited, of note is the apparent popularity of selling ready-
to-use or using homemade nasal sprays containing solutions for the administration of fentanils. These 
typically contain milligram amounts of dissolved substance. The preparation of such solutions is 
inherently prone to mistakes in weighing and dilution which may lead to solutions with higher (or 
lower) concentrations. This may constitute an increased risk of acute toxicity to the individuals, who 
are unlikely to be able to control the dose being consumed.  
In addition, recent seizures in Europe of nasal sprays containing other fentanils found that these have 
been sold in some cases as unlabelled bottles. In other cases, users have also filled nasal sprays 
previously containing medicines (such as nasal decongestants) with fentanils. The lack of labelling 
increases the potential for accidental use by others and therefore poses a risk of poisoning. 
Acute toxicity 
Safety pharmacological parameters have been studied both in laboratory animals and immobilised 
non-laboratory animals. Briefly, a common effect observed in many species is respiratory depression 
which may lead to respiratory arrest. The sensitivity to these effects differs greatly between species 
and those belonging to great apes are at greater risk of respiratory depression.  
The most serious acute risk in humans arising from the use of carfentanil is rapid and severe 
respiratory depression, which can lead to apnoea, respiratory arrest, and death. Although the 
pharmacology and toxicology of carfentanil largely remains unstudied in humans, the available data 
suggests that the nature of its effects share similarities with opioid analgesics such as fentanyl. The 
acute effects of these types of opioids include: euphoria, relaxation, analgesia, sedation, bradycardia, 
hypothermia, and respiratory depression.  
While there is limited data on the clinical features of poisoning caused by carfentanil, reported 
features include reduced level of consciousness or unconsciousness, respiratory depression and 
arrest, and miosis. 
The timely administration of antidote naloxone will reverse acute poisoning caused by carfentanil. 
Recent clinical and community experience in treating poisonings caused by carfentanil suggests that 
larger than normal doses and repeated doses of naloxone may be required to manage the poisoning 
in some cases; longer periods of observation may also be required.  
In general for fentanils, the risk of life-threatening poisoning may be exacerbated by: the difficulty in 
diluting/using fentanils (as they are typically highly potent), which can lead to a toxic dose being 
accidentally used; the apparent rapid onset of severe poisoning following use; using routes of 
administration that allow large amounts of the substance to rapidly reach the central nervous system 
(such as injecting, insufflation, and inhalation); availability of easy to use dosage forms (such as nasal 
sprays and e-liquids); lack of awareness and experience of users with these new substances (effects 
and dosage); use of other central nervous system depressants (such as other opioids, 
benzodiazepines, and alcohol); lack of tolerance to opioids in opioid-naïve persons (such as new or 
former users); use in environments where it may be difficult to summon help in the event of poisoning 
(e.g. alone in a home environment); and, limited availability of the antidote naloxone in community 
settings. 
In addition, and, often unknown to users, the fentanils are sold as heroin or mixed with heroin. They 
are also used to make counterfeits of highly sought-after analgesics and benzodiazepines. They have 
also been sold in or as drugs such as cocaine. Due to this, users may not be aware that they are 
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using a fentanil; in some cases these individuals will have no tolerance to opioids nor access to 
community naloxone programmes. Overall, these factors may increase the risk of life-threatening 
poisoning. 
Acute intoxications 
In total, 3 acute intoxications with confirmed exposure to carfentanil were reported to the EMCDDA by 
France (2 cases) and Lithuania (1). The cases occurred in November 2016, January 2017, and May 
2017. 
The analytical detection of other substances was not reported. The clinical features of the 
intoxications were generally consistent with opioid toxicity.  
The intoxications were considered life-threatening in at least 2 cases; all required hospitalisation of 
the patients. Naloxone was administered to the 3 patients; in at least 2 cases more than one dose 
was administered to the patient. It was reported that naloxone was effective in 1 case; in another 
case, it was reported that ‘several’ doses of naloxone were not effective; the response to naloxone 
was not reported in the remaining case. All patients survived. 
In one case, the patient believed he was using cocaine and apparently snorted a powder containing 
carfentanil; in another, the patient reportedly tried a powder they had found at home; while in the 
remaining case, the patient believed that they were taking carfentanil. 
Information from other sources 
Twenty nine cases of non-fatal intoxications with confirmed exposure to carfentanil were reported in 
the literature, mostly from the United States. Carfentanil blood concentrations were similar to those in 
fatal cases, on average below 1 ng/ml.  
Deaths 
A total of 61 deaths were reported by Belgium (1), Germany (1), Estonia (6), Finland (2), Lithuania 
(16), Norway (1), Sweden (3), and the United Kingdom (31 cases). Carfentanil was analytically 
confirmed from post-mortem samples in 55 deaths and carfentanil exposure was confirmed in all 
deaths. 
Of the 38 deaths where demographic data were available, 32 were male (84%) and 6 were female 
(16%). The mean age of the males was 37 years (median 38) and ranged from 15 to 54 years. Where 
age was known, the females were aged 21, 28, 32, 45 years. 
Where known, the deaths occurred between November 2016 and June 2017; the deaths in the United 
Kingdom deaths occurred between February 2017 and June 2017. 
Cause of death and toxicological significance 
The cause of death was reported in 6 cases, and, in 5 of these, intoxications with carfentanil was 
reported either as the cause of death or as likely to have contributed to death (even in presence of 
other substances). Where additional toxicology information was available, other substances were 
detected in practically all cases. 
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Carfentanil was quantified in 33 cases. Post-mortem blood concentrations ranged from 0.02 to 4.4 
ng/mL blood (median 0.50 ng/mL blood). Due to the toxicity of potent opioids and variability in user 
tolerance, determination of a ‘fatal’ concentration based on a post-mortem blood concentration is not 
reliable. In the majority of circumstances involving fentanils, the mere presence of the drug is of 
significance whether concentration has been determined or not, especially in situations of poly-drug 
use. 
A range of other substances were detected in the deaths, including: cannabinoids, benzodiazepines, 
amphetamines, cocaine, antidepressants, antipsychotics, antihistamines, and ethanol, etc. In 
particular, markers of heroin use (i.e. morphine, codeine, noscapine, papaverine, 6-
monoacetylmorphine) as well as other opioids (including tramadol, methadone, oxycodone and 
dihydrocodeine) were detected in the vast majority of deaths. In terms of fentanils; fentanyl, 
butyrylfentanyl, 4-fluorobutyrylfentanyl, furanylfentanyl, and alfentanil were detected in 23 deaths 
where additional toxicological information was available. 
Overall, while other substances may have contributed some toxicity, a synergistic effect with 
carfentanil would have been likely with other central nervous system depressants such as ethanol, 
benzodiazepines, opioids (including other fentanils), etc. Nevertheless, the highly potent opioid nature 
of carfentanil means that the primary toxic contribution could be attributed to carfentanil and death 
may not have occurred if carfentanil had not been used (even where heroin was used that may not 
have exceeded the deceased’s toxicity threshold). An assessment of the toxicological significance 
score (TSS) (8) incorporating the above considerations, shows that carfentanil had a TSS value of 3 
(high) in 35 out of 36 of the deaths (where it was cited as the cause of death or is likely to have 
contributed to death). In the remaining death, fentanyl was potentially the primary substance and 
carfentanil was deemed to be a secondary finding (TSS value of 2, medium). There was insufficient 
information available for the other cases to allow appropriate TSS assessment. 
Circumstances of death 
There was a lack of information regarding any symptoms experienced by the deceased prior to death. 
Consequently, it was not possible to identify or evaluate ante-mortem symptoms (especially in relation 
to acute intoxication). Drug paraphernalia (e.g. syringes) were reported as being present (often in situ 
and close by) in many cases, with some decedents still holding the equipment or a needle in the 
arm—suggesting that death may have occurred suddenly after administration. Whilst this is not 
uncommon with heroin deaths in general, it is a sign of the tolerance and toxicity threshold being 
reached and exceeded, likely due to the increased potency of the fentanils contributing to the 
opiate/opioid toxic burden. 
Information from other sources 
More than 800 deaths with confirmed exposure to carfentanil have been reported in the United States 
in the past few years. In some of these cases, carfentanil was reported as the cause of death or 
contributing to the death. 
Ability to operate machinery and drive 
There have been no studies of the effects of carfentanil on the ability to drive and operate machines. 
However, it is well established that opioid narcotic analgesics, such as fentanyl, impair the mental and 
physical ability required to drive and operate machines. This effect extends to carfentanil; with 
                                                          
(8) Elliott, S., Sedefov, R. and Evans-Brown, M. (2017), 'Assessing the toxicological significance of new psychoactive 
substances in fatalities', Drug Testing and Analysis. https://doi.org/10.1002/dta.2225 
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carfentanil positive cases of suspected driving under the influence of drugs have been reported in the 
literature. 
Chronic toxicity 
No studies were identified that investigated the chronic health effects of carfentanil and/or its 
metabolites. 
Abuse liability and dependence potential 
No studies have investigated the abuse liability or dependence potential of carfentanil in humans.  
Available data show that carfentanil is a potent opioid able to suppress withdrawal symptoms in 
morphine-dependent rhesus monkeys, but not in rats. In limited studies in rats and rhesus monkeys 
physical dependence and self-administration were not observed and carfentanil did not generalise 
with a κ or µ opioid receptor agonist in drug discrimination test. 
However, given what is currently known about carfentanil pharmacology, including some similarities to 
other fentanils and opioid narcotic analgesics, it may have a potential for abuse and dependence. 
Further research will be required in order to determine such effects. 
Public health risks 
The public health risks associated with carfentanil may be categorised in terms of patterns of use 
(extent, frequency, route of administration, etc.); availability and quality of the drug; information, 
availability and levels of knowledge amongst users; and, negative health consequences. Detailed 
information, including data on sporadic versus chronic use, that allow for a determination of public 
health risks associated with carfentanil are not available. In addition, risk of accidental exposure 
needs to be considered.  
Extent, frequency, and patterns of use 
There are no prevalence data on the use of carfentanil in the European Union or elsewhere, but the 
available information does not suggest wide use of the substance.  
In at least three Member States, carfentanil is being sold on the illicit opioid market, typically in 
mixtures with heroin, fentanyl, and/or other fentanils. In these cases, it is reasonable to assume that 
these individuals will not be aware that they are using carfentanil.  
Based on its known pharmacology and that it is sold as a ‘legal’ replacement to illicit opioids, it would 
be expected that carfentanil may be sought by those looking for substitutes to opioids, such as heroin 
and prescription opioids. It also appears that there is interest in this substance by some psychonauts.  
Availability and quality on the market 
While carfentanil was first detected in Europe in December 2012, in the past two years there has 
been an increase in the availability of the substance as well as seizures by law enforcement. In total, 
more than 800 seizures have been reported by seven Member States; approximately 25% of the 
seizures were made in the first half of 2017. Most of the seizures have been made by police at street-
level, with some seizures being made in custodial settings. Typically, carfentanil was seized as a 
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powder; in some cases it has also been seized as a liquid. In over 25% of seizures, carfentanil was 
the only substance reported as detected; while in more than 30% of the seizures, carfentanil was 
detected in mixtures with heroin. The largest single seizure of carfentanil was 440 grams of 
‘unadulterated’ carfentanil in powder form made by police in the United Kingdom in May 2017.  
It is important to note that as carfentanil is not routinely screened for it will be under-detected and 
under-reported. 
The available data suggests that carfentanil is sold on the surface web and darknet in small and bulk 
quantities. Typically it is offered as a powder and may be advertised as a ‘research chemical’ or/and 
as a ‘pharmaceutical intermediate’.  
Characteristics and behaviour of users 
No studies were identified that have examined the characteristics and behaviours of users of 
carfentanil. While no specific examples are available on the possible appeal of the substance, the 
available information from law enforcement seizures and deaths reported to the EMCDDA shows that 
in some countries carfentanil is being mixed with heroin and/or other opioids and used by those who 
inject heroin/opioids. Many of these users will be unaware that they are using carfentanil. 
More generally, it is reasonable to assume that carfentanil may be sought by those looking for ‘legal’ 
substitutes for illicit opioids, such as heroin and/or prescription opioids. There also appears to be 
some interest in the substance from psychonauts. 
Nature and extent of health consequences 
The available information shows that established opioid injectors (including heroin injectors) are using 
carfentanil. Drug injection is associated with health risks which include transmission of blood borne 
diseases. 
In addition to the individual health risks that are discussed above, there are some further 
considerations related to the fentanils as a group that should be considered in respect to potential 
risks to public health. 
Mirroring the increased availability of fentanils on the drug market over the past few years, there has 
also been an increase in the number of outbreaks of mass poisoning caused by fentanils, particularly 
in the United States and Canada. These types of outbreaks have had the potential to overwhelm 
emergency responders and other local healthcare systems, as well as deplete stocks of naloxone. 
Stocks and availability of the naloxone, as well as adequacy of training in how to resuscitate poisoned 
patients both in clinical and community settings may need to be assessed. This might also include a 
review of the availability of naloxone to users through take-home naloxone programmes. 
As noted, the open sale of fentanils on the surface web and darknet marketplaces along with the use 
of new dosage forms—such as ready-to-use nasal sprays and e-liquids for vaping—add to the 
complexity of the problem caused by this group of substances. They have become easier to get hold 
of and easier to use. The Committee is concerned about whether the availability of ‘novel’ dosage 
forms has the potential to make the use of fentanils more socially acceptable. 
An additional challenge in respect to reducing risk in users and potential users is the balance between 
providing information to prevent harm and the unintended consequences of communicating the risks 
of opioids. There is evidence that using terms to describe them as 'potent', 'strong', 'deadly', and 
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'toxic' can lead some individuals to specifically seek out these substances. Such unintended 
promotion of the substances may also extend to former users and other groups. 
Adding to these challenges is evidence from Europe, the United States, and Canada that fentanils are 
being sold to unsuspecting users in/as heroin and other opioids, counterfeit medicines (including 
commonly used opioid analgesics and benzodiazepines), cocaine, and other illicit drugs. As users will 
be unaware of this, it increases the risk of severe and fatal poisoning in both opioid users and 
especially other groups who may have no existing tolerance to opioids. Non-opioid users are unlikely 
to be aware of these risks and are unlikely to have access to community opioid overdose prevention 
programmes, including take-home naloxone programmes. 
Accidental exposure to fentanils may also pose a risk of poisoning to those who may come into 
contact with the substances. This includes the family and friends of users, law enforcement, 
emergency personnel, medical and forensic laboratory personnel, as well as those in custodial 
settings and postal services. Where necessary, specific risks should be identified and assessed, and, 
appropriate measures to reduce these risks should be implemented. This may include appropriate 
protective equipment, training in resuscitation, and making naloxone readily available to relevant 
personnel in sufficient quantities in the event of poisonings. Any required measures should continue 
to ensure the delivery of prompt and appropriate care to patients with suspected overdose. 
Long-term consequences of use 
There is no information on the long-term consequences of use of carfentanil. 
Conditions under which the substance is obtained and used 
There is limited information on the conditions which carfentanil is obtained and used. Carfentanil has 
been sold on the surface web and darknet marketplaces, typically as powders in small and bulk 
quantities. In addition, carfentanil has also been mixed with heroin, fentanyl, and other opioids and 
then sold on the illicit opioid market. In most cases users will be unaware that they are using 
carfentanil. This presents an inherent risk to the individuals. 
In addition, information suggests that carfentanil may be deliberately sought by some users. These 
include psychonauts and others who are experimenting with the substance (for example for its 
analgesic effects).  
Social risks  
While there have been no studies on the social risks of carfentanil, it is likely that some of the risks 
are similar to those seen with opioids such as fentanyl and heroin.  
When considering the possible social risks of the substance it is important to consider that the 
evidence from law enforcement seizures and death cases show that it is being used by people who 
inject opioids, including heroin. It is likely that many of these users are unaware that they are using 
carfentanil.  
Individual social risks 
There is no information on whether the use of carfentanil causes individual social risks; however, any 
such risks may have some similarities with those associated with the use of illicit opioids, including 
RISK ASSESSMENT I CARFENTANIL 
 
18 
 
fentanyl. These may impact on education or career, family or other personal and social relationships 
and may result in marginalisation. 
Possible effects on direct social environment (e.g. neglect of family, violence) 
There is no information on the possible effects of carfentanil on the direct social environment; 
however, any such risks may have some similarities with those associated with the use of illicit 
opioids.  
Possible effects on society as a whole (public order and safety, acquisitive crime) 
There is no specific information on the possible effects of carfentanil on society as a whole.  
As discussed above, accidental exposure of fentanils, and in particular carfentanil, may pose a risk of 
poisoning to those who may come into contact with the substances. This includes the family and 
friends of users, law enforcement, emergency personnel, medical and forensic laboratory personnel, 
as well as those in custodial settings and postal services. 
Economic costs  
There are no data on the effects of carfentanil in respect to its health and social costs. 
Possible appeal to specific population groups 
Whilst no specific examples are available on the possible appeal of carfentanil to user groups, the 
substance is being used by people who inject opioids, including heroin. It is likely that many of these 
users are unaware that they are using carfentanil.  
In addition, it is reasonable to assume that the substance may be sought by those looking for 
substitutes for illicit opioids, such as heroin and/or prescription opioids.  
As highlighted, concerns exist over the use of fentanils with novel dosage forms—such as ready-to-
use and homemade nasal sprays and e-liquids for vaping—which have the potential to make the use 
of these substances easier (with similar effects to injecting) and more socially acceptable. Further 
research is required on this topic to better understand the risks. 
Information on manufacturing, trafficking, distribution, and the level of 
involvement of organised crime  
There is limited information on the involvement of organised crime or established criminal groups in 
the manufacture, distribution, and supply of carfentanil. In this respect, Estonia reported that almost 
all trafficking and distribution of fentanils, including carfentanil, is linked with organised crime groups 
in the country. In addition, they reported that these groups are keeping dealers under control through 
violence. 
The United Kingdom reported to Europol that some online vendors of carfentanil have been identified 
as being run by more than one person; however there is little intelligence to confirm links to organised 
crime groups. Information suggests that carfentanil mixed with heroin was sold through travelling 
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communities and networks in the North East of England, with this carfentanil possibly being supplied 
by one of these via online platforms/vendors. The United Kingdom also reported that they had 
identified a supplier of carfentanil who was using the darknet to advertise and distribute carfentanil 
across the country and also internationally. A total of 19 customers in the United Kingdom are known 
to have purchased carfentanil from this site, placing a total of 37 orders. The size of orders varied 
from 50 milligrams (15 orders) to 1 gram (1 order). 
In the cases reported to Europol where the country of origin for the seizures was known, the countries 
were China (specifically Hong Kong), and, to a lesser extent, the United Kingdom and Germany.  
Germany reported a seizure of carfentanil by Canadian law enforcement in Vancouver, in June 2017. 
The carfentanil was detected in a package which was en route from Hong Kong to Canada via 
Germany, using express mail/courier service.  
Lithuania reported that there are indications that carfentanil may be imported from Russia or China. 
They also reported that carfentanil is often mixed with heroin and prepared for heroin users and most 
cases are related to heroin distribution in the local Roma community. 
Sweden indicated that carfentanil has been bought from internet vendors and delivered directly to the 
user from China, the United Kingdom and Germany. They reported that there are no indications of the 
domestic sale of carfentanil in Sweden.  
The United Kingdom reported that it was unclear how much, if any, carfentanil has been 
manufactured domestically. Information indicates that it has been shipped from China/Hong Kong and 
the substance has been used as received, or mixed with other drugs, for example heroin, or cutting 
agents before being used or sold on. 
Latvia reported 6 seizures of carfentanil to the EMCDDA which occurred inside a prison or custodial 
setting. 
The seizure of an illicit laboratory in Europe in 2013 that was producing fentanils demonstrates the 
capability to manufacture fentanils exists within the European Union. 
Information on any assessment in the United Nations system 
The World Health Organization (WHO) is the specialised United Nations agency designated for the 
evaluation of the medical, scientific and public health aspects of psychoactive substances under the 
Single Convention on Narcotic Drugs, 1961, and the Convention on Psychotropic Substances, 1971. 
In May 2017, the WHO informed the EMCDDA that carfentanil will be reviewed at the 39th meeting of 
the WHO Expert Committee on Drug Dependence (ECDD) that will be held in November 2017. 
Description of the control measures that are applicable in the Member 
States 
Twelve Member States (Belgium, Cyprus, Czech Republic, Denmark, Estonia, France, Germany, 
Ireland, Latvia, Lithuania, Sweden, and the United Kingdom), Turkey and Norway reported that 
carfentanil is controlled under drug control legislation. 
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 In Belgium, carfentanil is controlled by Royal Decrees of 31 December 1930 and 22 January 
1998.  
 In Cyprus, carfentanil is controlled as a Class A drug within the Narcotic Drugs and 
Psychotropic Substances Law 1977.  
 In the Czech Republic, carfentanil is controlled since April 2011. 
 In Denmark, carfentanil is controlled since 24 November 2016 by an amendment of the 
Executive Order on Euphoriant Substances. 
 In Estonia carfentanil is controlled by way of generic definition.  
 In France, carfentanil is controlled as of 5 September 2017. 
 In Germany, carfentanil is controlled under schedule I (narcotics not eligible for trade and 
medical prescription) of the German Narcotics Act (Betäubungsmittelgesetz, BtMG). 
 In Ireland, carfentanil is listed in schedule 2 of the Misuse of Drugs Act.   
 In Latvia, carfentanil is included in the Cabinet Regulation N 847 ‘Regulations regarding 
Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia’ 
and the law ‘On the Procedures for the Coming into force and Application of the Criminal 
Law’.  
 In Lithuania, carfentanil is subjected to control measures by The Republic of Lithuania 
Minister of Health Order No V-267 (21/02/2014) ‘On the amendment of the Ministry of Health 
of the Republic of Lithuania Order No. 5 of 6 January 2000’. 
 In Sweden, carfentanil is regulated as a narcotic since 1982. 
 In the United Kingdom, carfentanil is controlled under the Misuse of Drugs Act 1971 as well 
as by way of a generic definition.  
 In Turkey, carfentanil is controlled as of 23 May 2014. 
 In Norway, carfentanil is listed as a ‘prohibited substance’. 
Three Member States (Austria, Hungary, and Poland) reported that carfentanil is controlled under 
specific new psychoactive substances control legislation.  
 In Austria, carfentanil is covered by the phenethylamine generic definition within the Austrian 
Act on New Psychoactive substances.  
 In Hungary, carfentanil is controlled by way of generic definition within the Ministry of Human 
Resources decree 55/2014. 
 In Poland, carfentanil is controlled according to the general definition of the ‘substitute drug’ 
(Act of 8 October 2010 amending the Act on counteracting drug addiction and the Act on 
State Sanitary Inspection, Journal of Laws “Dz.U.” No. 213, item 1396). Pursuant to Article 
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44b of the Act on counteracting drug addiction, it is prohibited to manufacture and introduce 
substitute drugs to trade.  
Finland reported that carfentanil is controlled under medicines legislation.  
Twelve Member States (Bulgaria, Croatia, Greece, Italy, Luxembourg, Malta, the Netherlands, 
Portugal, Romania, Slovakia, Slovenia, and Spain) reported that carfentanil is not subject to control 
measures at the national level. 
Options for control and the possible consequences of the control 
measures 
Under Article 9.1 of the Council Decision, the option for control that is available at European Union 
level is for the Member States to submit the new psychoactive substance carfentanil to control 
measures and criminal penalties, as provided for under their legislation, by virtue of their obligations 
under the Single Convention on Narcotic Drugs, 1961.  
Carfentanil was controlled in China as of the 1 March 2017. This control measure may at least deter 
the open manufacture and sale of this substance by chemical companies in this country, which are 
linked to the supply of the substance in Europe. 
There are no studies on the possible consequences of such control measures on carfentanil. If this 
option of control is pursued, the Committee considers that the following consequences are possible. 
Some of these may apply to any new psychoactive substance. 
 Considering the use of carfentanil in PET studies, this control option could affect the use of 
this compound in scientific research.  
 Considering the possible limited use of extemporaneously produced carfentanil, this control 
option could affect veterinary practice. 
 This control option could be expected to limit the availability of carfentanil and hence the 
further expansion of the current open trade in this substance. 
 A health consequence that might result from this control option is the benefit brought about by 
the presumed reduction in availability and use.  
 This control option could facilitate the detection, seizure and monitoring of carfentanil related 
to its unlawful manufacture, trafficking and use. In so doing, it could facilitate cooperation 
between the judicial authorities and law enforcement agencies across the European Union. 
 This control option would imply additional costs for the criminal justice system, including 
forensic services, law enforcement, and the courts. 
 This control option could lead to replacement with other (established or new) psychoactive 
substances, which may in themselves have public health consequences and social risks.  
 This control option could create an illicit market in carfentanil with the increased risk of 
associated criminal activity, including the involvement of organised crime. 
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 This control option could impact on both the quality/purity and price of any carfentanil still 
available on the illicit market. The extent to which this will impact on public health, criminality, 
or levels of use, is difficult to predict. 
 It is difficult to predict the impact of this control option on current or future research by the 
pharmaceutical or chemical industries. 
 In order to examine the consequences of control, the Committee wishes to note that it will be 
important to monitor for the presence of carfentanil on the market post-control, should this 
control option be pursued. 
 Aside from the option for control under those stipulated in Article 9.1 of the Council Decision, 
other options for control may be available to Member States. These may include restricting 
the importation and supply of the substance as some Member States have already done.  
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Conclusion 
Methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil) is a 
synthetic opioid and is structurally related to fentanyl, a controlled substance widely used in medicine 
as an adjunct to general anaesthesia during surgery and for pain management. Carfentanil is one of 
the most potent narcotic opioid analgesics. 
In Europe, the substance is currently typically administered by intravenous injection. Other routes of 
administration, including use of nasal sprays, orally and nasal insufflation have also been reported. 
Carfentanil was mixed with heroin in more than 30% of the seizures reported by law enforcement. 
Sixty-one deaths with confirmed exposure to carfentanil have been reported by 8 Member States. 
Many of the deaths involved high-risk drug users, including heroin injectors. Other drugs, including 
morphine and other fentanils, were also detected in many of the cases. In at least 6 of the deaths 
carfentanil was reported to be either the cause of death or to have contributed to death; in many of 
the remaining cases the investigation into the death is ongoing. There have also been reports of more 
than 800 deaths from the United States; in at least some of these cases carfentanil was the cause of 
death or contributed to death. 
Similar to other opioid analgesics, the most serious acute risk arising from the use of carfentanil is 
rapid and severe respiratory depression, which can lead to apnoea, respiratory arrest, and death.  
Naloxone is an effective antidote to poisoning caused by carfentanil. Treatment may require repeated 
doses of naloxone.  
It is important to note that detections of carfentanil may be under reported since the substance is not 
routinely screened for. Routine commercially available immunoassays may not detect this compound.  
Information from law enforcement seizures as well as investigations into deaths shows that carfentanil 
is being used by opioid injectors, including those that use heroin.  
Accidental exposure to carfentanil, as well as to other fentanils, may pose a risk to law enforcement, 
emergency personnel, medical and forensic laboratory personnel, as well as to those in custodial 
settings and postal services. Where necessary, specific risks and appropriate measures to reduce 
these risks should be identified and implemented. Any required measures should continue to ensure 
the delivery of prompt and appropriate care to patients with suspected overdose. 
There is limited information on the involvement of organised crime or established criminal groups in 
the manufacture, distribution and supply of carfentanil. In this respect, Estonia reported that almost all 
trafficking and distribution of fentanils, including carfentanil, are linked with organised crime groups in 
Estonia. In addition, they reported that these groups are keeping dealers under control through 
violence. 
There is limited information on the chemical precursors and the synthetic routes used to manufacture 
the carfentanil detected within the European Union. Most of the synthetic routes are straightforward, 
make use of common laboratory equipment and readily available precursors, and require only basic 
knowledge of chemistry. Information from seizures suggests that some carfentanil on the market in 
Europe has been produced by chemical companies based in China.  
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There is no marketing authorisation (existing, on-going, or suspended) for carfentanil in the European 
Union or in the Member States that responded to the request for information, which was undertaken 
as part of the Joint Report process. However, the data collection is incomplete and some countries 
indicated that this information is not known. 
Carfentanil it is authorised as a veterinary medicine in the United States for the immobilisation of large 
animals. It is possible that the substance may have limited use in veterinary medicine in Europe 
based on a medicinal product that is prepared extemporaneously in accordance with national 
legislation. 
A radiolabelled form of carfentanil is widely used in scientific research. Carfentanil is also used as an 
analytical reference standard and in scientific research. 
Carfentanil is not listed for control in the Single Convention on Narcotic Drugs, 1961, nor in the 
Convention on Psychotropic Substances, 1971. Carfentanil is currently under assessment by the 
United Nations system.  
Twelve Member States, Turkey, and Norway control carfentanil under drug control legislation. Four 
Member States control carfentanil under other legislation. 
As for any new psychoactive substance, many of the questions related to carfentanil that are posed 
by the lack of data on the risks to individual health, risks to public health, and social risks, could be 
answered through further research. Areas where additional information would be important include 
studies on: rationale for use, prevalence and patterns of use (including studies that examine user 
groups and risk behaviours); the market; chemical profiling; complete pharmacological profiling; 
metabolic pathways; behavioural effects; acute and chronic toxicity; the potential interaction between 
carfentanil and other substances; the dependence and abuse potential; and the public health risks 
associated with its use. 
The Committee notes that a decision to control carfentanil has the potential to bring with it both 
intended and unintended consequences. Potential intended consequences include reduced levels of 
availability and ultimately use. This may reduce the health and social risks and consequences arising 
from the use of carfentanil. It is important to recognise that a potential unintended consequence of 
control may be the manufacture and availability of other substances. Indeed, since carfentanil was 
first detected at least twenty new fentanils and a number of other new opioids that may replace it are 
already being sold on the drug market. The implementation of control measures may also lead to the 
criminalisation of those who continue to use this substance with the possible attendant risks of socio-
economic stigmatisation and marginalisation.  
Finally the Committee notes that it is important to continue to collect and disseminate accurate 
information on carfentanil to users, practitioners, policy makers, decision makers and those who may 
be at risk of accidental exposure. An additional challenge in respect to reducing risk in users and 
potential users is the balance between providing information to prevent harm and the unintended 
consequences of communicating the risks of opioids. There is evidence that using terms to describe 
them as 'potent', 'strong', 'deadly', and 'toxic' can lead some individuals to specifically seek out these 
substances. Such unintended promotion of the substances may also extend to former users and other 
groups. 
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ANNEX 1 
 
Introduction 
In accordance with Article 5 of the Council Decision 2005/387/JHA on the information exchange, risk-
assessment and control of new psychoactive substances (1), on 18 May 2017, the EMCDDA and 
Europol launched the Joint Report procedure for methyl 1-(2-phenylethyl)-4-
[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil) on the basis of data reported by the 
Member States to the European Union Early Warning System in accordance with Article 4 of the 
Council Decision. The information collection process for the Joint Report was completed in June 
2017. The report was submitted to the EU Institutions on 27 July 2017 (EMCDDA, 2017a). In 
accordance with Article 6 of the Council Decision, on 14 September 2017, the Council of the 
European Union requested that a risk assessment on carfentanil should be carried out by the 
extended Scientific Committee of the EMCDDA. 
In order to prepare for the risk assessment, and, to facilitate the risk assessment process, the 
EMCDDA is responsible for the collection and analysis of data on the substance to be assessed as 
well as drafting a technical report. This technical report has been prepared for the risk assessment of 
carfentanil that will be held at the EMCDDA premises in Lisbon on Wednesday 8 November 2017.  
Some of the sections in this report were prepared under EMCDDA contracts (ref. CT.17.SAT.0103.1.0 
and CT.17.SAT.0110.1.0). 
Data sources 
The information in this technical report is derived from: 
 data reported by the Member States, Turkey, and Norway to the EMCDDA and Europol in 
accordance with Council Decision 2005/387/JHA (EMCDDA, 2017a); and,  
 data collected through systematic searches of open source information, including the 
scientific and medical literature, patents, official reports, grey literature, online drug 
discussion forums and related websites, and online vendors selling carfentanil. 
Search strategy  
Literature searches used both chemical structure and text queries in online databases; searches were 
conducted in August 2017. The retrieved publications were then scanned for additional relevant 
references (snowballing technique). 
                                                          
(1) OJ L 127, 20.5.2005, p. 32.  
Technical report on methyl 1-(2-phenylethyl)-4-
[phenyl(propanoyl)amino]piperidine-4-carboxylate 
(carfentanil) 
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Medline and Web of Science were searched for ‘carfentanil’, ‘carfentanyl’, and the IUPAC name of 
this compound stated in this document. Publications retrieved by exact structure-based search in 
SciFinder® (2) have also been included where appropriate. The references were screened for 
relevance and included in the review where appropriate. Additional references were gathered from the 
sources mentioned in the collected papers. 
The REACH registered substances database hosted by the European Chemicals Agency (ECHA) 
was searched using the CAS registry numbers listed above. The searches returned no hits. 
Note 
It is important to note that when interpreting the information on self-reported user experiences in this 
report, it is not possible to confirm the specific substance(s) that have been claimed to be used; 
similarly it is also not possible to confirm the strength, purity, dose/amount, etc., used. Moreover, the 
actual composition of the substance/product may differ over time and different geographical areas. In 
addition, the information provided on user websites may not necessarily be representative of other 
users of carfentanil and should be regarded as illustrative only. In general, given the difficulties of 
collecting accurate self-reported data, it should be interpreted with due caution. 
Report prepared by 
Leon van Aerts (3), Simon Elliott (4), Michael Evans-Brown (5), Helgi Valur Danielsson (5), Anabela 
Almeida (5), Rachel Christie (5), Rita Jorge (5), Sofía Sola (5), Ana Gallegos (5), and Roumen Sedefov 
(5). 
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Section A. Physical, chemical, pharmaceutical and pharmacological 
information 
A1. Physical, chemical, and pharmaceutical information 
A1.1. Physical and chemical description 
Chemical description and names 
Methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil) is a 4-
carboxylic acid methyl ester derivative of N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propionamide 
(fentanyl). Carfentanil does not contain a chiral centre. The molecular structure, molecular formula, 
and molecular mass of carfentanil are provided in Figure 1. 
Carfentanil belongs to the 4-anilidopiperidine class of synthetic opioids.  
Fentanyl and a number of fentanyl analogues (6) are internationally controlled under the United 
Nations Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol. Two 
additional fentanils (7) have recently subjected to risk assessment by the extended Scientific 
Committee of the EMCDDA (EMCDDA, 2017b; EMCDDA, 2017c).  
FIGURE 1  
Molecular structure, molecular formula, and molecular mass of carfentanil. The structure of 
fentanyl is provided for comparison. 
Carfentanil Fentanyl 
  
C24H30N2O3 C22H28N2O 
394.52 g/mol 336.48 g/mol 
Carfentanil, which is also known as 4-carbomethoxyfentanyl, has two positional isomers: 2- and 3-
carbomethoxyfentanyl (8). These positional isomers differ in the position of the methoxy-carbonyl 
moiety on the piperidine ring. The synthesis and characterisation of 3-carbomethoxyfentanyl is 
reported in the literature (Mićović et al., 1998). 
Names and other identifiers 
Systematic International Union of Pure and Applied Chemistry (IUPAC) names: 
                                                          
(6) 3-Methylfentanyl, 3-methylthiofentanyl, acetyl-alpha-methylfentanyl, acetylfentanyl, alpha-methylfentanyl, alpha-
methylthiofentanyl, beta-hydroxy-3-methylfentanyl, beta-hydroxyfentanyl, para-fluorofentanyl, and thiofentanyl are controlled 
under Schedule I and IV; alfentanil, butyrfentanyl, fentanyl, sufentanil and remifentanil are controlled under Schedule I. 
(7) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl) and N-(1-phenethylpiperidin-4-yl)-N-
phenylacrylamide (acryloylfentanyl). 
(8) Throughout this report, ’carfentanil’ refers to 4-carbomethoxyfentanyl. 
N
O
O
N
O
N
N
O
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Methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate 
Chemical synonyms: 
4-((1-Oxopropyl)-phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylic acid methyl ester 
4-Piperidinecarboxylic acid, 4((1-oxopropyl)phenylamino)-1-(2-phenylethyl)-, methyl ester 
Methyl 1-phenylethyl-4-(N-phenylpropionamido)isonipecotate 
Methyl 4-(N-(1-oxopropyl)-N-phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylate 
Methyl 4-(N-propionyl-N-phenylamino)-1-(2-phenylethyl)-4-piperidine-carboxylate 
Methyl 1-(2-phenylethyl)-4-[phenyl(propionyl)amino]piperidine-4-carboxylate 
Other names:  
4-Methoxycarbonylfentanyl 
4-Carbomethoxyfentanyl 
3-Demethyllofentanil 
R33799 (citrate) 
NIH 10570 
R 31 833 
R31833 (base) 
DEA No. 9743 
FDA Unique Ingredient Identifier: UNII:LA9DTA2L8F; 7LG286J8GV (citrate salt) 
ChEBI ID: CHEBI:61084 
CHEMBL compound ID: CHEMBL 290429  
Commonly used names: 
Carfentanyl 
Carfentanil 
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Chemical Abstract Service Registry Numbers (CAS RNs) (9): 
59708-52-0 (free base) 
60645-15-0 (free base, alternative CAS RN) 
61380-27-6 (citrate salt) 
61086-44-0 (oxalate salt) 
PubChem CID (10):  
62156 
IUPAC International Chemical Identifier Key (InCHI Key) (11):  
YDSDEBIZUNNPOB-UHFFFAOYSA-N 
SMILES (12):  
O=C(C1(CCN(CC1)CCC2=CC=CC=C2)N(C(CC)=O)C3=CC=CC=C3)OC 
International Nonproprietary Name (INN):  
Carfentanil (English INN) 
Carfentanila (Spanish INN) 
Carfentanilum (Latin INN) 
карфентанил (Russian INN) 
كارفانتانيل (Arabic INN) 
卡芬太尼 (Chinese INN) 
Proprietary names: 
Wildnil® 
  
                                                          
(9) The Chemical Abstract Service Registry Number (CAS RN) is a unique numeric identifier assigned by the Chemical Abstract 
Service Division of the American Chemical Society to a specific, single chemical substance. 
(10) https://pubchem.ncbi.nlm.nih.gov/compound/62156 
(11) InChI Key is a unique, non-proprietary structural identifier of chemical substances useful in electronic sources. 
(12) The simplified molecular-input line-entry system (SMILES) is a unique, non-proprietary structural identifier of chemical 
substances useful in electronic sources. 
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Street names: 
C.50 (13) 
Gray death (14)  
Identification and analytical profile 
Carfentanil has been seized in powder form and as a liquid (EMCDDA, 2017a) (15). In some cases it 
has been identified along with other substances, including other opioids.  
Approximately 2.7 kg of powders containing carfentanil have been seized in Europe. In at least 278 
seizures, carfentanil was mixed with heroin. Carfentanil has also been detected in mixtures with other 
opioids: fentanyl (81 cases), methadone (13), fentanyl and furanylfentanyl (10), fentanyl and 
acryloylfentanyl (7), furanylfentanyl (4), tramadol (3) and acryloylfentanyl (2). In 4 cases, cocaine was 
present in addition to heroin and carfentanil (EMCDDA, 2017a). 
In seizures, carfentanil was frequently found in ranging from white and pale yellow to brown.  
In the United States, the Drug Enforcement Administration Special Testing and Research Laboratory 
has provided an overview of confirmed carfentanil cases examined by local, state, and federal 
forensic laboratories during 2016. Of 407 cases, 67 contained carfentanil only. Other substances 
contained were fentanyl (5 cases), furanylfentanyl (8), heroin (27), heroin/fentanyl (12), 
heroin/furanylfentanyl (1), heroin/fentanyl/furanylfentanyl (4), and other controlled substances (10) 
(including cocaine, U-47,700, methamphetamine, FUB-AMB and other cannabinoids). The remaining 
273 cases did not contain detailed reporting (Casale, Mallette, & Guest, 2017). 
Detailed laboratory analyses are necessary to identify the substance. 
Physical description  
Carfentanil (base) is described as a white powder (SWGDRUG, 2016) or pale yellow solid (Toronto 
Research Chemicals Inc., 2011). The reported melting points of carfentanil base are 92–93 ºC 
(Janssen and Van Daele, 1979) and 94.9 ºC (Walz et al., 2014). The reported logP values (16) are 
3.85 (Tollenaere et al., 1986) and 3.58 (Henriksen et al., 2005). The pKa value, measured at 20 ºC, 
was found to be 8.10 (Tollenaere et al., 1986). No data for the boiling point or other physical 
characteristics were found in the literature. The high LogP:Octanol-water indicates that carfentanil is a 
lipophilic compound. 
The Material Safety Data Sheet (MSDS) for carfentanil from Toronto Research Chemicals states that 
the melting/freezing point of carfentanil is 98–100 ºC (Toronto Research Chemicals Inc., 2011). 
According to this MSDS, carfentanil is soluble in chloroform, dichloromethane and ethyl acetate. 
Cayman Chemical offers a 0.1% solution of carfentanil in methanol, indicating the substance is 
                                                          
(13) Norway reported a collected sample of carfentanil to the EMCDDA that was detected in powder from a zip-lock bag that 
was labelled ‘C.50’. 
(14) ‘Gray Death’, a street drug resembling concrete that surfaced late 2016 in Hamilton County, is often laced with heroin, 
fentanyl, carfentanil, furanyl fentanyl or acrylfentanyl (Coroner: Carfentanil resurfaces, ‘Gray Death’ and cocaine mixed with 
fentanyl hit the streets - WCPO Cincinnati, OH,” n.d.). 
(15) A seizure of carfentanil in plant material has also been reported to the EMCDDA.  
(16) LogP is logarithmic measure of the lipophilicity of a compound by its partition coefficient between an apolar solvent (here 1-
octanol) and an aqueous buffer. 
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soluble in this solvent to this extent (Cayman Chemical, 2016). Similarly, Cerilliant offers a 0.1% 
methanol solution of the oxalate salt of carfentanil (Cerilliant, n.d.). 
A carfentanil formulation for veterinary use was commercially available as its citrate salt (US FDA, 
n.d.) under the trade name Wildnil®. The melting point is 152.2 ºC (Janssen & van Daele, 1979).  
The melting point for carfentanil oxalate is reported as between 182 and 189.5 °C (Marton et al., 
2012; Van Daele et al., 1976). 
Analyses of seized powders in the United States suggest that illicit carfentanil entered the country as 
a hydrochloride salt (Casale, Mallette, & Guest, 2017). No data on the physical properties of this salt 
are available. 
Chemical stability and typical reactions 
The MSDS for carfentanil from Toronto Research Chemicals and Cayman Chemical indicate that no 
data on reactivity are available, but that the compound or the 0.1% solution in methanol, respectively, 
are stable under recommended storage conditions (Cayman Chemical, 2016; Toronto Research 
Chemicals Inc., 2011).  
Extracted biological samples that were positive for carfentanil, stored in a refrigerated auto-sampler 
(8 ºC) and re-injected on Ultra-High Performance Liquid Chromatography (UHPLC) after 24 and 48 
hours showed no loss of signal, indicating good stability under these conditions (Shoff et al., 2017). 
Analytical profile 
Since carfentanil has been studied as an immobilisation agent in animals and used as a research tool 
for opioid research, many papers contain information on analytical methods. In Table 1, recently 
developed methods in forensic and analytical toxicology (mainly LC tandem MS) are summarised. 
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TABLE 1  
Analytical methods for the detection of carfentanil. 
Method LOD LLOQ Matrix Comments Reference 
UHPLC-Ion 
Trap-MSn 
0.1 
ng/mL 
N.A. Blood, urine, 
liver, brain 
Qualitative screening method Shoff et al., 
2017 
LC-MS-MS 0.05 
ng/mL 
0.1 
ng/mL 
Blood, vitreous 
humour  
Quantitative method Sofalvi et al., 
2017 
LC-MS-MS 0.005 
ng/mL 
0.01 
ng/mL 
Blood Quantitative method Shanks & 
Behonick, 2017 
LC-MS-MS 0.01 
ng/mL 
 Blood, urine No detailed description of 
method 
Seither & Reidy, 
2017 
HPLC-API-
MS-MS 
0.003 
ng/mL 
 Urine LOD norcarfentanil 0.027 
ng/mL 
Wang & 
Bernert, 2006 
LC-MS-MS 0.03 
ng/mL 
 Blood No detailed description of 
method 
Papsun et al., 
2017 
NACE-ESI-
MSn 
0.55 
ng/mL 
 Forensic 
exhibits 
 Rittgen et al., 
2012 
ELISA 0.5 
ng/mL 
 Serum fentanyl antibody-coated 
nanoparticles. Cross-reactivity 
with carfentanil 85% 
Mao et al., 2006 
1 ng/mL  Urine 
 
Carfentanil may go undetected in routine screening assays such as the Immunalysis ELISA fentanyl 
assay due to lack of cross-reactivity or because the concentration is below the limit of detection (Shoff 
et al., 2017; Sofalvi et al., 2017). It is therefore necessary to use specific and sensitive screening and 
quantification analytical techniques. Immunoassays kits developed specifically for carfentanil are 
available. 
Nuclear magnetic resonance (NMR) spectroscopic characterisation of carfentanil has been published 
(Marton et al., 2012, Walz et al., 2014; SWGDRUG, 2016); infrared and mass spectroscopy spectra 
have also become available (SWGDRUG, 2016). 
Methods and chemical precursors used for the manufacture  
The methods of synthesis, precursors and main reagents used for the manufacture of carfentanil are 
summarised in Table 2. 
Carfentanil was first synthesised by a group of chemists at Janssen Pharmaceutica on May 2, 1974 
(Stanley, Egan, & Van Aken, 2008). An initial description of the route of synthesis for carfentanil used 
in the context of the preparation of a wide range of fentanyl derivatives for explorative purposes was 
published in 1976 (Van Daele et al., 1976). Subsequently Janssen Pharmaceutica patented a method 
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in 1979. The latter synthesis consists of eight steps, among which is the preparation of a key α-
aminonitrile via a Strecker reaction from 1-phenethyl-4-piperidone (NPP) (17). This α-substituted nitrile 
must be hydrated and the obtained amide hydrolyzed, the aniline acylated and finally the acylamino 
acid must be methylated (Malaquin et al., 2010). This route of synthesis reportedly gives a low yield 
(Malaquin et al., 2010; Marton et al., 2012). An improved method for the conversion of the aminonitrile 
intermediate to the corresponding amino ester has been published (Taber & Rahimizadeh, 1992). 
In a novel route, the α-aminonitrile is prepared by an anhydrous Strecker reaction and subsequently 
reacted with chlorosulfonyl isocyanate and methylene chloride, followed by cyclization of the resulting 
amide by treatment with 1 M HCl to yield a 1-phenyl-spirohydantoin derivate. Alkaline hydrolysis of 
the 2,4-imidazolidinedione derivative yielded α-amino acid in an overall yield of 39%. Finally the 
acylamino acid must be converted to its methyl ester (Feldman & Brackeen, 1990) 
An alternative method for the synthesis of fentanyl, known as the Siegfried method, has been 
mentioned in the literature in which NPP is used as starting material (Lurie et al., 2012; Siegfried, 
n.d.). Such a method has been published also for the synthesis of carfentanil (Lu et al., 1990; Reiff 
and Sollman, 1992) and its analogues (Wen et al., 1993). 
A simple two-step method known as the Ugi multicomponent reaction provides a 70% yield under 
optimal conditions (Malaquin et al., 2010).  
Additional methods for the preparation of radiotracers have been described in the literature as well 
(Blecha et al., 2017; Dannals et al., 1985; Jewett, 2001; Saji et al., 1992; Shao et al., 2011; Shao et 
al, 2014; Shao & Kilbourn, 2009; Wang et al., 2011; Zhang et al., 2011). The desmethyl, that is the 
free acid derivative of carfentanil, 4-((1-oxopropyl)-phenylamino)-1-(2-phenylethyl)-4-
piperidinecarboxylic acid, is an important starting material for the synthesis of the radiotracers. Marton 
et al., 2012 reported various routes of synthesis to prepare this precursor.  
N-Phenethyl-4-piperidone (NPP) was scheduled in 2017 and is listed in Table I of the United Nations 
Convention against Traffic in Narcotic Drugs and Psychotropic Substances, 1988. The scheduling 
came into force on 18 October 2017 (INCB, 2017).  
Due to the typical high potency of fentanils there is a risk of severe poisoning following accidental 
exposure during their manufacture. Extreme care must be taken when carrying out the final synthetic 
step as well as when purifying and handling the substances. Likewise, accidental exposure to the 
fentanils could pose a risk of poisoning to the public, law enforcement, emergency personnel, as well 
as medical and forensic laboratory personnel. In addition to exercising extreme caution when handling 
materials suspected to contain fentanils, personnel should be equipped with appropriate protective 
equipment. The antidote naloxone should be readily available to personnel in sufficient quantities; 
training in resuscitation, including the administration of naloxone, should also be available (IAB, 2017; 
US CDC, 2013; US DEA, 2017) 
 
 
 
                                                          
(17) NPP known as 1-phenethyl-4-piperidone and N-phenethyl-4-piperidone 
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TABLE 2 
Methods of synthesis for carfentanil 
Method Starting material Main reagents Reference 
Explorative methyl 4-
[phenyl(propanoyl)amino]piperidine-4-
carboxylate 
2-bromoethylbenzene; 
dimethylacetamide; ethanol; 
MgSO4; chloroform; methanol; 
methylisobutylketone; oxalic 
acid 
Van Daele et 
al., 1976 
‘Janssen’ method 1-phenethyl-4-piperidone(18) KCN; aniline; acetic acid; 
H2SO4; KOH; ethylene glycol; 
methanol; propionic anhydride 
Malaquin et al., 
2010 
Anhydrous 
Strecker/amide 
cyclization 
1-phenethyl-4-piperidone trimethylsilyl cyanide; aniline; 
acetic acid; chlorosulfonyl 
isocyanate; methylene chloride; 
HCl; NaOH; methyl iodide; 
DMF 
Feldman & 
Brackeen, 1990 
´Siegfried´ method 
(19) 
1-phenethyl-4-piperidone  Aniline; NaBH4; propionyl 
chloride; HCl; NaOH; 
dichloromethane; 
Siegfried, n.d.  
Ugi 
multicomponent 
reaction 
propionic acid; aniline; 1-phenylethyl-
4-piperidone; 1- cyclohexenyl 
isocyanide 
Acylchloride 10% /methanol; 
ethylacetate; NaHCO3; MgSO4; 
brine 
Malaquin et al., 
2010 
Radiotracer 
synthesis 
[11C]iodomethane, 4-((1-oxopropyl)-
phenylamino)-1-(2-phenylethyl)-4-
piperidinecarboxylic acid (20) 
Dimethylformamide, H2; 
palladium-on-charcoal; NaOH 
Dannals et al., 
1985 
Radiotracer 
synthesis 
[11C]methyl triflate; 4-((1-oxopropyl)-
phenylamino)-1-(2-phenylethyl)-4-
piperidinecarboxylic acid (21) 
DMSO, tetrabutylammonium 
hydroxide; NH4OH 
 Jewett, 2001 
t-butyl ester route 4-((1-oxopropyl)-phenylamino)-1-(2-
phenylethyl)-4-piperidinecarboxylic 
acid (22) 
Methanol; H2SO4; NH4OH; 
Na2SO4; methylisobutylketone; 
oxalic acid dihydrate 
Marton et al., 
2012 
Radiotracer 
synthesis 
[11C]methyl triflate; 4-((1-oxopropyl)-
phenylamino)-1-(2-phenylethyl)-4-
piperidinecarboxylic acid - 
tetrabutylammonium salt 
Ethanol; NH4OH Blecha et al., 
2017 
. 
                                                          
(18) N-phenethyl-piperidone (NPP) can be synthesized from piperidone and phenethyl-tosylate or phenethyl-bromide through a 
simple SN2 mechanism (Siegfried, n.d.). 
(19) A brief description of this method for the synthesis of fentanyl is found in internet (Siegfried, n.d.). It does not describe how 
the method can be used for the synthesis of carfentanil. 
(20) The synthesis of this precursor is described in Dannals et al., (1985). 
(21) The synthesis of this precursor is described in Jewett (2001). 
(22) Various routes of synthesis of this precursor is described in Marton et al., (2012). 
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Typical impurities encountered in seized and collected samples 
Analytical profiles were provided for three carfentanil submissions to the Drug Enforcement 
Administration Special Testing and Research Laboratory in the United States. Acetylcarfentanil was 
characterized as an impurity in two exhibits. According to the authors, acetylcarfentanil presumably 
arises from the clandestine synthesis of carfentanil, similar to that of acetylfentanyl in illicit fentanyl 
exhibits (Casale, Mallette, & Guest, 2017).  
A1.2. Physical/pharmaceutical form  
Carfentanil has been seized as a powder and as a liquid (EMCDDA, 2017a) (23). 
A1.3. Route of administration and dosage  
Carfentanil can be administered orally as a powder, as tablets, or as a solution; it can also be 
administered intranasally or sublingually via spray or snorted (insufflated); inhaled by vaporising e-
liquid type solutions (‘vaping’); inhaled by smoking or vaporising the ‘free base’; administered 
transdermally, and injected. In view of its high potency, users may also prepare appropriately diluted 
solutions for intranasal application using nasal sprays. 
Limited information is available regarding the dose and the dose regimens of carfentanil. It is not 
possible to currently discern the ‘typical’ dosages administered by users. Doses appear to differ 
depending on factors such as the route of administration, the tolerance of the users, the use of other 
drugs, and the desired effects. Furthermore, the purity, amount and/or composition of the substance 
ingested are not typically known by the user. Moreover, the actual composition of the substance may 
differ over time and different geographical areas. Given the difficulties of collecting such data, it 
should be used with caution. This issue is further complicated by the fact that carfentanil is mixed with 
or sold as heroin and other illicit opioids, meaning that users will not be aware that they are using the 
substance. 
A 26-year-old man with a history of polysubstance use obtained 100 mg of carfentanil via a ‘dark web’ 
source. He injected approximately 60 µg carfentanil and ingested 4.9 mg of what he believed to be 
‘clonazolam’. He was found unconscious and with respiratory depression. In the emergency room he 
was given a total of 4.4 mg of naloxone intravenously resulting in partial arousal and improvement in 
respiratory rate. Subsequently, he was given a naloxone infusion, initiated at 5 mg/h for 7h until 
recovery. His blood contained 1.1 ng/mL carfentanil and alprazolam (Shulman et al., 2017). 
A2. Pharmacology, including pharmacodynamics and pharmacokinetics  
In this section only primary pharmacology is described. Analgesia and sedation are considered the 
primary pharmacological effects in this report. Safety pharmacology data are summarized in Section 
D.1.1. As both efficacy and safety were considered in studies with non-laboratory animals, some of 
these may be mentioned in both the sections on primary pharmacology and safety pharmacology. 
 
                                                          
(23) A seizure of carfentanil in plant material was reported to the EMCDDA  
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Pharmacodynamics 
In vitro studies 
Carfentanil is a full µ-opioid agonist. 
Binding and activity at the opioid receptors has been measured in many studies. These are 
summarized in Table 3. 
Binding studies show a high affinity of carfentanil for opioid receptors, with a high specificity towards 
the µ opioid receptor. The data presented by Yeaden and Kitchen (1988) appear to be an exception 
compared to the data reported by others. 
Fitzgerald and Teitler made a quantitative autoradiographic analysis of [3H]carfentanil binding to µ 
opioid receptors in the rat brain. Thirty-five brain regions were examined for specific [3H]carfentanil 
and [3H]DAMGO binding. The absolute and relative densities of the sites were essentially identical. 
The highest levels of binding were observed in the ‘patch’ areas of the striatum. The lowest levels 
were observed in the cerebellum where no specific binding of either radioligand was observed. Other 
areas with high levels of binding (>70 fmol/mg tissue equivalent) were striatum (matrix), superior 
colliculus superficial layer and nucleus accumbens (Fitzgerald & Teitler, 1993). 
In order to investigate the receptor interactions of carfentanil in detail [3H]carfentanil was used as a 
radioligand for labelling receptors in rat and human brain tissue homogenates. [3H]Carfentanil was 
found to bind saturably and with high affinity (KD = 0.08 ± 0.01 nM) to membranes prepared from 
human cortical (Bmax = 42 ± 3 fmol/mg) and thalamic (Bmax = 84 ± 3 fmol/mg) tissues and rat cortex 
(Bmax = 82 ± 4 fmol/mg) and diencephalon (Bmax = 105 ± 5 fmol/mg). Association (1.23 ± 0.19 ˣ 1010 
Mol-1 ˣ min-1 and dissociation rate (0.19 ± 0.03 Mol-1 ˣ min-1) constants were determined in human 
cortical tissues; results from studies in rat cortical, and rat diencephalon tissue homogenates 
produced similar kinetic rate constants (Titeler et al., 1989). 
µ1-Specificity of carfentanil binding 
In rats, the receptor subtype specificity of binding of carfentanil to µ1 and µ2 opioid receptor subtypes 
was studied in brain sections in vitro and with PET imaging in vivo (Table 4). Receptor subtype-
selective inhibition of [11C]carfentanil binding was studied by pharmacologic intervention, using the µ-
receptor inhibitor cyprodime or the µ1-specific inhibitor naloxonazine. In vitro, binding to µ1 occurs with 
higher (> 100-fold) relative affinity than for µ2. The apparent affinity to µ receptors, which is just above 
the nanomolar range, thus consists of a mixture of very high affinity for µ1 and medium high affinity for 
µ2. [11C]Carfentanil binding to µ2 in vivo could not be detected following specific blocking of µ1. If the 
results obtained in this study in rats are translatable to the human situation this would mean that 
previous and future clinical studies employing [11C]carfentanil will be biased to measure µ1 rather than 
µ2 (Eriksson & Antoni, 2015). See Table 4.
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TABLE 3 
In vitro binding and activity of carfentanil at opioid receptors. 
Parameter µ δ κ µ/δ µ/κ Other receptor 
preparation 
Comments μ (reference opioid) Reference 
Ki in guinea pig whole 
brain membranes 
0.024 nM 3.3 nM 43 nM 138 1792  µ-agonist DAGO; δ-agonist 
DPDPE; κ-agonist: U-
69593 
1.2 nM (fentanyl) Maguire et al., 
1992 
IC50 in guinea pig ileum 
and mouse vas deferens 
0.019 nM 17 nM 59 nM 895 26000   3.6 nM (fentanyl) Maguire et al., 
1992 
Ki in SH-SY5Y cells 0.15 nM      µ-agonist DAGO 0.39 nM (fentanyl) Costa et al., 
1992 
ED50 GTPase inhibition <0.1 nM       1.3 nM (fentanyl) Costa et al., 
1992 
ED50 cAMP inhibition <0.01 nM       0.42 nM (fentanyl) Costa et al., 
1992 
Ki in rat brain homogenate 0.42 nM 0.42 
nM 
 1.09   µ-agonist DAGO; δ-agonist 
DPDPE 
3.3 (fentanyl) Yeaden & 
Kitchen, 1988 
IC50 in rat brain minus 
cerebellum 
     0.093 nM [3H]fentanyl 2.7 nM (fentanyl) Leysen et al., 
1977 
IC50 in rat forebrain      0.17 nM [3H]sufentanil 7.9 nM (fentanyl; 27 
nM (morphine) 
Leysen & 
Gommeren, 
1986 
Ki in cloned human opioid 
receptor 
0.07 nM      µ-agonist DAMGO 2.1 nM ([18F]fentanyl) Henriksen et al., 
2005 
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Ki in human prefrontal 
cortex homogenate 
     0.1 nM [3H]carfentanil 1.4 nM (morphine), 
2.4 nM (naloxone) 
Titeler et al., 
1989 
Ki in rat frontal cortex 
homogenate 
     0.1 nM [3H]carfentanil 3.7 nM (morphine), 
5.5 nM (naloxone) 
Titeler et al., 
1989 
IC50 in rat brain 
homogenate (2 sites, 
biphasic kinetics) 
0.0006 & 
0.087 nM 
0.74 & 
40 nM 
0.0008 & 
0.125 nM 
   µ-agonist DHM; δ-agonist 
DADLE; κ-agonist: EKC 
 Thompson et al., 
1987 
IC50 in rat brain 
homogenate 
0.2 nM      [3H]naltrexone 27 nM (morphine); 25 
nM (fentanyl) 
Maryanoff et al., 
1982 
IC50 in rat forebrain 
homogenate 
     0.089 nM [3H]fentanyl 2.5 nM (fentanyl) Leysen & 
Laduron, 1978 
EC50 rat brain membrane 
homogenate 
     72 nM  0.5 nM 3H-etorphine Jacobson, 1988 
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TABLE 4  
Bmax and KD of [11C]Carfentanil to rat µ, µ1 and µ2 receptors from Eriksson & Antoni (2015) 
 Thalamus Cortex 
 µ µ1 µ2 µ µ1 µ2 
Bmax (fmol/mg 
tissue) 
72.5 ± 10.1 16.6 ± 1.6 89.6 ± 40.4 64.9 ± 9.3 6.5 ± 1.2 92.8 ± 41.8 
KD (nM) 12.6 ± 4.4 0.4 ± 0.4 45.5 ± 30.0 12.6 ± 4.4 0.4 ± 0.4 45.5 ± 30.0 
Binding 
Potential 
5.8 40.2 2.0 5.2 15.7 2.0 
 
Animal studies 
In vivo pharmacology studies 
The analgesic and sedative effects of carfentanil has been studied in both laboratory animals and 
non-laboratory animals (Table 5). 
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TABLE 5  
Sedative and analgesic activity of carfentanil in laboratory animals 
Species 
(N) 
Route Dose Test Endpoint Result Comments Reference 
Rat ♂ 
Wistar 
(130) 
IV  Tail 
withdrawal 
ED50 0.44 
µg/kg 
Potency ratio 
compared to 
morphine: 7682 
Van Daele 
et al., 1976 
Mouse ♂ 
Swiss-
Webster 
(10/group) 
IV  Hot-plate ED50 0.8 µg/kg  Bagley et 
al., 1991 
Rat ♂ 
Wistar 
(10/group) 
IV  Tail 
withdrawal 
ED50 0.37 
µg/kg 
TEmax = 15 
min; Potency 
ratio compared 
to morphine: 
10031 
Van Bever 
et al., 1976 
Rats S.D. 
♂ 
(5/group) 
IV 10 
µg/kg 
Sedation Duration of 
loss of 
righting 
reflex 
(LORR) 
100 min. Reduction of 
LORR to 
22.69% and 
8.46% with 9.4 
or 150 µg/kg IM 
nalmefene 
Yong et al., 
2014 
Mice 
albino ICR 
♂ 
SC  Hot-plate ED50 <0.4 
µg/kg 
 Jacobson, 
1988 
Mice 
albino ICR 
♂ 
SC  Phenyl-
quinone 
writhing test 
ED50 0.06 
µg/kg 
 Jacobson, 
1988 
Mice 
albino ICR 
♂ 
SC  Tail flick ED50 0.2 µg/kg  Jacobson, 
1988 
Mice 
albino ICR 
♂ 
SC  Nilsen32  negative  Jacobson, 
1988 
Rat ♂ 
Wistar 
IV  Tail 
withdrawal 
ED50 0.6 μg/kg 11 μg/kg for 
fentanyl 
Leysen & 
Laduron, 
1978 
New 
Zealand 
white 
IV  Tooth pulp 
assay 
ED50 0.11 
μg/kg 
7.4 μg/kg for 
fentanyl 
Wynn et al., 
1986 
                                                          
(32) In the Nilsen assay electrical pulsations are given to the mouse tail. A drug is considered active at a given dose level in an 
individual mouse if that mouse responded consecutively in at least two of the four time periods by vocalisation (Perrine et al., 
1972). 
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rabbit 
IV: intravenous; SC: subcutaneous; IM: intramuscular. 
The efficacy of carfentanil as an immobilizing agent for members of Cervidae family has been 
demonstrated in 19 well controlled pivotal and corroborative clinical field trials conducted with 158 
moose, 295 elk, 18 Axis deer (Axis axis), 9 Sika deer (Cervus nelsoni) and 29 exotic Cervidae (mainly 
Indian hog deer (Hyelaphus porcinus) and a few pampas deer (Ozotoceros bezoarticus), muntjac 
(Muntiacus spec.) and Eld’s deer (Panolia eldii) (US FDA, n.d.). Based on these data the United 
States Food and Drug Administration approved Wildnil® for use in Cervidae. The recommended dose 
for use as an immobilising agent in Cervidae is 5-20 µg/kg bodyweight, administered in a large 
muscle mass (US FDA, n.d.). 
Based on field trials in South African national parks in more than 200 animals, dose recommendations 
were made for 19 wild animal species ranging from 1 µg carfentanil/kg bodyweight (African elephant 
and square-lipped rhinoceros) to 12.5 µg/kg (warthog) (De Vos, 1978). 
In addition to these species, carfentanil has also been used for the immobilisation of many other 
species (Table 6). In the majority of reports carfentanil was administered intramuscularly (IM). Most 
doses are in the range of 5-20 µg/kg. However, administration by mouth (PO), facilitating 
transmucosal transport, was reported as well. In these cases carfentanil is readily absorbed 
transmucosally in the buccal cavity or sublingually. These tissues have a dense vasculature. Reports 
showing that orogastric administration greatly increases time of onset of sedation and require higher 
doses support this view (Mortenson, 1994; Walsh & Wilson, 2002). Of note, studies of non-human 
primates, especially those belonging to the great apes (Hominidae) have shown that transmucosal 
(TM) doses as low as 2 µg/kg can lead to deep sedation of these animals (Kearns et al., 1999; 
Kearns et al., 2000) 
The use of carfentanil (usually in combination with the α 2 adrenergic agonist xylazine) has been 
compared with other anaesthetic drugs or drug combinations such as medetomidine/ketamine, 
sufentanil, sufentanil/xylazine, telazol/xylazine, detomidine, medetomidine/xylazine/atipamezol, 
ketamine/xylazine and etorphine/xylazine. In several studies carfentanil showed some disadvantages 
compared to the comparators, such as longer induction time and larger risk of renarcotisation. The 
latter may be related to a longer clearance time and/or recirculation from tissue depots. 
To reverse the narcosis, naltrexone is most often chosen as antidote for carfentanil, usually in a 100:1 
ratio. Lower ratios or the use of naloxone may increase the risk of re-narcotisation. Usually naltrexone 
was partly administered intravenously (IV) and partly subcutaneously (SC), however, intranasal 
administration can also be effective. For humans a naltrexone solution is not available and naloxone 
solutions are used for opioid antagonism (Section 3.4). 
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TABLE 6 
Sedative activity of carfentanil in non-laboratory animals. 
Species 
(N) 
Route Dose 
(average) 
Result Reference 
Grey seals 
(Halichoerus 
grypus) (46) 
IM 10 µg/kg 
(range: 4.2-
24.9) 
Variable depth of narcosis (difficulty to 
administer). Naloxone as antidote (46-177x 
carfentanil dose). 5% died. Probably narrow 
safety margin 
Baker & 
Gatesman, 
1985 
Impala 
(Aepyceros 
melampus) (36) 
IM 14-17 µg/kg 8.6 min to recumbency. Diprenorphine as 
antidote. 
Cheney & 
Hattingh, 
1988 
Common eland 
(Taurotragus oryx) 
(6) 
IM 17 µg/kg + 
230 µg/kg 
xylazine 
4.3 min to recumbency. Naltrexone as antidote 
(100x carfentanil dose) 
Cole et al., 
2006 
Tibetan yak (Bos 
grunniens) (16) 
IM 15 µg/kg + 
250 µg/kg 
xylazine 
5-7 min to recumbency. Naltrexone as antidote 
(100x carfentanil dose) 
Cushing et 
al., 2011 
Moose (Alces 
alces) (72) 
IM 7.1 µg/kg + 
180 µg/kg 
xylazine 
88% complete and 8% partial immobilisation. 6.6 
min to recumbency. Naltrexone as antidote 
(100x carfentanil dose). 6% died. 
Delvaux et 
al., 1999 
Wood bison 
(Bison bison 
athabascae) (107) 
IM 6.0-8.8 µg/kg 
+ 54-133 
µg/kg 
xylazine 
Naloxone and low levels of naltrexone (<90x 
carfentanil dose) permit narcotic recycling. A 
125:1 ratio is recommended. 
Haigh & 
Gates, 1995 
North American 
bison (Bison 
bison) (26) 
IM 2.4 µg/kg + 
70 µg/kg 
xylazine 
Mean induction time 14.2 min. Naloxone as 
antidote (≈100x carfentanil dose) 
Kock & 
Berger, 1987 
Rhebok (Pelea 
capreolus) (6) 
IM 10 µg/kg + 
400 µg/kg 
xylazine 
4 min until recumbency.  Howard et 
al., 2004 
Desert bighorn 
sheep (Ovis 
canidensis 
nelson) (23) 
IM 44 µg/kg + 
190 µg/kg 
xylazine 
Induction time 6.3 min. Diprenorphine (299 
µg/kg) or naloxone (4 mg/kg) as antidote. 2 
sheep died. 
Jessup et 
al., 1985 
Tule elk (Cervus 
elaphus 
nannodus) (17) 
IM 19 µg/kg + 
235 µg/kg 
xylazine 
Induction time 9.2 min. Diprenorphine (105 
µg/kg) or naloxone (1.03 mg/kg) as antidote. 3 
elk died. 
Jessup et 
al., 1985 
Wild horses 
(Equus caballus) 
(4) 
IM 17 µg/kg + 
610 µg/kg 
xylazine 
Induction time 8 min. Diprenorphine (27 µg/kg) + 
naloxone (1.1 mg/kg) as antidote. 
Jessup et 
al., 1985 
Guanaco (Lama IM 22-50 µg/kg Time to recumbency 3.7 min. Naltrexone (100 Karesh et 
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guanicoe) (14) mg ≈ 1 mg/kg) as antidote. al., 1998 
Chimpanzee (Pan 
trochlodytes) (3) 
TM 2-4 µg/kg Deep sedation after 22 minutes. Severe 
respiratory depression at 25 minutes. 
Kearns et 
al., 1999 
Chimpanzee (Pan 
trochlodytes) (5) 
TM 2 µg/kg 
(after 2.5 mg 
dropiderol 
PO)  
Naltrexone (100x carfentanil 
dose)/tiletamine/zolazepam as antidote. 
Premedication with droperidol diminished 
respiratory depression. 
Kearns et 
al., 2000 
Bonobo (Pan 
paniscus) (2) 
TM 2 µg/kg 
(after 2.5 mg 
dropiderol 
PO)  
Naltrexone (100x carfentanil 
dose)/tiletamine/zolazepam as antidote. Mild to 
moderate respiratory depression. 
Kearns et 
al., 2000 
Capuchin 
monkeys (Cebus 
apella) (2) 
TM 2 µg/kg Mild sedation ; no respiratory depression. Kearns et 
al., 1999 
Gibbons 
(Hylobates lar) (2) 
TM 2 µg/kg Mild to moderate sedation ; no respiratory 
depression 
Kearns et 
al., 1999 
Gemsbok (Oryx 
gazelle) (6) 
IM 21 µg/kg + 
116 µg/kg 
xylazine 
Time to recumbency 4.1 min. Antidote 
naltrexone (≈ 1 mg/kg). 
Kilgallon, 
Lamberski, & 
Larsen, 2010 
Gray wolves 
(Canis lupis) (2) 
IM 7.5 µg/kg + 
500 µg/kg 
xylazine 
Induction time 8 min. Kreeger & 
Seal, 1990 
Grizzly bears 
(Ursus arctos) (7) 
IM 11 µg/kg + 
120 µg/kg 
xylazine 
Induction time 4.3 min. Antidote: naltrexone 1 
mg/kg + 2 mg/kg tolazoline. 
Kreeger et 
al., 2013 
Black bear (Ursus 
arctos) (3) 
IM 14 µg/kg + 
150 µg/kg 
xylazine 
Induction time 5.2 min. Antidote: naltrexone 1 
mg/kg + 2 mg/kg tolazoline. 
Kreeger et 
al., 2013 
Alaskan moose 
calves (Alces 
alces gigas) (13) 
IM 7 µg/kg + 
360 µg/kg 
xylazine 
Induction time 4.5 min. Antidote: naltrexone 1.2 
mg/kg + 2.4 mg/kg tolazoline 
Kreeger & 
Kellie, 2012 
Hartebeest 
(Alcelaphus 
buselaphus major) 
(24) 
IM 7-10 µg/kg + 
azaperone 
or xylazine 
Induction time 8.5 min Kupper et al, 
1981 
Kob (Kobus kob) 
(16) 
IM 5-33 µg/kg + 
azaperone 
or xylazine 
Induction time 5.3 min. Many animals showed 
nervous excitement. 2 died. 
Kupper et al, 
1981 
Caribou calves 
(Rangifer 
tarandus granti) 
(21)  
IM 1.5-1.8 
mg/animal + 
20-25 
mg/animal 
Induction time 3.2 min. Naltrexone (100x 
carfentanil dose) as antidote. 
Lian et al., 
2016 
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xylazine 
White-tailed deer 
(Odo- coileus 
virginianus) (29) 
IM 7.75–46.84 
µg/kg + 
0.16–0.27 
mg/kg 
xylazine 
 
Initial excitement. Induction time 4.7±3.3 min. 
Naltrexone (100x carfentanil dose) + yohimbine 
as antagonist.  
Miller et al., 
2003 
White-tailed deer 
(Odo- coileus 
virginianus) (11) 
IM 30 µg/kg + 
0.3 mg/kg 
xylazine 
Induction time 3 min. Reversal with naltrexone (3 
mg/kg) and yohimbine (0.15 mg/kg). Induction 
time slightly decreased with addition of 
ketamine, but quality of anaesthesia decreased. 
Storms et 
al., 2006 
Rocky mountain 
elk (Cervus 
elaphus nelsoni) 
(12) 
IM 10 µg/kg Induction time 3.1 min. Naltrexone administered 
as 0, 25, 50 or 100 mg/mg carfentanil. 
Recopvery time independent of naltrexone dose. 
No renarcotisation at 100 mg/mg. 3/8 and 7/9 
renarcotisised at 50 and 25 mg/mg.  
Miller et al., 
1996 
Rocky mountain 
wapiti (Cervus 
elaphus nelsoni) 
(8) 
IM 10 µg/kg + 
0.1 mg/kg 
xylazine 
Induction time 3.9 min. Not significantly different 
when 2 µg naloxone/µg carfentanil was added. 
Moresco et 
al., 2001 
Brown bears 
(Ursus arctos) (5) 
PO 
(mixed 
in 
honey) 
6.0-15.2 
µg/kg 
Required dose for anaesthesia: 7.6 µg/kg in 
winter and 12.7 µg/ kg. Sternal recumbency at 
7.5 min, complete sedation at 21 min. Antidote 
naltrexone (100x carfentanil dose). Reversal 
time 6 min. 
Mortenson & 
Bechert, 
2001 
Gaur (Bos gaurus) 
(8) 
IM 10 
mg/animal + 
100 mg 
xylazine/ani
mal 
Time to recumbency 4.6 min. 1,000 mg 
naltrexone and 24 mg yohimbine as antidote. 
Napier et al., 
2011 
Brazilian tapir 
(Tapirus 
terrestrus)  
PO 
(TM) 
7.88 µg/kg 
20 min after 
0.17 µg/kg 
detomidine 
(PO) 
Time to recumbency 10.8 min after carfentanil 
dose. Naltrexone and yohimbine as antidote. 
Pollock & 
Ramsay, 
2003 
White rhinoceros 
(Ceratotherium 
simum) 
IM Adult: 1.2 
mg/animal 
Naltrexone is choice of drug for reversal. 
Naloxone gives renarcotisation.  
Portas, 2004 
Black rhinoceros 
(Diceros bicornis) 
Juvenile: 0.9 
mg/animal; 
adult: 1-1.5 
mg/animal 
Greater one 
horned rhinoceros 
(Rhinoceros 
unicornis) (1) 
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Ostriches 
(Struthio camelus) 
(20) 
IM 3 mg/animal 
+ 150 mg 
xylazine/ani
mal 
Recumbency after 4.7 min following initial 
excitement. Reversal with naltrexone (300 mg) 
and yohimbine (0.125 mg/kg). 
Raath et al., 
1992 
Himalayan tahr 
(Hemitragus 
jemlahicus) (12) 
IM 9 µg/kg + 
0.08 mg/kg 
xylazine 
Time to recumbency 4 min. Reversal with 
naltrexone (867 µg/kg) and atipamezole (105 µg/ 
kg). 
Rainwater et 
al., 2013 
Black bears 
(Ursus 
americanus) (10) 
PO 
(mixed 
with 
honey) 
6.8-18.8 
µg/kg 
Time to sternal recumbency 7.7 min. Time to 
total sedation 19.7 min. Reversal with 100 mg 
naltrexone/mg carfentanil.  
Ramsay et 
al., 1995 
Bongo antelopes 
(Tragelaphus 
eurycerus) 
IM 8.3 µg/kg + 
0.079 mg/kg 
xylazine 
Induction time 6 min. Reversal with Naltrexone 
(0.82 mg/kg) and yohimbine (0.12 mg/kg) 
Schumacher 
et al., 1997 
Dama gazelles 
(Gazella dama) 
(16) 
IM 18.4 µg/kg Induction time 6 min. Reversal with naltrexone 
(1.8 mg/kg) 
Schumacher 
et al., 1997 
Moose (Alces 
alces) (21) 
IM 3-4 
mg/animal + 
100-175 
mg/animal 
xylazine 
Induction time 4.1 min. No excitement phase 
evident. 2 animals died. 
Seal et al., 
1985 
White-tailed deer 
(Odocoileus 
virginianus) 
IM 14.2 µg/kg 
carfentanil 
and 17.8 
µg/kg of 
medetomidin
e 
Induction time 13.3 min. 2/16 animals had 
incomplete narcosis. Reverasal with intranasal 
or intramuscular naltrexone (1.5 mg/kg) and 
atipamezole (0.1 mg/kg). Both routes were as 
effective. 
Shury et al., 
2010 
Domestic goats 
(Capra hircus) (8) 
buccal 60 µg/kg + 
60 µg/kg 
detomidine + 
0.5% 
saponin 
Induction time 22 min after long excitement 
phase (9.6 min). Reversal with naltrexone (3 
mg/kg + yohimbine 0.375 mg/kg or atipamezole 
Sleeman et 
al., 1997 
IM: intramuscular; PO: by mouth; TM: transmucosal. 
Human studies 
In vivo binding to opioid receptors 
Binding of [11C]diprenorphine was compared with [11C]carfentanil binding in the brain of volunteers. 
This showed that carfentanil had a tenfold higher binding potential as shown by competition with 
naloxone. The ED50 values were 1.7 and 13 µg/kg respectively. The in vivo ‘Hill coefficient’ of – 1.05 
for [11C]carfentanil is consistent with its high selectivity for µ receptors (Villemagne et al., 1994).  
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The high and specific affinity of [11C]carfentanil for µ opioid receptors has made it an important tool for 
studying the opioid system with PET imaging in humans. Since the seminal work of Frost and 
Dannals many research papers have been published where [11C]carfentanil has been used (Dannals 
et al., 1985; Frost et al., 1985). This literature is not reviewed in this report, but some additional data 
illustrating tissue and brain distributions are discussed in the pharmacokinetics section on distribution. 
Pharmacokinetics 
General pharmacokinetics and metabolism 
Absorption 
Animal data 
In female (N=6) common eland (Taurotragus oryx), carfentanil was rapidly absorbed after 
intramuscular (IM) administration of 16.9 µg/kg (co-administered with 0.23 mg/kg xylazine). The mean 
Tmax was 13.8 min. Mean plasma AUC0-∞ was 30 ± 5 hr.ng/mL. Cmax was 13 ± 6.7 ng/mL. In this 
species carfentanil had a plasma T½ of 7.7 h (Cole et al., 2006). 
In adult (N=8) domestic goats (Capra hircus), carfentanil was rapidly absorbed after IM administration 
of 40 µg/kg. The mean Tmax was 10.8 min. Mean plasma AUC0-∞ was 11 ± 6.3 hr.ng/mL. Cmax was 9 ± 
5.6 ng/mL. In this species carfentanil had a plasma T½ of 5.5 h (Mutlow et al., 2004). 
Absorption of carfentanil/detomidine (1:1) 60 µg/kg in 0.5% saponin solution (absorption enhancer) 
after buccal administration was studied in (N=8) domestic goats (Capra hircus). Interanimal variability 
was large with some animals showing peak plasma levels at the first measurement after 
administration, whereas others showed only gradual and lesser increases of plasma levels (Sleeman 
et al., 1997).  
Other studies investigating the feasibility of administration of carfentanil in the mouth in wild animals 
indicate that carfentanil is readily absorbed transmucosally (Mortenson & Bechert, 2001; Pollock & 
Ramsay, 2003; Ramsay et al., 1995), as was also shown for non-human primates (Kearns et al., 
1999; Kearns et al., 2000). 
Orogastric absorption appears to be much less. Chimpanzees, given 2.0 µg/kg in grapes or pieces of 
orange, showed minimal, if any, sedative effect. These food items do not appear to promote mucosal 
contact with the drug efficiently (Kearns et al., 1999). Another study investigated carfentanil 
administered to gibbons in juice (Mortenson, 1994). Each gibbon was given a mean dose of 381 
µg/kg of carfentanil, far more higher than a transmucosal administered dose (mixed with honey) of 2 
µg/kg which produced stage 3-4 anaesthesia in this species (Kearns et al., 1999). 
While no pharmacokinetic measurements were included by Wong et al., (2017) in a study on the 
effects of inhaled aerosolized carfentanil on real-time physiological responses in mice, the data show 
that carfentanil is rapidly absorbed after inhalation, as the mice lost consciousness within one minute 
after the start of exposure (Wong et al., 2017). 
Human data 
An aerosolized mixture containing carfentanil and remifentanil and/or halothane allegedly used by 
Russian military when ending a Chechen hostage in Moscow led to the death of 127 hostages. This 
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also suggests an effective uptake of carfentanil by inhalation (Riches et al, 2012; Stanley, 2003; Wax 
et al., 2003). For further details see Section D.1.2. 
Finally a case report on a veterinarian who had been exposed by splashing of a 1.5 mg carfentanil/50 
mg xylazine solution in his face, eyes and mouth, while trying to dislodge a dart from a tree trunk 
reported that the victim became drowsy within minutes, even when he had washed his face 
immediately with water. While it is not possible to discern the effects of carfentanil from xylazine in 
this case, nor the contribution of each route of exposure (dermal/ocular/transmucosal), it appears that 
carfentanil was readily absorbed (George et al., 2010). 
Distribution 
Protein binding 
In human plasma, fentanyl, sufentanil, alfentanil and lofentanil are 84.4, 92.5, 92.1 and 93.6% protein-
bound, respectively (Meuldermans et al., 1982). Based on structural similarity and the lipophilic 
nature, it may be hypothesized that carfentanil should also be highly bound. 
Animal data 
Biodistribution was studied in male ddY mice after intravenous injection of 1.11 MBq (5 µg/kg) of 
[11C]carfentanil. Carfentanil was rapidly cleared from blood. High initial uptake was observed in the 
lungs, kidneys, and liver, with the radioactivity in the lungs and kidneys clearing rapidly and the 
radioactivity in the liver increased with time. A good uptake in brain was observed. A brain/blood ratio 
of 1.5-1.8 was found from 5 to 30 min (Table 7) (Saji et al., 1992).  
TABLE 7  
Biodistribution of [11C]carfentanil in mice (% dose/g organ) (from Saji et al., 1992). 
Organ Time (min) 
5 15 30 60 
Blood 2.09 (0.17) 1.79 (0.39) 1.47 (0.47) 1.18 (0.14) 
Liver 8.53 (0.47) 9.89 (1.15) 9.89 (3.48) 12.46 (1.39) 
Kidney 14.66 (2.82) 9.03 (2.83) 6.97 (1.22) 5.88 (0.71) 
Lung 6.43 (1.86) 3.86 (0.89) 2.86 (0.74) 1.90 (0.51) 
Heart 3.91 (0.58) 2.35 (0.31) 1.83 (0.17) 1.22 (0.25) 
Brain 3.73 (0.34) 2.85 (0.94) 2.13 (0.55) 1.28 (0.25) 
Brain/blood ratio 1.79 (0.14) 1.54 (0.42) 1.46 (.027) 1.09 (0.17) 
Human data 
In a Positron Emission Tomography (PET) scan study, 13 healthy non-drug-using volunteers (25 ± 3.2 
years, 46% male, 80% white) received an IV bolus of 19 ± 19 ng/kg [11C]carfentanil. The calculated 
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T½ was 41.8 ± 17.5 minutes. However, blood samples were collected only during 90 minutes, i.e. in 
the distribution phase, so that the terminal elimination phase is likely to have been missed (Minkowski 
et al., 2012). 
During studies on the brain uptake of intravenously administered [11C]carfentanil in eight healthy 
human volunteers, high accumulation of radioactivity were seen in basal ganglia, thalamus, and 
cortical regions (Hirvonen et al., 2009). 
The distribution of [11C]carfentanil was studied in humans (two males and three females) using whole-
body PET imaging. The greatest uptake initially was in the liver and subsequently, over the course of 
the imaging, more radioactivity appeared in the bladder (Newberg et al., 2009). In Table 8 the mean 
organ-absorbed doses are given. 
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TABLE 8  
Absorbed dose estimates for each organ (µGy/MBq) (from Newberg et al., 2009). 
Organ Mean ± S.D. 
Urinary bladder wall 36.50 ± 1.84 
Liver 9.68 ± 2.44 
Kidneys 4.26 ± 1.89 
Gallbladder wall 4.21 ± 1.11 
Brain 3.98 ± 0.96 
Uterus 3.89 ± 0.50 
Osteogenic cells 3.22 ± 0.69 
Spleen 3.15 ± 1.20 
Heart wall 3.14 ± 0.57 
Ovaries 2.98 ± 0.49 
Lower large intestine wall 2.96 ± 0.48 
Lungs 2.93 ± 0.56 
Pancreas 2.76 ± 0.58 
Small intestine 2.75 ± 0.54 
Upper large intestine wall 2.71 ± 0.54 
Adrenals 2.69 ± 0.56 
Red marrow 2.54 ± 0.57 
Stomach wall 2.40 ± 0.51 
Testes 2.33 ± 0.40 
Thymus 2.04 ± 0.43 
Muscle 1.99 ± 0.28 
Thyroid 1.98 ± 0.41 
Breasts 1.77 ± 0.39 
Skin 1.62 ± 0.34 
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Regional brain distribution 
Animal data 
Regional cerebral distribution studies in the mouse show a significantly higher uptake of 
[11C]carfentanil by the thalamus and striatum than by the cerebellum, with the radioactivity in the 
striatum disappearing more rapidly than that in the thalamus (Saji et al., 1992). 
Regional brain distribution was also studied in the CD-rat and CD-1 mice. Preferential binding 
compared to cerebellum in the rat was hypothalamus > striatum > thalamus > cortex > hippocampus 
> pons/medulla. In mice preferential binding was similarly distributed: hypothalamus > thalamus ≈ 
striatum > cortex (Jewett & Kilbourn, 2004).  
Human data 
The specific binding and cerebral uptake of [11C]carfentanil and its radioactive metabolites in human 
subjects was studied (Frost et al., 1989; Endres et al., 2003). Depending on the compartmental model 
used, thalamus or amygdala showed the highest level of binding, with caudate displaying similar 
binding potential as the amygdala, closely followed by the putamen. Lower levels of binding 
potential—but still higher than in reference tissue (blood or occipital)—was observed in cingulate, 
periaqueductal, cerebellum and temporal, frontal and parietal cortex. Using compartmental modelling, 
it was estimated that [11C]carfentanil-associated radioactivity appeared rapidly in all brain regions 
(thalamus, cingulate, cerebellum and occipital), but occipital showed a rapid initial clearance 
(approximately 50% of radioactivity had disappeared within 20 minutes, whereas in regions with 
higher binding potential radioactivity disappeared more gradually (in thalamus approximately 75% of 
radioactivity still remained after 90 minutes) (Endres et al. 2003). 
Metabolism 
Metabolism of carfentanil was studied in human liver microsomes and hepatocytes. Twelve 
metabolites were identified. N-Dealkylation and monohydroxylation of the piperidine ring were the 
dominant metabolic pathways, leading to metabolites M2 (norcarfentanil) and M8 (Figure 2), 
respectively. Two N- oxide metabolites and one glucuronide metabolite were observed. Ester 
hydrolysis was not a major metabolic pathway for carfentanil (Feasel et al., 2016). 
Limited information from blood and urine samples from drug users confirms the presence of the major 
hydroxy metabolite M8, while the hydroxyl metabolite M7 and norcarfentanil are detected as well 
(Hudson, 2017). Another report confirms the presence of norcarfentanil in serum and urine in a drug 
user (Müller et al., 2017). 
In human liver microsomes, carfentanil half-life was 7.8 min (Feasel et al., 2016). Based on this figure, 
the authors estimated an in vivo intrinsic clearance of 16.2 mL/min/kg. However, when cryopreserved 
human hepatocytes were used to investigate carfentanil metabolism, carfentanil peak intensity did not 
decrease significantly over 6 h.  
In vivo, rapid metabolism was shown in a study in 6 human volunteers who received a bolus IV 
injection of [11C]carfentanil (19.0 ± 1.5 mCi carfentanil with a specific activity of 4807 ± 1303 
mCi/µmole; ≈ 1,5 µg carfentanil/person). By 40 min post-injection, radioactive metabolites account for 
more than 50% of the total plasma radioactivity. The main metabolite was more polar than carfentanil 
and suggested to be norcarfentanil. In addition a more lipophilic metabolite was observed (Endres et 
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al., 2003). In an earlier study in 5 volunteers it was found that after 20 minutes 50% of [11C]carfentanil 
associated radioactivity in plasma was present as metabolites. After 90 minutes approximately 25% of 
carfentanil was unmetabolised. In the presence of naloxone carfentanil metabolites appeared 10–15% 
more rapidly (Frost et al., 1989).  
For fentanyl systemic elimination occurs primarily by hepatic metabolism (Labroo et al., 1997). The 
main metabolic route is N-dealkylation mediated by CYP3A4 (Guitton et al., 1997; Labroo et al., 1997; 
Saari et al., 2008), but CYP3A5 may be of relevance as well (Kuip et al., 2017). Based on its similarity 
in structure and N-dealkylation being a common route of metabolism, it is expected that carfentanil 
will also be eliminated primarily by hepatic metabolism involving CYP3A4/5.  
FIGURE 2  
Proposed metabolic pathway for carfentanil in human hepatocytes. Metabolite structures 
derived from MS/MS and chromatographic analysis (Feasel et al., 2016). 
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Excretion 
A 16-year-old male patient was found unconscious and analysis of powder found in the patient’s 
belongings was identified as carfentanil. A urine drug screening immunoassay was negative, but 
analysis with LC-MS/MS showed a urine concentration of 1.3 ng/mL for carfentanil and 0.5 ng/mL for 
its main metabolite norcarfentanil. This case demonstrates that carfentanil and its main metabolite 
norcarfentanil are excreted renally. However, calculation of the renal excretion fraction for carfentanil 
in this case revealed a value of 1.4%. The low value may be related to high protein binding or renal 
tubular reabsorption (Müller et al., 2017). Based on structural similarity to sufentanil, alfentanil and 
lofentanil and the lipophilic nature, it may be hypothesized that carfentanil should also be highly 
bound (Meuldermans et al., 1982). Furthermore, it is reasonable to expect that a significant proportion 
of the administered dose will be extracted by the liver, as is also suggested by distribution data 
obtained in mice (Saji et al., 1992) and human volunteers (Newberg et al., 2009). Data obtained in the 
latter study also show that a large part of radioactivity ultimately appears in the urinary bladder 
(Newberg et al., 2009). 
Inter-individual genetic variability in metabolising enzymes 
As mentioned earlier, fentanyl is thought to be mainly metabolized by CYP3A4 ()Guitton et al., 1997; 
Labroo et al., 1997; Saari et al., 2008). Of note, CYP3A5 contributes to CYP3A-dependent drug 
clearance and thus may lead to changes in fentanyl pharmacokinetics as well (Kuip et al., 2017). As 
carfentanil is expected to have similar clearance patterns as fentanyl, polymorphisms in CYP3A 
genes may also be relevant for subjects exposed to carfentanil. Patients with the CYP3A5*3 gene 
single nucleotide polymorphism (SNP) had about a 2-fold higher fentanyl plasma concentration 
normalized by measured absorption rate than patients with the wild-type (*1*1) gene polymorphism 
and the patients with the heterozygous (*1*3) gene polymorphism. The total clearance of fentanyl is 
also 30–50% lower for the *3*3 group compared to the other two groups, though Barratt and co-
workers found no influence of CYP3A5*3 or the recently discovered CYP3A4*22 SNP on serum 
fentanyl concentrations (Barratt et al., 2014). 
Interactions with other substances and other interactions  
N-dealkylation is a main route of metabolism for carfentanil in human liver microsomes. As for 
fentanyl this metabolic step is likely catabolized by CYP3A4 (Guitton et al., 1997; Labroo et al., 1997; 
Saari et al., 2008), but CYP3A5 may be of relevance as well (Kuip et al., 2017). This opens the 
possibility for drug-drug interactions, notably by strong inhibitors of CYP3A4. Concomitant exposure 
to such compounds, e.g. the antimycotic drugs voriconazole, ketoconazole and troleandomycin or the 
anti-HIV drug ritonavir, could decrease clearance of carfentanil and thus increase plasma exposures 
(Kuip et al., 2017; Labroo et al., 1997; Saari et al., 2008). For weaker inhibitors this scenario is 
unlikely, since carfentanil is only present at very low concentrations and remaining CYP3A4 activity 
would still suffice. 
Effects on ability to drive and operate machines 
No studies of the effects of carfentanil on the ability to drive and operate machines have been 
performed. However, it is well established that opioid analgesics, such as fentanyl, impair the mental 
and physical ability required to drive and operate machines. This effect is likely to extend to 
carfentanil. 
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A3. Psychological and behavioural effects 
A3.1 Animal data 
Animals administered carfentanil for immobilisation often display an initial excitement phase. Such 
effects were reported in a wide range of species, including ostriches, goats, gaur, rhinoceros, bison, 
white-tailed deer and black bears (Kock & Berger, 1987; Napier et al., 2011; Portas, 2004; Raath et 
al., 1992; Ramsay et al., 1995; Shury et al., 2010; Sleeman et al., 1997; Storms et al., 2005). 
However, not all species display an excitement phase (Mortenson & Bechert, 2001; Seal et al., 1985). 
Mice exposed to carfentanil through the inhalatory route (see Section D.1.1) showed restlessness 
(spinning/flipping/circling), weakened stressor-provoked response and reduced alertness after 
recovering from sedation throughout a 24-hour post-exposure period (Wong et al., 2017). 
A3.2 Human data 
No formal studies on the psychological and behavioural effects of carfentanil in humans have been 
identified. 
From the available data, the psychological and behavioural effects of carfentanil share similarities with 
fentanyl and other opioid analgesics. Dizziness, drowsiness and incoordination have been reported. 
Other effects common to opioids such as relaxation and euphoria can be expected; at higher doses, 
sedation and profound intoxication occur. 
A study by Baylon and co-workers is of interest though. In this study subjective responses in 
experienced opioid users (mild to moderate dependence according DSM III-R) to fentanyl and 
remifentanil, an ultra-short acting fentanyl analogue, were compared (Baylon et al., 2000). 
Measurement of pupil diameters as a pharmacodynamic endpoint showed peak activity for 
remifentanil within a minute, while pupil diameter was normal after 20 minutes. Fentanyl peak effect 
on pupil diameter was approximately after 5 minutes and wore off only gradually, with some 
constriction still present after 3 hours. Both compounds show significant increases in subjective 
effects compared to a placebo control. Overall fentanyl showed higher AUCs in VAS scores for 
subjective effects (liking, good and high effect) than remifentanil. For measures evaluated within 3 
minutes of drug administration, remifentanil peak score for high effect was greater in magnitude than 
for fentanyl (High VAS [p = 0.0053]). Yet, when later time points were evaluated fentanyl scored 
higher on all subjective endpoints. 
Drowsiness/dizziness is a common side effect observed in volunteers participating in PET scan 
studies who have been administered labelled carfentanil in the lower microgram range (Minkowski et 
al., 2012). 
Discordant experiences regarding the euphorigenic effects of carfentanil have been posted on drug 
forums (21–23). 
A4. Legitimate uses of the product  
Carfentanil is used in veterinary medicine as a tranquilising agent in zoological parks and wildlife 
environments to rapidly incapacitate large animals in order to facilitate veterinary procedures.  
(Lust et al., 2011).  
RISK ASSESSMENT I CARFENTANIL 
 
54 
 
Carfentanil was first introduced to the market for veterinary use in 1986 (Stanley et al., 2008). 
Carfentanil was marketed in the United States under the proprietary name Wildnil® and is approved 
by the United States Food and Drug Administration (US FDA) for use as an immobilising agent in 
free-ranging or confined members of the family Cervidae (deer (Cervidae), elk (Cervus elaphus) and 
moose (Alces aces) (US FDA, n.d.).  
Commercial production of Wildnil® ceased in 2003, and the substance is available only as a 
compounded dosage form in a concentration of 3 mg/mL, in 10-mL vials (Lust et al., 2011). 
There is no information to suggest that carfentanil is currently used in the manufacture of a medicinal 
product in the European Union. However, in the absence of a database on the synthetic routes of all 
medicinal products it is not possible to confirm whether or not carfentanil is currently used in the 
manufacture of a medicinal product.  
Besides its use as an immobilising agent in animals, carfentanil is believed to have been used for this 
purpose in humans. In October 2002, Russian special forces are thought to have used a gas mixture 
containing carfentanil as part of a counter terrorism operation (Stanley, 2003; Riches et al., 2012; 
Wax et al., 2003) (see Section D.1.2). 
[11C]-Carfentanil is a selective radiotracer for in vivo positron emission tomography (PET) imaging 
studies of the μ-opioid system. It has been widely used for pre-clinical and clinical PET imaging 
studies since its introduction in the early 1980s (Dannals et al., 1985, Frost et al., 1985). The 
carfentanil dose administered IV as a tracer varies from less than 1 µg to 6.9 µg (Endres et al, 2003; 
Frost et al., 1989; Hirvonen et al., 2009) 
Section B. Dependence and abuse potential 
B1. Animal data  
In the United States, carfentanil (NIH 10570) has been evaluated for its dependence potential and 
abuse liability at the University of Michigan (Woods et al., 1988) and the Medical College of Virginia 
(Aceto et al., 1988), under co-ordination of the National Institutes of Health, Bethesda, Maryland 
(Jacobson, 1988). 
Carfentanil was shown to have a high antinociceptive potency, as shown in Table 5 (Jacobson, 1988). 
The EC50 for displacement of [3H]-etorphine binding in rat brain membranes was 72 nM. Inhibition of 
twitch in electrically-driven mouse vas deferens preparations was observed with an ED50 of 0.01 nM, 
which was antagonised by naltrexone. These data confirm high affinity and agonist activity at µ opioid 
receptors (Jacobson, 1988; Woods et al., 1988). 
In a primary physical dependence (PPD) study, rats received carfentanil for 6 days and then were 
placed in abrupt withdrawal. No signs of physical dependence were observed (Aceto et al., 1988). 
When rats where administered morphine for 6 days and subsequently administered carfentanil, 
carfentanil could not substitute morphine when rats were evaluated for changes in body weight and 
behavioural-withdrawal signs (Aceto et al., 1988). 
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In a primary physical dependence (PPD) test in rhesus monkeys, the animals received carfentanil 
every 4–6 hr for 30–50 days. They were placed in abrupt withdrawal and challenged with naloxone 
periodically. No signs of physical dependence were observed (Aceto et al., 1988).  
The single-dose suppression (SDS) test determines the ability of a drug to suppress the signs of 
withdrawal in morphine-dependent rhesus monkeys. Carfentanil showed complete suppression of 
withdrawal signs in the tested dose range (0.07–0.5 µg/kg), already showing half maximal 
suppression of withdrawal at the lowest dose tested. Its potency was considered to be 25000 times 
the potency of morphine in this regard (Aceto et al., 1988; Jacobson, 1988). 
Carfentanil did not precipitate withdrawal signs in morphine-dependent rhesus monkeys (Aceto et al., 
1988). 
Carfentanil did not induce self-administration in rhesus monkeys trained to self-administer codeine 
(Aceto et al., 1988). 
Carfentanil was not recognised by rhesus monkeys trained to discriminate either the κ opioid receptor 
agonist ethylketazocine (EKC) or the µ opioid receptor agonist codeine from saline (Aceto et al., 
1988).  
The data described above show that carfentanil is a very potent analgesic compound able to 
suppress withdrawal symptoms in morphine-dependent rhesus monkeys, but not in rats. Furthermore, 
the data suggest that carfentanil does not cause physical dependence in rats or rhesus monkeys, 
does not induce self-administration and does not generalise with a κ or µ opioid receptor agonist in 
drug discrimination test in rhesus monkeys. Similarly, it has been shown that rats trained to 
discriminate fentanyl from saline did not develop tolerance to the discriminative stimulus effects and 
did not display any withdrawal effects when treated with naloxone or when fentanyl was withheld from 
the animals (Colpaert et al., 1976).  
B2. Human data  
Positive subjective effects including euphoria are thought to contribute to the initiation of dependence 
to µ-opioid agonists. Once dependence has been developed, daily craving and/or dysphoria present 
in humans prior to drug taking are considered to contribute to the maintenance of dependence. µ-
Opioid agonists are known for developing tolerance (Gerrits et al., 2003).  
No specific studies investigating dependence potential of carfentanil in humans have been reported.  
In the previously mentioned study by Baylon and co-workers, the Cole/ARCI Abuse Potential and 
POMS scale in opioid users were significantly larger for fentanyl AUCs and peak scores than the 
corresponding remifentanil scores (Baylon et al., 2000). The authors suggest that users seeking 
longer-lasting drug effects might select fentanyl over remifentanil, but those who prefer briefer, 
repeated effects might possibly prefer remifentanil, if it would be available. 
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Section C. Prevalence of use 
Information from seizures, collected and biological samples 
Carfentanil was formally notified on 12 February 2013 by the EMCDDA on behalf of Latvia, in 
accordance with Article 4 of the Council Decision. The Reporting Form details a seizure of 70.139 
grams of light yellow powder that was seized on 8 December 2012 by Latvian Police in Riga. The 
substance was analytically confirmed by GC-MS by the State Police forensic service department and 
by GC-MS and HPLC by the Latvian Institute of Organic Synthesis. 
Since then, 8 additional countries (Belgium, Estonia, Germany, Finland, Lithuania, Sweden, the 
United Kingdom and Norway) have reported detections (33) of carfentanil (EMCDDA, 2017a). In 
addition, Austria reported a collected sample containing carfentanil. 
It is important to note that detections of carfentanil may be under-reported since the substance is not 
routinely screened for. Three Member States (Belgium, Lithuania and Sweden) reported that 
carfentanil is part of routine screening in some (but not all) laboratories. 
An increase in detections of carfentanil in Europe has been observed since 2016. Between 2012 and 
2015 the substance was only detected in Latvia and Lithuania. It subsequently appeared in the 
neighbouring countries of Estonia and Finland. In the last 18 months, a further 5 countries have 
reported detections of carfentanil for the first time (EMCDDA, 2017a). 
Information from seizures 
A total of 7 Member States reported a total of 801 seizures (34) of carfentanil to the EMCDDA and/or 
Europol: Estonia (116 cases), Germany (3), Finland (2), Latvia (387), Lithuania (279), Sweden (4) and 
the United Kingdom (10). At least 209 seizures have been reported for the first 7 months in 2017. 
Most of the seizures have been made by Police at street-level, with additional seizures being made in 
custodial settings. One seizure of 100 grams was made by Customs in Cologne/Bonn airport and 
reported by Germany. 
Since the first detection of carfentanil in 2012, there has been an observed increase in availability of 
the substance, as seen from the following breakdown of seizures cases by year and country:  
 1 seizure in 2012 (Latvia),  
 27 seizures in 2013 (Latvia and Lithuania),  
 48 seizures in 2014 (Latvia),  
 160 seizures in 2015 (Latvia and Lithuania).  
                                                          
(33) Detections’ is an all-encompassing term and may include seizures and/or collected and/or biological samples that are 
analytically confirmed. Seizure means a substance available (seized) through law enforcement activities (police, customs, 
border guards, etc.). Collected samples are those that are actively collected by drug monitoring systems (such as test 
purchases) for monitoring and research purposes. Biological samples are those from human body fluids (urine, blood, etc.) 
and/or specimens (tissues, hair, etc.) 
(34) Many ‘seizures’ relate to individual case-level data, however, some data provided to the EMCDDA are aggregated at the 
country level. Data is drawn from the Joint Report Questionnaires and data provided in the bi-annual data gathering (EU EWS 
progress and final reports) and from individual Reporting forms submitted on an ad hoc basis. 
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 345 seizures in 2016 (Latvia, Lithuania, Estonia and Finland) 
 209 seizures in the first half of 2017 (Estonia, Germany, Finland, Latvia, Lithuania, Sweden 
and the United Kingdom). 
The largest single seizure of carfentanil was reported by the United Kingdom. The seizure was made 
by West Yorkshire Police in May 2017, and amounted to 440 grams of ‘unadulterated’ carfentanil in 
powder form. In addition to this seizure, 6 seizures, each of which comprising over 100 grams of 
carfentanil were reported by 4 Member States; as follows: 
 Estonia (209.8 grams, seized in April 2017),  
 Germany (100 grams reported through Police correspondence in 2017),  
 Lithuania (2 seizures of 200 and 138.5 grams, reported in 2016 and 2017, respectively) and, 
 United Kingdom (2 seizures of 209 and 150 grams, both in 2017). 
Powders 
Carfentanil was detected in powder form in a total of 736 cases that amounted to nearly 3.3 kg of 
seized material: Estonia (110 cases), Germany (2), Finland (2), Latvia (383), Lithuania (226), Sweden 
(3) and the United Kingdom (10).  
In 224 of these seizures, carfentanil was the only substance reported. In 279 seizures, carfentanil was 
detected in mixture with heroin. In these cases, in addition to heroin, other substances detected were: 
cocaine, caffeine, paracetamol, levamisole and phenacetin (4 cases), methadone (3), acryloylfentanyl 
(3), alpha-PHP (2) and caffeine and paracetamol (1). 
Excluding heroin, carfentanil has also been detected in mixtures with a number of opioids. These 
include: fentanyl (81 cases), methadone (17), fentanyl and furanylfentanyl (10), fentanyl and 
acryloylfentanyl (7), furanylfentanyl (4), tramadol (3) and acryloylfentanyl (2). 
Other combinations include: 12 seizures where carfentanil was found mixed with the synthetic 
cathinone alpha-PHP; 1 seizure, mixed with the synthetic cannabinoids AM-2201 and XLR-11, and in 
1 seizure, mixed with diazepam. 
Where reported, the powders were typically ‘yellowish’, both in cases where carfentanil was reported 
on its own and when mixed with heroin.  
Liquids 
Ten seizures of liquids were reported by Estonia (6), Latvia (3), and Sweden (1), amounting to a total 
of 1.75 grams. All the seizures took place in 2017. In 3 cases reported by Latvia, the liquids were 
found in syringes, of which two samples also contained alpha-PHP. 
In 3 cases reported by Estonia, fentanyl was also detected in the liquid samples. 
Other physical forms 
In 53 cases, no information on the physical form was reported. These amounted to over 136 grams 
and 0.5 ml of material seized. 
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Purity 
The quantification of carfentanil is not routinely performed; however, Lithuania provided information 
on the purity of carfentanil for 44 analysed samples. In 25 of the cases, heroin was also detected and 
the relative concentrations of both substances were provided. 
In these cases, the purity ranged from 0.00034 to 0.13% carfentanil (35) (mean: 0.043%; median: 
0.04%). Thirty seven of the cases (86%) were in the range of 0.03-0.09% purity. 
In addition, the concentration of heroin was reported for 63 of the samples that contained carfentanil, 
with a significant inter-variation found between samples, ranging from 0.008 to 23.9% pure heroin. 
Information from collected samples 
A total of 4 collected samples were reported to the EMCDDA by 4 countries: United Kingdom (2 
cases), Belgium (1) and Norway (1) (EMCDDA, 2017a). In addition, Austria reported a collected 
sample containing carfentanil. 
Both cases reported by the United Kingdom were samples submitted to the Welsh drug-checking 
service WEDINOS. Both samples were submitted as ‘Fentanyl-HCL + Mannitol 15% fentanyl’, but 
instead, carfentanil and mannitol were identified. 
The sample reported by Belgium was recovered from the scene of a death (apparent suicide), where 
a small quantity of powder (approximately 0.005 grams), was identified as carfentanil. 
The sample reported by Norway was also recovered from the scene of a death. The powder was in a 
plastic bag labelled ‘C.50’. 
Information from biological samples 
Serious adverse events with confirmed exposure to carfentanil from biological samples are discussed 
in Section D. 
No other biological detections of carfentanil were reported to the EMCDDA. 
Availability, supply, price 
Information on production 
The United Kingdom reported that there are indications that carfentanil has been shipped from 
predominantly China/Hong Kong. 
Information on trafficking 
Information related to trafficking routes is limited to the seizures reported above. In cases where the 
country of origin was known, China and specifically Hong Kong were primarily reported with the 
United Kingdom and Germany also mentioned, but to a lesser extent. 
Lithuania reported that there are indications that carfentanil may be imported from Russia and China. 
                                                          
(35) One very small sample was reported as ‘pure’ carfentanil, amounting to 0.00002 grams. This was considered as an outlier 
and, therefore, it was not included in the calculation. 
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Information from ongoing investigations in Sweden indicates that carfentanil has been bought from 
internet vendors and delivered directly to the user (and/or to relatives of the user) from China, the 
United Kingdom and Germany. There are no indications that carfentanil is sold in Sweden. 
Information from the United Kingdom indicates that carfentanil has been shipped from China/Hong 
Kong and the substance is either used as received, or mixed with other drugs, for example heroin, or 
cutting agents (caffeine, paracetamol) before being used or sold on. 
Additionally, the National Crime Agency in the United Kingdom reported that they identified a supplier 
of carfentanil who was using the darknet to advertise and distribute carfentanil both nationally and 
internationally. 
Availability from Internet vendors 
The available data shows that carfentanil is sold both on the surface web and on the darknet. A 
structured search of online vendors on the surface web by the EMCDDA, as well as information from 
acute intoxications, law enforcement seizures and collected samples suggests that on the surface 
web the substance is sold as a ‘research chemical’ or/and as a ‘pharmaceutical intermediate’(36). In 
the websites identified, carfentanil was typically sold as a powder, in amounts ranging from 0.1 grams 
to 3 kg.  
Prevalence of use  
No studies were identified that have investigated the prevalence of use of carfentanil in the general 
population. Given its pharmacology and that it is sold openly as a replacement to illicit opioids, it 
would be expected that those looking for substitutes for opioids may seek out carfentanil and other 
fentanils. This group includes individuals who use illicit opioids such as heroin and/or prescription 
opioids to self-medicate with the aim of alleviating pain and/or opioid withdrawal. It also appears that 
there is interest in this substance by some psychonauts. Overall, the available information does not 
suggest wide use of the substance. 
Data from law enforcement seizures and death investigations confirm that carfentanil is being used by 
high risk opioid users, including those who inject heroin and other illicit opioids. As carfentanil is being 
sold as or in heroin and other illicit opioids, many users will not be aware that they are using 
carfentanil.  
Data from Europe, the United States, and Canada shows that as well as being sold to users in or as 
heroin or other illicit opioids, fentanils may also be sold as or in other illicit drugs such as cocaine, as 
well as used to make counterfeit medicines (such as opioid analgesics and benzodiazepines) 
(EMCDDA, 2017b). 
 
                                                          
(36)  The search for online vendors of carfentanil on the surface web was performed on 10/07/2017 using previously 
established methodology (EMCDDA, 2017b). The search identified 11 vendors that appeared to be based in, and/or 
claimed to have presence in China (n=5), the United States (n=2), Algeria (n=1) and Turkey (n=1); for the remaining 
site there was no apparent location mentioned. Seven of the sites listed quantities and prices for carfentanil. The 
remaining four sites only provided prices on request. 
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Section D. Health risks 
D1. Acute health effects 
D1.1. Animal data 
Safety pharmacology 
Safety pharmacological parameters have been studied both in laboratory animals and immobilized 
non-laboratory animals. These data are summarized in Table 9. The administration of carfentanil in 
non-laboratory animals may induce excitement and erratic behavior (see also Table 5). This effect 
may partially be induced by the darting of the animals, but could also be pharmacologically related. 
The sensitivity to induction of excitement seems to differ between species. For example in a report on 
the use of carfentanil in kob, many animals showed excitement, whereas in a study in moose it was 
reported that animals did not show excitement (Kupper et al., 1981; Seal et al., 1985). The extent of 
excitement may also be influenced by the co-administration of other drugs. 
A common effect observed in many species is hypoventilation, which may cause hypoxemia, and 
acidosis. Heart rate in many studies not affected, but can also be increased or decreased. 
Arrhythmias have also been observed. The co-administration of other compounds (in most cases 
xylazine) complicates the interpretation of the cardiovascular effects. In addition the arousal due to 
the hunt and the darting is a confounding factor. Hyperthermia may be observed, but generally body 
temperature is unaffected.  
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TABLE 9 
Safety pharmacological effects of carfentanil in animals. 
Species 
(N) 
Route Dose Results Reference 
Chimpanzee 
(Pan 
trochlodytes) 
(3) 
TM 2-4 µg/kg deep sedation after 22 minutes. 
Severe respiratory depression at 25 
minutes. 
Kearns et al., 1999 
Bonobo (Pan 
paniscus) (2) 
TM 2 µg/kg 
(after 2.5 mg 
dropiderol 
PO)  
Mild to moderate respiratory 
depression. 
Kearns et al., 1999 
Western 
lowland 
gorillas 
(Gorilla 
gorilla) (2) 
TM 14 µg/kg 
(after 1.75 
mg 
dropiderol 
PO)  
Respiratory arrest 10-12 min after 
carfentanil dose, followed by cardiac 
arrest (37) 
Kearns et al., 1999 
Mule deer (3) 
and mule 
deer/white-
tailed deer 
hybrids (4) 
IM 10 µg/kg 
+0.3 mg/kg 
xylazine 
Blood pH↑; base excess↑; 
hypoventilation; hypoxemia; 
Ventricular premature contractions, 
atrial premature contractions, and a 
junctional escape rhythm; 
hyperthermia 
Caulkett, Cribb, & 
Haigh, 2000 
Impala 
(Aepyceros 
melampus) 
(36) 
IM 14-17 µg/kg Hyperthermia; cortisol↑ (darting-
evoked excitement); 
Cheney & Hattingh, 
1988 
Mice ♂ Balb/c IM 3 µg/kg + 15 
mg/kg 
etomidate 
HR↓; Parterial↓; RR↓;  Erhardt et al., 1984 
Rhebok 
(Pelea 
capreolus) (6) 
IM 10 µg/kg 
+400 µg/kg 
xylazine 
RR↓; No significant changes in HR; 
hypoxemia; glucose↑ 
Howard et al., 2004 
Chimpanzee 
(Pan 
trochlodytes) 
(5) 
TM 2 µg/kg 
(after oral 
dropiderol)  
RR↓;PaCO2↑; pH↓ Kearns et al., 2000 
Gray wolves 
(Canis lupis) 
(2) 
IM 7.5 µg/kg + 
500 µg/kg 
xylazine 
Transient tachypnea followed by RR↓ Kreeger & Seal, 
1990 
Grizzly bear 
(Ursus arctos) 
IM 11 µg/kg + 
120 µg/kg 
RR↓; hypoxemia Kreeger et al., 2013 
                                                          
(37) This experiment concerns elective euthanasia. 
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(7) xylazine 
Black bear 
(Ursus arctos) 
(3) 
IM 14 µg/kg + 
150 µg/kg 
xylazine 
RR↓; hypoxemia Kreeger et al., 2013 
Caribou 
calves 
(Rangifer 
tarandus 
granti) (21)  
IM 1.5-1.8 
mg/animal + 
20-25 
mg/animal 
xylazine 
Hypoxemia; hypercapnia; lactate↑; 
body temperature↑ 
Lian et al., 2016 
White-tailed 
deer (Odo- 
coileus 
virginianus) 
(29) 
IM 7.75–46.84 
µg/kg + 
0.16–0.27 
mg/kg 
xylazine 
 
Rectal T↑ but during anaesthesia 
gradual ↓. HR, RR and SpO2 normal.  
Miller et al., 2003 
White-tailed 
deer (Odo- 
coileus 
virginianus) 
(13) 
IM 15–45 µg/kg 
+ 0.15–0.45 
mg/kg 
xylazine 
Median optimal dose was 30 µg/kg + 
0.3 mg/kg xylazine. At this dose 
induction time was <3.0 min and 
PaCO2<60 mmHg. 
Storms et al., 2005 
White-tailed 
deer (Odo- 
coileus 
virginianus) 
(11) 
IM 30 µg/kg + 
0.3 mg/kg 
xylazine 
Compared to carfentanil/xylazine 
alone, ketamine caused: PaCO2↑; 
blood pH↓; frequency of hyperthermia 
(>41 ºC) increased. 
Storms et al., 2006 
Rocky 
mountain 
wapiti (Cervus 
elaphus 
nelsoni) (8) 
IM 10 µg/kg + 
0.1 mg/kg 
xylazine 
Hypoxemia; Arterial pH↓; HR↓; ECG 
tracings consistent with S-T segment 
depression, occasional premature 
ventricular contractions, and short 
episodes of ventricular tachycardia. 
Naloxone (2 µg/µg carfentanil) 
reversed hypoxemia increased arterial 
pH and RR. 
Moresco et al., 2001 
Brown bears 
(Ursus arctos) 
(5) 
PO (mixed in 
honey) 
6.0-15.2 
µg/kg 
hypoventilation and respiratory 
acidosis. 
Mortenson & 
Bechert, 2001 
Black bears 
(Ursus 
americanus) 
(10) 
PO (mixed 
with honey) 
6.8-18.8 
µg/kg 
Hypoxemia, hypoventilation Ramsay et al., 1995 
Bongo 
antelopes 
(Tragelaphus 
eurycerus) (8) 
IM 8.3 µg/kg + 
0.079 mg/kg 
xylazine 
Hypoxemia; RR↓; HR↓; Parterial↑; 
plasma norepinephrine↑; plasma 
DOPAC↓; Body T normal. 
Schumacher et al., 
1997 
Dama 
gazelles 
IM 18.4 µg/kg Induction time 6 min. HR↓; RR↓; blood 
pressure normal; Body T normal; 
Schumacher et al., 
1997 
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(Gazella 
dama) (16) 
blood glucose↑. 
Domestic 
goats (Capra 
hircus) (8) 
Buccal 60 µg/kg + 
60 µg/kg 
detomidine + 
0.5% 
saponin 
Bradycardia; Parterial↓; Sleeman et al., 1997 
Rats S.D. ♂ 
(5/group) 
IV 20 µg/kg RR↓. Nalmefene reversed 
hypoventilation more effective than 
naloxone. 
Yong et al., 2014 
IM: intramuscular; PO: Oral; TM: transmucosal. 
 
Sensitivity to carfentanil-induced adverse respiratory effects in non-human primates 
The observations made by Kearns at co-workers in non-human primates listed in Table 6 and Table 9 
are of interest. Compared to most other species listed, the dose administered is fairly low (2 µg/kg), 
also considering that the route of administration was transmucosal. Nevertheless chimpanzees 
developed severe respiratory depression within 25 minutes, shortly after reaching deep sedation 
(unresponsive to noxious stimuli) and needed immediate rescue with naltrexone. A tenfold higher 
dose was administered to gorillas for elective euthanasia, which was achieved within 12 minutes 
(Kearns et al., 1999). Bears receiving similar doses as the gorillas either transmucosally or IM did 
show hypoventilation and hypoxemia and needed oxygen supply, but did survive (Kreeger et al., 
2013; Mortenson & Bechert, 2001; Ramsay et al., 1995). Deer received even higher doses i.m, but 
did not react with respiratory distress (Miller et al., 2003; Storms et al., 2005; Storms et al., 2006). 
This shows that the sensitivity to the adverse respiratory effects of carfentanil differs greatly between 
species. Even between primate species differences are observed, since gibbons and capuchin 
monkey only had mild to moderate sedative effects and no respiratory depression after a 
transmucosal dose of 2 µg/kg, whereas in chimpanzees, bonobos and gorillas, three species 
belonging to the great apes (Hominidae), this dose caused deep sedation and respiratory depression, 
or a tenfold dose was effective in order to euthanize the animals (Kearns et al., 1999). 
Physiological responses in mice after inhaled aerosolized carfentanil exposure 
The Biochemistry and Toxicology Branch of the US Army Medical Research Institute of Chemical 
Defence in the United States examined the real-time exposure–response effects of inhaled 
aerosolized carfentanil on opioid-induced toxicity, respiratory dynamics and cardiac function in mice 
(Wong et al., 2017). Unrestrained, conscious male CD-1 mice (25–30 g) were exposed to 0.4 or 4 
mg/m3 of aerosolized carfentanil for 15 min (Ct = 6 or 60 mg.min/m3) in a whole-body plethysmograph 
chamber. Minute volume (MV), core body temperature (Tc), mean arterial blood pressure (MAP) and 
heart rate (HR) were evaluated in animals exposed to carfentanil or sterile H2O. Loss of 
consciousness and Straub tail were observed within 1 min following initiation of exposure to 6 or 60 
mg.min/m3 of carfentanil. Based on the measured minute volume (43 mL/min) and a bodyweight of 
25-30 g, the total inhaled dose equals 8.6–10.3 and 86–103 µg/kg for the low and high dose groups, 
respectively. 
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Clinical signs of opioid-induced toxicity were observed in a dose-dependent manner: 
dyspnoea/laboured breathing; lack of grooming; piloerection; ocular protrusion; abdominal bloating; 
urinary incontinence; rectal prolapse; ataxia; restlessness (spinning/flipping/circling); weakened 
stressor-provoked response; and, reduced alertness. Dyspnoea/laboured breathing was severe in 
both dose groups and observed both during the exposure period and 24 hours after. However, 
mortality was not observed. The reasons for a lack of mortality are unclear according to the authors, 
but could be related to species-dependent differences in metabolism, 
pharmacokinetics/pharmacodynamics, physiology and anatomy.  
Exposure to 6 or 60 mg.min/m3 of carfentanil resulted in significant decrease in MV as compared to 
the controls. MAP, HR and Tc decreased 24h in animals exposed to either 6 or 60 mg.min/m3 of 
carfentanil as compared to the controls. Post-exposure administration of naloxone (0.05 mg/kg, IM) 
did not increase the MV of animals exposed to carfentanil to control levels within 24 h, but decreased 
clinical signs of opioid-induced toxicity and the duration of respiratory depression. 
Acute toxicity 
The IV LD50 of carfentanil in rats was determined as 3.39 mg/kg. This is 10594 times the ED50 for 
analgesic potency as measured in the rat tail withdrawal test (Van Bever et al., 1976). In this study, 
the LD50 value for morphine and fentanyl were 223 and 3.05 mg/kg, respectively. 
The acute, metabolic, and neurological effects of 8 opioids ranging in analgesic potency (not including 
carfentanil) was investigated in dogs by de Castro and coworkers (de Castro et al., 1979a, 1979b, 
1979c). A general trend towards metabolic acidosis and hypermetabolism was noticed but important 
differences appeared according to the drugs and doses chosen. The safety margin for metabolic 
toxicity (ratio between IV doses producing severe metabolic side-effects and doses necessary for 
deep surgical analgesia) were calculated for each narcotic and found as follows: 1 for pethidine, 3.3 
for piritramide, 13 for morphine and phenoperidine, 12.5 for alfentanil, 60 for fentanyl, 800 for 
sufentanil and 4 000 for lofentanil (R 34 995). Co-administration of other drugs may decrease or 
increase the metabolic safety margin of the narcotics. Beneficial associations with morphinomimetics 
are found with droperidol, etomidate and flunitrazepam (de Castro et al., 1979c). Comparing the IV 
doses producing severe convulsions with the doses necessary for deep surgical analgesia a safety 
margin of neurological toxicity was calculated. This was 2.2 for pethidine, 6.6 for piritramide, 16 for 
phenoperidine, 62.5 for alfentanil, 72 for morphine, 160 for fentanyl, 1,000 for sufentanil, and 10,000 
for lofentanil (R 34 995). The authors conclude that for ‘pure’ narcotics there exists an inverse 
relationship between analgesic potency and neurological toxicity (de Castro et al., 1979b). 
Safety margins as described in the previous paragraphs can be referred to in the literature as a 
therapeutic index. A high therapeutic index is often interpreted as a margin of safety. However it 
should be noted it is derived from data obtained in animal studies, not human studies. As discussed 
above, great apes (Hominidae) are far more sensitive to carfentanil-induced respiratory depression 
and arrest than rodents. 
In a study in 3 domestic horses (Equus spec.), 10-15 µg/kg carfentanil and 1 mg/kg xylazine 
administered IM caused muscle fasciculations, running motions and excitement followed by fore limb 
rigidity, tachycardia, hypertension, increase of rectal temperature and one horse had serosanguinous 
fluid dripping from a nostril. After administration of naltrexone or naloxone, muscle rigidity decreased 
and respiratory rate increased. Haemoconcentration and mild acidosis was evident and the horse with 
serosanguinous fluid dripping had tachypnea. After deterioration of the condition the horse was 
euthanized. Postmortem investigation showed peribronchial and myocardial edema and severe 
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pulmonary edema (Shaw et al, 1995). Carfentanil/xylazine (20µg/kg:1-2 mg/kg) has been used 
successfully in Przewalski horses, but muscle contractions, fasciculations, tachycardia and mild 
hypotonia and hyperthermia were also observed. The reasons why severe adverse reactions 
occurred in these domestic horses is unknown (Shaw et al. 1995). 
D1.2. Human data 
No clinical studies were identified that have examined the acute health effects of carfentanil and/or its 
metabolites in humans.  
The available non-clinical in vitro pharmacodynamic data on carfentanil suggests some functional 
similarity to morphine and fentanyl, which also suggests that some toxicological similarity might exist 
with other opioid analgesics (Moffat et al., 2016). The acute effects of these types of opioids include: 
euphoria, relaxation, analgesia, sedation, bradycardia, hypothermia, miosis, and respiratory 
depression or arrest. They are also known to display abuse liability and dependence potential (Cox, 
2011; Dahan et al., 2001; Pattinson, 2008; Romberg et al., 2003). 
Similar to other opioid analgesics, the most serious acute health risk associated with carfentanil use is 
rapid and profound respiratory depression, which can lead to apnoea, respiratory arrest and 
death(Cox, 2011; Dahan et al., 2001; Pattinson, 2008; White & Irvine, 1999). This risk may be greater 
due to: the difficulty in diluting the substance; a lack of experience with its effects and dosing; the use 
of other central nervous system depressants at the same time (such as other opioids, 
benzodiazepines, gabapentanoids, and alcohol); a lack of tolerance to opioids; and, using the 
substance alone (such as at home) which would make it more difficult for users to call for help in the 
case of poisoning. 
The antidote naloxone can reverse acute poisoning caused by carfentanil (Kim and Nelson, 2015, 
Ujváry et al., 2017). Recent clinical and community experience in treating poisonings caused by 
fentanils suggests that larger than normal doses and repeated doses of naloxone may be required to 
manage poisoning in some cases; longer periods of observation may also be required (Klar et al., 
2016; Moss et al., 2017; Somerville et al., 2017; Sutter et al., 2017). (Section D3.4.) 
Data from serious adverse events associated with carfentanil are discussed below. Based on the data 
reported, the clinical features presented in cases of intoxication involving carfentanil appear to be 
similar to those found with fentanyl and other opioid analgesics. These included unconsciousness or 
reduced level of consciousness and respiratory depression or arrest. 
Acute intoxications reported by the Member States 
In total, 3 acute intoxications with confirmed exposure to carfentanil were reported to the EMCDDA by 
France (2 cases) and Lithuania (1). The cases occurred in November 2016, January 2017, and May 
2017 (38). 
The analytical detection of other substances was not reported. The clinical features of the 
intoxications were generally consistent with opioid toxicity.  
The intoxications were considered life-threatening in at least 2 cases; all required hospitalisation of 
the patients. Naloxone was administered to the 3 patients; in at least 2 cases more than one dose 
                                                          
(38) In addition, France also reported an acute intoxication with suspected exposure to carfentanil. This case is not discussed 
further in this report. 
RISK ASSESSMENT I CARFENTANIL 
 
66 
 
was administered to the patient. It was reported that naloxone was effective in 1 case; in another 
case, it was reported that ‘several’ doses of naloxone were not effective; the response to naloxone 
was not reported in the remaining case. All patients survived. 
In one case, the patient believed he was using cocaine and apparently snorted a powder containing 
carfentanil; in another, the patient reportedly tried a powder they had found at home; while in the 
remaining case, the patient believed that they were taking carfentanil. 
Acute intoxications identified from other sources 
Mild symptoms as reported in PET scan studies 
Minkowski and colleagues studied the potential differential responses to IV [11C]carfentanil in chronic 
cocaine users and health controls (Minkowski et al., 2017). Healthy controls (N=15) participating in 
PET scan study received an average IV bolus injection of 0.049 µg/kg (range 0.025-0.069) 
[11C]carfentanil just at the start of the PET scan. The subjects were regularly asked to score whether 
they experienced any of five common physical symptoms commonly reported during clinical use of 
opioid analgesics (itching, nausea, headache, vomiting, and dizziness). During the scan 6.7% 
reported itching, 33.3 % nausea, 6.7 % vomiting, 60.0% dizziness and 0% headache. Ninety minutes 
after the scan, 0 % reported itching, 26.7 % nausea, 20.0 % vomiting, 60.0% dizziness and 0% 
headache. Of note, scores for dizziness and total symptom count during the scan were significantly 
lower for experienced cocaine users. Ninety minutes after the scan, the cocaine users scored 
significantly less for nausea, dizziness, any symptom and total symptom count compared to non-
cocaine users. Cocaine users (N=23) participating in PET scan study received an average IV bolus 
injection of 0.045 µg/kg (range 0.011-0.075) [11C]carfentanil just at the start of the PET scan. During 
the scan 0.0% reported itching, 17.4 % nausea, 0.0 % vomiting, 21.7% dizziness and 4.3% headache. 
Ninety minutes after the scan, 0 % reported itching, 4.3 % nausea, 4.3 % vomiting, 8.7% dizziness 
and 4.3% headache (Minkowski et al., 2012).  
Accidental intoxications in veterinary use 
Cases of human exposure to veterinary injectable anaesthetics were reviewed following a literature 
search and completion of an online questionnaire (Haymerle et al., 2010). Only one case of 
carfentanil intoxication was reported. A similar—perhaps the same—case was also separately 
reported (George et al., 2010). Haymerle and co-workers describe sedation, decreased respiratory 
and heart rate, dizziness, nausea, alcohol-like intoxication, abnormal behaviour, incoordination, ataxia 
and hypotension as clinical symptoms. Naltrexone was administered as antidote. On arrival to the 
emergency department 1 hour later, the patient appeared well and complained only of mild and 
transient chest discomfort. His vital signs were as follows: temperature, 36.8°C; blood pressure, 
134/88 mm Hg; heart rate, 75 bpm; respiratory rate 18 breaths per minute; and 98% oxygen 
saturation on room air. On examination, his face appeared flushed. Pupils were normal in size and 
reactive. His heart, lung, abdominal, and neurologic examinations were normal. The 
electrocardiogram, complete blood count, basic metabolic profile, and cardiac markers were within 
normal limits. The patient was observed for 24 hours, remained asymptomatic, and was discharged 
home in stable condition (George et al., 2010). The interpretation of the role of carfentanil in this case 
is complicated by the co-exposure to xylazine. 
Carfentanil as an immobilization agent in humans 
On 26 October 2002, Russian military special forces used an incapacitating ‘gas’ in a counter 
terrorism operation to overthrow Chechen rebels holding hostages at the Moscow Dubrovka Theater 
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Center. Of the 800 hostages in the theater, 127 (16%) died, and more than 650 of the survivors 
required hospitalization. According to attending physicians, ‘many patients had classic signs of opioid 
intoxication: pinpoint pupils, unconsciousness, and depressed breathing’. The opioid hypothesis was 
supported by reports from Russian physicians that naloxone was successful in reversing the effects of 
the intoxication. The Russian Health Minister announced 4 days after the event that, ‘a fentanyl 
derivative was used to neutralize the terrorists ‘ (Wax et al., 2003). It was speculated that the fentanyl 
derivative concerned could have been carfentanil (Stanley, 2003; Wax et al., 2003). Many years after 
the incident, LC-MS-MS analysis of extracts of clothing from two British survivors, and urine from a 
third survivor provided evidence that the aerosol comprised a mixture of two fentanils: carfentanil and 
remifentanil (Riches et al., 2012). These authors conclude that ‘This account suggests that carfentanil 
exposures may cause severe intoxication or fatality in the absence of prompt and appropriate medical 
treatment. The same conclusion can be drawn for remifentanil. Both carfentanil and remifentanil have 
narrow safety margins, meaning that potentially fatal side effects, including respiratory depression, 
can occur at doses only slightly higher than those that impart medical benefits’.  
This conclusion is in line with animal data demonstrating a high sensitivity to the adverse respiratory 
effects of carfentanil in great apes (Hominidae) and underlines that extrapolating safety margins 
derived from rat studies (Cole & Nelson, 2017; Janssen, 1982) may be inappropriate. The actual 
narrow safety margin in humans may also be reflected by the extensive overlap in carfentanil blood 
concentrations in postmortem samples and samples from subjects whose blood was examined due to 
driving under influence of drugs (Sofalvi et al., 2017) (see Figure 4). However, it is unknown whether 
carfentanil undergoes significant postmortem redistribution, which complicates the interpretation of 
the blood concentration data. 
Non-fatal carfentanil intoxications in drug users 
The information on non-fatal intoxications associated with carfentanil use is limited in available 
literature. When toxicology has been performed, the levels are not always quantifiable. 
Table 10 provides a summary of non-fatal intoxications and cases of driving under the influence 
identified in the literature involving confirmed exposure to carfentanil. The range of carfentanil 
concentration in blood ranged from 0.055 to 1.4 ng/mL.  
The clinical features were generally consistent with opioid toxicity, and typically included reduced 
consciousness and respiratory depression/ arrest. While other opioids were typically detected, 
positive responses to naloxone were reported.
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TABLE 10 
Non-fatal intoxications associated with confirmed exposure to carfentanil (39) 
Country Analytical method 
(LOD) 
Cohort/case description Matrix Reference 
Bern, Switzerland GC-MS and LC-
HR-MS-MS for 
powder. 
LC-MS-MS for 
serum and urine 
A 16-year-old male patient was found unconscious (Glasgow Coma Scale 3), hypotensive 
(71/58mmHg), tachycardic (126 bpm), hypopneic and cyanotic (peripheral oxygen saturation 
70%, no signs of pulmonary edema) following the use of an unknown substance via unknown 
route. Body temperature was normal, pupils of normal size responding to light. After intravenous 
administration of naloxone and flumazenil, he regained consciousness. The urine drug screening 
immunoassay (Triage® TOX Drug Screen, Alere, Cologne, Germany) was negative, the blood 
alcohol concentration below the limit of detection. A white powder was found in the patient’s 
belongings. And identified as carfentanil. Analysis of samples collected approximately 1 h after 
use with LC-MS/MS showed a serum concentration of 0.6 ng/mL for carfentanil and 0.2 ng/mL 
for its main metabolite norcarfentanil; urine concentrations were 1.3 ng/mL and 0.5 ng/mL, 
respectively.  
Powder, 
serum, urine 
Müller et al., 
2017; Müller et 
al., 2017 
Pennsylvania, 
United States 
LC–MS-MS (0.03 
ng/mL) 
Case1 was a 36 year old female found unresponsive by EmergencyMedical Services (EMS) in 
her vehicle, which was located in the middle of a highway; EMS administered 2mg of naloxone 
and the individual responded immediately. She was an IV heroin user and a used syringe was 
found on scene. Carfentanil 0.41 ng/mL; furanylfentanyl 0.17 ng/mL; delta-9 THC 0.50 ng/mL; 
delta-9 carboxy THC 8.5 ng/mL. 
Case 2 was a 39 year old female who was located by police after 911 calls reporting erratic 
driving. Police found her car parked in a driveway shortly after the calls were made, conscious, 
but clearly under the influence of central nervous system depressants, and more specifically, 
narcotics. Carfentanil 0.63 ng/mL; fentanyl 3 ng/mL; norfentanyl 2.4 ng/mL. 
Case 3. This human performance-related case history is not known; Male 39 years old. 
Carfentanil 1.3 ng/mL; furanylfentanyl 1.1 ng/mL. 
Case 3. This human performance-related case history is not known; male 36 years old. 
Carfentanil 1.4 ng/mL; fentanyl 4.6 ng/mL; norfentanyl 1.9 ng/mL. 
Whole blood Papsun et al., 
2017 
                                                          
39 Carfentanil figures are in bold. 
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United States LC-MS-MS (0.01 
ng/mL) 
Unconscious 28-year-old male in the driver seat of a vehicle. Took a ‘bump of heroin ‘ and 
subsequently passed out. Blood sample for the driving under the influence (DUI) investigation 
over 2 h post arrest. 
Initial analysis: fentanyl <0.5 ng/mL; alprazolam 55 ng/mL; synthetic opioids targeted LC–MS-MS 
confirmed presence of carfentanil, fentanyl, furanyl fentanyl, para-fluoroisobutyryl fentanyl, U-
47700 and its metabolite. 
blood Seither & 
Reidy, 2017 
United States LC-MS-MS (0.05 
ng/mL) 
17 of 26 suspected driving under influence of drugs (DUID) cases analyzed contained carfentanil 
at mean and median concentrations of 0.23 and 0.19 ng/mL, respectively. A single case 
involving carfentanil alone was summarized. 
Case 5. A 54-year-old male was involved in a car accident and transported by fire department 
ambulance to a local hospital. In the ambulance, he admitted to snorting brown heroin. He was 
later released from the hospital. Carfentanil 0.33 ng/mL; cotinine. 
Peripheral 
whole blood 
Sofalvi et al., 
2017 
United States LC-MS-MS (blood) 
GC-MS (urine) 
A 26-year-old man with a history of polysubstance abuse obtained 100mg of carfentanil via a 
‘dark web’ source. He injected approximately 60 µg, and ingested 4.9 mg of what he believed to 
be ‘clonazolam,’ obtained from a separate online source. He was found unresponsive and 
bradypneic by his parents. In the emergency department, he was given a total of 4.4mg of 
naloxone intravenously, with partial arousal and improvement in respiratory rate. Subsequently, a 
naloxone infusion was initiated at 5mg/h and maintained for 7 h. The infusion was discontinued 
when patient had returned to baseline. Initial laboratory workup showed mild transaminase 
elevation and rhabdomyolysis, with peak CPK 6885 IU/L. Toxicologic studies were notable for 
urine immunoassay positive for opiates, benzodiazepines and cocaine. Of note, the patient also 
endorses using cocaine and heroin in the days prior. Benzodiazepine confirmation test was 
positive for alprazolam, and opiate confirmation test was positive for codeine, hydromorphone, or 
hydrocodone metabolite and dihydromorphine or dihydrocodeine metabolite. Urine gas 
chromatography/mass spectrometry (GC/MS) analysis was positive for caffeine, cocaine 
metabolite, and nicotine. Serum carfentanil 1.1 ng/mL. 
Blood, urine Shulman et 
al., 2017 
West Virginia, 
United States 
 CHHD identified 20 opioid overdose cases within a 53-hour period in Cabell County; all cases 
included emergency department (ED) encounters. The most commonly reported clinical signs 
were altered consciousness (13; 65%) and respiratory failure (11; 55%). EMS personnel, other 
first responders, and ED providers administered the opioid antidote naloxone to 16 (80%) 
patients, six of whom were administered multiple doses. Fourteen patients (70%) reported using 
blood Massey et al., 
2017 
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heroin immediately before being evaluated in the ED. Among eight (40%) patients who had 
toxicology screenings, opioids were detected in six. In four of these cases confirmation was 
sought in a public safety investigation. All four samples contained carfentanil. Other opioids 
confirmed in these samples where fentanyl and furanyl fentanyl. All 20 patients survived. 
Ohio, United 
States 
LC-MS-MS There were two cases with levels where the sample was antemortem. In these two cases, the 
levels were 0.055 ng/mL (also identified with acetyl fentanyl and furanyl fentanyl) and 0.370 
ng/mL (also identified with alprazolam and clonazepam). 
Peripheral 
blood 
Yin, 2017 
RISK ASSESSMENT I CARFENTANIL 
 
71 
 
Deaths reported by the Member States 
A total of 61 deaths were reported by Belgium (1), Germany (1), Estonia (6), Finland (2), Lithuania 
(16), Norway (1), Sweden (3) and the United Kingdom (31 cases). Carfentanil was analytically 
confirmed from post-mortem samples in 55 deaths and carfentanil exposure was confirmed in all 
deaths. 
Demographics 
Of the 38 deaths where demographic data were available, 32 were male (84%) and 6 were female 
(16%). The mean age of the males was 37 years (median 38) and ranged from 15 to 54 years. Where 
age was known, the females were aged 21, 28, 32, 45 years. 
Number of deaths by year 
Where known, the deaths occurred between November 2016 and June 2017 with all United Kingdom 
deaths occurring between February 2017 and June 2017. 
Cause of death  
There was a lack of information regarding any symptoms experienced by the deceased prior to death. 
Consequently, it was not possible to identify or evaluate ante-mortem symptoms (especially in relation 
to acute intoxication). Drug paraphernalia (e.g. syringes) were reported as being present (often in situ 
and close by) in many cases, with some decedents still holding the equipment or a needle in the arm - 
suggesting that death may have occurred suddenly after administration. Whilst this is not uncommon 
with heroin deaths in general, it is a sign of the tolerance and toxicity threshold being reached and 
exceeded, likely due to the increased potency of the fentanils contributing to the opiate/opioid toxic 
burden. 
The cause of death was reported only in 6 cases and in 5 of these intoxications with carfentanil was 
reported either as the primary cause of death or as likely to have contributed to death (even in 
presence of other substances). Where additional toxicology information was available, other 
substances were detected in practically all cases. 
Carfentanil was quantified in 33 cases. Post-mortem blood concentrations ranged from 0.02 to 4.4 
ng/mL blood (median 0.50 ng/mL blood). Due to the toxicity of potent opioids and variability in user 
tolerance, determination of a ‘fatal’ concentration based on a post-mortem blood concentration is not 
reliable. In the majority of circumstances involving fentanils, the mere presence of the drug is of 
significance whether concentration has been determined or not, especially in situations of poly-drug 
use. 
A range of other substances were detected in the deaths, including: cannabinoids, benzodiazepines, 
amphetamines, cocaine, antidepressants, antipsychotics, antihistamines and ethanol, etc. However, 
in particular, markers of heroin use (i.e. morphine, codeine, noscapine, papaverine, 6-
monoacetylmorphine) as well as other opioids (including tramadol, methadone, oxycodone and 
dihydrocodeine) were detected in the vast majority of deaths. In terms of fentanils; fentanyl, 
butyrylfentanyl, 4-butyrylfentanyl, furanylfentanyl and alfentanil were detected in 23 deaths where 
additional toxicological information was available. 
Overall, whilst other substances may have contributed some toxicity, a synergistic effect with 
carfentanil would have been likely with other central nervous system depressants such as ethanol, 
benzodiazepines, opioids (including other fentanils), etc. Nevertheless, the highly potent opioid nature 
of carfentanil means that the primary toxic contribution could be attributed to carfentanil and death 
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may not have occurred if carfentanil had not been used (even where heroin was used that may not 
have exceeded the deceased’s toxicity threshold). An assessment of the Toxicological Significance 
Score (TSS) (Elliott, Sedefov, and Evans-Brown, 2017) incorporating the above considerations, 
shows that carfentanil had a TSS value of 3 (high) in 35 out of 36 of the deaths (where it was cited as 
the cause of death or is likely to have contributed to death). In the remaining death, fentanyl was 
potentially the primary substance and carfentanil was deemed to be a secondary finding (TSS value 
of 2, medium). There was insufficient information available for the other cases to allow appropriate 
TSS assessment. 
Deaths identified from other sources 
Recently a large number of deaths involving carfentanil have been reported; mostly in the United 
States and Canada. Table 11 provides a summary of deaths identified in the literature involving 
confirmed exposure to carfentanil. 
The distribution of blood carfentanil concentrations in 355 acute drug death cases were reported by 
Papsun and co-workers and is shown in Figure 3 (Papsun et al., 2017). 
FIGURE 3  
Histogram depicting positive carfentanil test results (From Papsun et al., 2017) (40). 
 
 
The same authors reported 4 human performance-related cases, where carfentanil concentrations 
(0.41, 0.63, 1.3 and 1.4 ng/mL) were more in the upper than in the lower range of the post-mortem 
samples (Papsun et al., 2017). 
A graphic representation of blood concentrations in post-mortem cases (1; lower bar) compared to 
suspected driving under the influence of drugs (DUID) cases (2; upper bar)was provided by Sofalvi 
and co-workers as shown in Figure 4 (Sofalvi et al., 2017). 
 
 
                                                          
(40) Includes 4 human performance-related (non-fatal) cases. 
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FIGURE 4 
Five-number summary for carfentanil concentrations (from Sofalvi et al., 2017) (41). 
 
 
 
In another report, carfentanil was identified in 262 post-mortem blood specimens. Blood 
concentrations stretched a similar range from 0.0102 to 2.0 ng/mL, with a mean concentration equal 
to 0.193 ng/mL and a median concentration equal to 0.0984ng/mL (Shanks & Behonick, 2017). 
These data indicate that the ranges of carfentanil blood concentrations of post-mortem samples and 
those seen in samples from non-deceased (DUID cases) largely overlap. Similarly, overlapping 
ranges were shown for fentanyl and other fentanyl derivatives (Sofalvi et al., 2017). 
 
                                                          
(41) Postmortem (1) (n = 23) and DUID (2) (n = 12) carfentanil concentration in blood: the minimum, Q1 (first quartile), the 
median, Q3 (third quartile) and the maximum. 
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TABLE 11 
Fatal intoxications associated with confirmed exposure to carfentanil (42). 
Region/Country Analytical 
method (LOD) 
Cohort/case description Matrix Reference 
Ohio, United 
States 
LC-MS-MS In 281 unintentional overdose fatalities during January–February 2017, 21 (7.5%) tested positive for 
carfentanil. Among these 21 cases, 15 (71.4%) decedents also tested positive for fentanyl, five 
(23.8%) for acryl fentanyl, and eight (38.1%) for furanyl fentanyl. Many of the carfentanil decedents 
tested positive for other central nervous system depressants, such as pharmaceutical opioids 
(23.8%) and benzodiazepines (42.9%). Among carfentanil cases, 42.9% were positive for cocaine. 
Blood, urine Daniulaityte et 
al., 2017 
United States HPLC-MS-MS Case 1: A 24-year-old woman with a peripheral blood carfentanil level of 0.53ng/mL. Other 
substances identified included delta-9 THC (0.84 ng/mL) benzoylegonine (200ng/mL), dextrorphan 
(200ng/mL), chlopheniramine (240ng/mL), and dextromethoraphan (2800ng/mL). Carfentanil was 
considered likely the primary cause of death. 
Case 2: A 21-year-old man with a peripheral blood carfentanil level of 0.34 ng/mL. The remainder of 
his toxicology report indicated a qualitative positive result for naloxone and quantitated delta-9 THC 
(0.62 ng/mL), dextrorphan (91ng/mL), dextromethorphan (280 ng/mL), and chlorpheniramine 
(210ng/mL). Carfentanil was considered likely the primary cause of death. 
Case 3: A 20-year-old woman with a cardiac blood carfentanil level of 0.2ng/mL. Additional cardiac 
blood levels were furanyl fentanyl (2.5ng/mL), alprazolam (19ng/mL), cocaine (84 ng/mL), 
benzoylecgonine (2000 ng/mL), delta-9 THC (0.59ng/mL), and cyclobenzaprine. Carfentanil was 
considered likely the primary cause of death, but furanyl fentanyl and alprazolam may have 
contributed to death. 
Peripheral 
(case 1, 2) 
and cardiac 
(case 3) 
post-mortem 
blood 
Lynch et al., 
2017 
United States LC–MS-MS (0.03 
ng/mL) 
355 Samples from forensic investigations submitted between October 2016 and April 2017. Most of 
these cases were acute drug deaths with histories of heroin abuse where carfentanil was substituted 
or added to the suspected heroin obtained by the decedent. 54% of the subjects were between the 
ages of 25 and 40; 75% of the subjects were male. 
Although not all 355 cases were tested for other drugs, when they were ~48% of positive carfentanil 
cases included one other opioid of which the majority were morphine and/or fentanyl; 6-
Whole-blood Papsun et al., 
2017 
                                                          
(42) Carfentanil concentrations are depicted in bold. When carfentanil was considered the cause of death (i.e. not a combined drug intoxication), the figure has a white font on a dark background. 
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acetylmorphine was confirmed in 10% of these cases. Cocaine and its metabolites was another 
common finding (32%). 
United States Blood samples: 
LC–MS-MS 
(0.005 ng/mL); 
Urine samples (if 
available) were 
subjected to 
routine drugs of 
abuse 
immunoassay 
screening. 
From1 September 2016 to 1 January 2017, carfentanil was identified in 262 out of 657 postmortem 
blood specimens. Blood concentrations ranged from 0.0102 to 2.0 ng/mL, with a mean concentration 
equal to 0.193ng/mL and a median concentration equal to 0.0984ng/mL. 13 cases were 
summarised. 
Case 1. A 26-year-old female who had a history of drug use was seen using heroin during the night 
and found deceased the next morning. Autopsy findings were not available. Toxicological analysis of 
the iliac blood revealed carfentanil (0.234 ng/mL), 11-nor-9-carboxy-delta- 9-tetrahydrocannabinol 
(10.1 ng/mL) and topiramate (7.5 µg/mL). Urine was positive for buprenorphine, norbuprenorphine, 
11-nor-9- carboxy-delta-9-tetrahydrocannabinol, norfentanyl and morphine. Cause of death was 
certified as carfentanil intoxication. Manner of death was accident. 
Case 2. A 38-year-old male with a history of heroin use was found unresponsive by his family in the 
bathroom at home. Drug paraphernalia was present at the scene. At autopsy, pulmonary congestion 
and cardiomegaly were observed. Toxicological analysis of the femoral blood revealed carfentanil 
(0.221 ng/mL). No other drugs were detected in the blood. Urine was positive for morphine, codeine, 
hydromorphone and norfentanyl. Cause of death was certified as carfentanil drug toxicity. Manner of 
death was accident. 
Case 3. A 36-year-old female who had a history of drug use was found unre- sponsive in a bedroom 
of her residence. Drug paraphernalia was found in the night stand next to the bed. She was 
pronounced deceased at the scene. Autopsy findings included frothy pulmonary edema. 
Toxicological analysis of the femoral blood was positive for carfentanil (0.107ng/mL), delta-9-
tetrahydrocannabinol (4.9 ng/mL) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (67.5 ng/mL). 
Urine was positive for temazepam, nordiazepam, oxazepam, buprenorphine, nor- buprenorphine, 
11-nor-9-carboxy-delta-9-tetrahydrocannabinol, nor- fentanyl, morphine and hydromorphone. Cause 
of death was certified as carfentanil drug toxicity. Manner of death was accident. 
Case 4. A 33-year-old female was found deceased on the bathroom floor. A Narcan kit was found 
next to her and a dose had been used. Drug paraphernalia was found in her bedroom. The decedent 
had been transported to the hospital for an overdose a week prior. No other medical history was 
documented. Autopsy findings were not avail- able. Toxicological analysis of the iliac blood revealed 
carfentanil (0.145 ng/mL), morphine (10.9 ng/mL), delta-9-tetrahydrocannabinol (2.7 ng/mL) and 11-
nor-9-carboxy-delta-9-tetrahydrocannabinol (29.0 ng/mL). Urine was positive for 11-nor-9-carboxy-
delta-9-tetrahydrocannabinol, morphine and codeine. Cause of death was mixed drug intoxication. 
Blood, urine Shanks & 
Behonick, 
2017 
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Manner of death was accident. 
Case 5. A 25-year-old male who had a history of drug abuse and who had just been released from 
prison came home, ate a meal, and then went to bed. He was found lying in bed around 9AM and 
was in full rigor mortis when emergency personnel and investigators arrived a short time later. White 
frothy foam and purge fluid were found around the mouth and ears. A capped syringe was found in 
his pants pocket and vomit and other bodily fluids were found on the floor next to him. Track marks 
were documented on the body. Findings at autopsy included pulmonary oedema. Toxicological 
analysis of the heart blood revealed carfentanil (0.241 ng/mL), benzoylecgonine (54.3 ng/mL), 
naloxone (qualitative) and caffeine (qualitative). Urine was positive for benzoylecgonine and 
norfentanyl. Cause of death was certified as cocaine and carfentanil intoxication. Manner of death 
was accident. 
arrived a short time later. White frothy foam and purge fluid were found around the mouth and ears. 
A capped syringe was found in his pants pocket and vomit and other bodily fluids were found on the 
floor next to him. Track marks were documented on the body. Findings at autopsy included 
pulmonary edema. Toxicological anal- ysis of the heart blood revealed carfentanil (0.241 ng/mL), 
benzoylecgo- nine (54.3 ng/mL), naloxone (qualitative) and caffeine (qualitative). Urine was positive 
for benzoylecgonine and norfentanyl. Cause of death was certified as cocaine and carfentanil 
intoxication. Manner of death was accident. 
Case 6. A 44-year-old female was found deceased. She had a history of alprazolam (Xanax®) and 
heroin use. No autopsy was performed. Femoral blood was positive for carfentanil (0.105 ng/mL) 
and cotinine (qualitative). No urine was available for testing. Cause of death was certified as 
carfentanil intoxication. Manner of death was accident. 
Case 7. A 28-year-old male who had a history of heroin use was found deceased in bed in jail. Drug 
use the previous night had been suspected. Autopsy was negative with exception of pulmonary 
edema. Toxicological analysis of the iliac blood revealed carfentanil (0.0233 ng/mL) and 11-nor-9-
carboxy-delta-9-tetrahydrocannabinol (9.6 ng/mL). Cause of death was certified as acute carfentanil 
intoxication. Manner of death was accident. 
Case 8. A 38-year-old male, who was staying with a friend, was found lying in the bathroom 
deceased. A syringe, spoon and powdery substance were found on the bathroom sink. The powdery 
substance was identified by the local crime laboratory as a mixture of heroin, fentanyl and 
carfentanil. Needle marks were observed on the arms. Family stated he only had a history with 
drinking alcohol and no other drug history was known. No autopsy was completed. Toxicological 
analysis of the subclavian blood revealed carfentanil (0.0301 ng/mL). Urine was positive for 
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morphine, hydromorphone, fentanyl and norfentanyl. Cause of death was certified as acute 
carfentanil toxicity. Manner of death was accident. 
Case 9. A 44-year-old male was found unresponsive in bed by his girlfriend. He had a history of 
heroin and ethanol use. He was prescribed multiple medications including alprazolam (Xanax®), 
atorvastatin (Lipitor®), ondansetron (Zofran®), phenytoin (Dilantin®), quetiapine (Seroquel®) and 
ibuprofen (Advil®). Naloxone was administered during resuscitative attempts. Autopsy findings 
included needle puncture sites on both arms and the lungs were suggestive of asthmatic type 
bronchitis. Toxicological analysis of the femoral blood revealed carfentanil (0.114 ng/mL), 
furanylfentanyl (0.61 ng/mL), alprazolam (3.4 ng/mL), delta-9-tetrahydrocannabinol (2.6 ng/mL), 11-
nor-9- carboxy-delta-9-tetrahydrocannabinol (3.4 ng/mL), codeine (40.0 ng/mL), buprenorphine (0.6 
ng/mL), phenytoin (4.0 µg/mL), quetiapine (370 ng/mL), naloxone (qualitative), nicotine (qualitative) 
and cotinine (qualitative). Cause of death was certified as multiple drug (carfentanil, furanylfentanyl, 
codeine, buprenorphine and alprazolam) intoxication. Manner of death was accident. 
Case 10. A 50-year-old male was found unresponsive in his truck, which was stopped and parked off 
the road. He was transported to the hospital and pronounced deceased. Findings at autopsy 
included severe pulmonary congestion and oedema, asymmetric cardiac hypertrophy, congestive 
splenomegaly, steatosis of the liver and left adrenal adenoma. Toxicological analysis of the 
subclavian blood revealed carfentanil (0.617 ng/mL) and fentanyl (2.9 ng/mL). Urine was positive for 
ethanol (0.2 mg/mL), fentanyl and norfentanyl. Cause of death was certified as fentanyl and 
carfentanil toxicity. Manner of death was accident. 
Case 11. A 27-year-old male who had been living in his car was brought to the hospital by a friend. 
The male was unresponsive on arrival and declared deceased. Toxicological analysis of the femoral 
blood revealed carfentanil (0.529 ng/mL) and 11-nor-9-carboxy-delta-9- tetrahydrocannabinol (10.1 
ng/mL). Urine was positive for 11-nor- 9-carboxy-delta-9-tetrahydrocannabinol, fentanyl, norfentanyl 
and morphine. Cause of death was certified as carfentanil toxicity. Manner of death was accident. 
Case 12. A 62-year-old female was found deceased in her home. She had a history of illicit and 
prescription drug abuse including heroin and fentanyl. She was prescribed several medications 
including sertraline (Zoloft®), clonidine (Catapres®), tramadol (Ultram®), gabapentin (Neurontin®) 
and lisinopril (Prinivil®). No autopsy was completed. Femoral blood was positive for carfentanil 
(0.0457 ng/mL) and fentanyl (1.1 ng/mL). No urine was available for testing. Cause of death was 
certified as carfentanil and fentanyl toxicity. Manner of death was accident. 
Case 13. A 39-year-old male, who had a history of heroin use, was found on the ground outside of 
his vehicle. Resuscitative attempts by emergency personnel were unsuccessful and he was 
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pronounced deceased at the scene. The autopsy revealed no significant trauma to explain death. 
The lungs were congested and oedematous. Hypertensive heart disease (enlarged heart with 
thickened left ventricle) and hepatic steatosis were present. Needle punctures were present on the 
arm and hand. Toxicological analysis of the femoral blood revealed carfentanil (0.0104 ng/mL), 
ethanol (1.54 mg/mL), amitriptyline (29.9 ng/mL), nicotine (qualitative) and cotinine (qualitative). 
Urine was positive for ethanol (2.91 mg/mL). Cause of death was certified as mixed drug (carfentanil 
and ethanol) intoxication. Manner of death was accident. 
United States UHPLC-Ion Trap-
MSn 
(0.1 ng/mL) 
Of ≈500 postmortem samples, 375 were positive for illicit fentanyl and/or one or more fentanyl 
analogues. The fentanyl analogues were detected in 176 of these cases from 2015 to the end of 
2016. Beginning in July 2016, carfentanil first emerged (134). Out of the 375 cases positive for illicit 
fentanyl and/or one or more fentanyl analogues, 70% were white males, 16% were white females, 
12% were black males, and black females comprised the remaining 2%of cases. Decedents ranged 
in age from 17 to 73 years with a mean of 38 years and a median of 36 years. Summaries of 12 
cases were provided. Below only those involving carfentanil (7) are listed. 
Case 5. 34 year old white female found slumped over in front seat of minivan. Mother of four minor 
children, history of illicit drug use. Carfentanil; furanyl fentanyl; despropionyl fentanyl; cocaine 11 
ng/mL; benzoylecgonine 124 ng/mL; methylecgonidine; methylecgonine; levamisole; cannabinoids. 
Cause and manner of death: Acute combined drug toxicity (carfentanil, furanyl fentanyl and cocaine) 
- accident. 
Case 6. 37 year old white male found behind bushes decomposed. Carfentanil; ethanol 0.089% 
(bile), 0.051% (brain); dextromethorphan; diphenhydramine; hydroxyzine; ibuprofen; meprobamate; 
quetiapine; sertraline; norsertraline; cannabinoids. Cause and manner of death: Carfentanil toxicity - 
accident. 
Case 7. 27 year old white female. Prostitute found unresponsive in a field with drug paraphernalia 
littering the area. Carfentanil; fentanyl 12 ng/mL; morphine 13 ng/mL; codeine <0.01 µg/mL; 6-
monoacetylmorphine <1 ng/mL; cocaine <10 ng/mL; benzoylecgonine 125 ng/mL; methylecgonine; 
chlorcyclizine; hydroxyzine. Cause and manner of death: Acute combined drug toxicity (cocaine, 
heroin, carfentanil, fentanyl) – accident. 
Case 8. 23 year old white male found unresponsive in bathroom by his family with drug 
paraphernalia. Carfentanil; parafluoroisobutyryl fentanyl; ethanol 0.084% (blood), 0.107% (ocular); 
dextromethorphan. Cause and manner of death: Acute combined drug toxicity (carfentanil, para-
fluorobutyryl/para-fluoroisobutyryl fentanyl and ethanol) – accident. 
Blood, urine, 
tissue 
Shoff et al., 
2017 
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Case 9. 19 year old white male. Suspected supplier of fentanyl on house arrest Transported to 
hospital unresponsive and died 6 days later. Carfentanil; furanyl fentanyl; Despropionyl fentanyl; 
morphine <10 ng/mL; codeine <10 ng/mL; cocaine <10 ng/mL; benzoylecgonine 209 ng/mL; 
methylecgonidine; methylecgonine; levamisole; 7-aminoclonazepam; ibuprofen; lidocaine; 
desethyllidocaine; naloxone; cannabinoids. Cause and manner of death: Acute cocaine and 
synthetic opiate toxicity – accident. 
Case 10. 41 year old white male found unresponsive in a field. Carfentanil; U-47700; fentanyl <1 
ng/mL; morphine 32 ng/mL; codeine <10 ng/mL; cocaine <0.01 mg/L; methylecgonine; atropine; 
diphenhydramine; gabapentin; ibuprofen; naloxone; quetiapine; norquetiapine; quinine. Cause and 
manner of death: Acute combined drug toxicity (carfentanil, fentanyl, probable heroin, U-47700, 
diphenhydramine and cocaine) – accident. 
Case 12. 30 year old white male found unresponsive on the street with a foamy discharge around 
his mouth. Carfentanil; parafluoroisobutyryl fentanyl; U-47700; sertraline; norsertraline; 
diphenhydramine. Cause and manner of death: Acute bronchopneumonia acute combined drug 
toxicity (carfentanil, para-fluoroisobutyryl fentanyl, diphenhydramine and U-47700) – accident. 
United States LC-MS-MS (0.05 
ng/mL) 
31 of 98 postmortem cases contained carfentanil at mean and median concentrations of 0.34 and 
0.30 ng/mL, respectively. A single case involving carfentanil was summarized. 
Case 4. A 31-year-old female presented to a local hospital from home via EMS and died 10 min after 
arrival. She had a history of heroin and prescription pill abuse, seizures and asthma. At autopsy, she 
was found with numerous recent and healing puncture wounds of ankles, hands and wrists. She had 
bilateral pulmonary edema with the increased lung weights of 670 and 540 g for the right and left 
lungs, respectively. Carfentanil 1.9 ng/mL (heart blood), 0.36 ng/mL (femoral blood); <1 ng/mL 
fentanyl; 88 ng/mL morphine; <10 ng/mL codeine; <4 ng/mL 6-AM; 19 ng/mL clonazepam; 22 ng/mL 
oxazepam; 110 ng/mL temazepam; 100 ng/mL cyclobenzaprine in femoral blood. The femoral blood 
was also positive for diphenhydra- mine, nicotine, meprobamate and 7-aminoclonazepam. The 
cause of death was ruled as acute intoxication by the combined effects of carfentanil, heroin, 
benzodiazepines and cyclobenzaprine. 
Blood, 
vitreous 
humour 
Sofalvi et al., 
2017 
Florida, United 
States 
 Case 1. A 34-year-old white male was found dead in a van located in a car wash. The deceased was 
slumped over in the driver’s seat of the van with the car running. 9-1-1 was called, paramedics 
responded and he was pronounced dead at the scene. A syringe, spoon and a yellow baggy with a 
brown coloured substance was located in the cup holder in the centre console. He had a history of 
tobacco, alcohol, marijuana and heroin abuse. Autopsy findings were unremarkable except for mild 
Peripheral 
and heart 
blood, 
vitreous 
humour 
Swanson et 
al., 2017 
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hypertensive heart disease with left ventricular hypertrophy and mild hepatic steatosis. No other 
disease was noted. Carfentanil 1.3 ng/mL (heart blood); furanyl fentanyl 0.34 ng/mL (heart blood); 
fentanyl 6 ng/mL (heart blood); morphine <20 ng/mL (heart blood), present (urine); hydromorphone 
<20 ng/mL (heart blood), present (vitreous humour, urine); 6-MAM present (vitreous humour, urine); 
hydrocodone present (vitreous humour, urine). Cause and manner of death: Intoxication by the 
combined effects of heroin, fentanyl, carfentanil and furanyl fentanyl - accident. 
Case 2. A 25-year-old white male was having financial and relationship problems and was living in a 
tent with his mother at a county park. He last spoke with his sister by phone and sounded ‘very 
intoxicated ‘. His mother noted he was ‘itching all over ‘, left for work, and when she returned home 
her son was lying prone on a mattress in the tent. 9-1-1 was called, paramedics responded and he 
was pronounced dead at the scene. A baggy with a brown substance was found next to the 
deceased. He had a history of tobacco, alcohol, marijuana, spice and prescription pain medication 
abuse. Autopsy findings were unremarkable except for mild left ventricular hypertrophy. No other 
disease was noted. Carfentanil 0.12 ng/mL (heart blood); benzoylecgonine 460 ng/mL (peripheral 
blood), 510 ng/mL (vitreous humour); cocaine 40 ng/ml (vitreous humour). Cause and manner of 
death: Intoxication by carfentanil - accident. 
United States  Case 1: A 31-year old male with reported history of heroin abuse found deceased near drug 
paraphernalia. Blood testing revealed evidence of both carfentanil and ethanol. Carfentanil 0.13 
ng/mL; ethanol 0.226 g/dL. Cause of death was attributed to mixed carfentanil and ethanol toxicity. 
Case 2: A 33-year old male with reported history of substance abuse, including heroin and fentanyl, 
found deceased near drug paraphernalia. Blood testing revealed evidence of carfentanil and ethanol. 
Carfentanil 0.64 ng/mL; ethanol 0.177 g/dL. Cause of death was attributed to acute carfentanil and 
ethanol toxicity. 
Case 3: A 42-year-old female with history of recent overdose reversed with naloxone found 
deceased near drug paraphernalia. Carfentanil 0.27 ng/mL; methamphetamine 20 ng/mL; morphine 
30 ng/mL; alprazolam 15 ng/mL; ethanol 0.02 g/dL. Cause of death was attributed to mixed drug 
toxicity. 
Case 4: A 34-year-old female with history of substance abuse including heroin found deceased near 
drug paraphernalia. Carfentanil 0.44 ng/mL; methamphetamine 180 ng/mL; benzoylecgonine 150 
ng/mL; morphine 60 ng/mL; clonazepam 2.7 ng/mL; 7-amino-clonazepam 160 ng/mL. Cause of 
death was attributed to mixed drug toxicity. 
Case 5: A 23-year-old male with history of heroin abuse found deceased near drug paraphernalia. 
Blood, urine 
 
Olives et al., 
2017 
RISK ASSESSMENT I CARFENTANIL 
 
81 
 
Carfentanil 0.14 ng/mL; ethanol 0.023 g/dL; urine 6-monoacetyl morphine 6 ng/mL. Cause of death 
was attributed to acute carfentanil toxicity 
Ohio, United 
States 
LC-MS-MS43 There were a total of 49 deaths. The mean age was 42 (range 21–63). Gender breakdown was 
males 35 (71.4%), female 14 (28.6%). Race makeup was white 43 (88%), black 4 (8%), and 
Hispanic 2 (2%). Deaths peaked in the month of September with 22. 32 of the 49 cases had known 
quantitative carfentanil levels which ranged from 0.013 to 1.3 ng/mL. The mean carfentanil level was 
0.259 ng/mL. Fentanyl, fentanyl analogues, or morphine/6-monoacetylmorphine (6-MAM) were 
found in 33 of the cases. Eleven cases with quantitative levels did not have another opioid identified. 
The mean carfentanil level for those 11 cases was 0.350 ng/mL. The most common other agents 
were fentanyl (15), morphine/6-MAM (30), ethanol (14), and cocaine (11). Acetyl fentanyl and furanyl 
fentanyl were the only other fentanyl analogues identified. 
Peripheral 
blood 
Yin, 2017 
                                                          
(43) Part of the samples have been analysed by NMS labs, Willow Grove, PA. Therefore, some of these cases are likely included in those reported by Papsun et al., (2017). 
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D2. Chronic health effects 
D2.1. Animal data 
There are no studies identified on the long-term effects of carfentanil in animals. Due to its high 
potency, the pharmacological dose of carfentanil is very low. This makes it less likely that unexpected 
toxicity would occur, even after repeated exposure. The adverse effects to be anticipated are those 
related to the pharmacological action of carfentanil.  
Fentanyl toxicity has been summarized in the European Assessment Report for Effentora®, a fentanyl-
containing buccal tablet (EMA, 2008). In rats, deaths occurred following oral doses of 10 mg/kg/day or 
more and following IM doses of 0.1 to 0.4 mg/kg/day. The main findings in these studies were weight 
loss or reductions in weight gain. There was no clear-cut evidence of target organ toxicity, although 
the data are limited, and the cause of death was considered to be associated with respiratory 
depression.  
In rabbits, fentanyl was well-tolerated when administered by the transcutaneous route for up to 90 
days at a dose of 0.66 mg/kg/day (EMA, 2008). 
In dogs, IM administration of fentanyl at doses of 0.1 and 0.4 mg/kg/day for 30 days produced weight 
loss and/or no weight gain over the 30 day test period. Intravenous administration of 0.1, 0.3 and 1.0 
mg/kg fentanyl to dogs for 30 days again produced a decrease in body weight at the highest dose, 
with dose-related clinical signs of sedation and convulsions. All dogs survived both the 30 day IM and 
IV dosing periods (EMA, 2008). 
Fentanyl is not considered to be genotoxic; carcinogenicity studies have not been performed (EMA, 
2008). 
Studies with fentanyl in female rats revealed reduced fertility and enhanced embryonal mortality. More 
recent studies showed that effects on the embryo were due to maternal toxicity and not to direct 
effects of the substance on the developing embryo. In a study on pre- and postnatal development the 
survival rate of offspring was significantly reduced at doses which slightly reduced maternal weight. 
This effect could either be due to altered maternal care or a direct effect of fentanyl on the pups. 
Effects on somatic development and behaviour of the offspring were not observed. Teratogenic 
effects have not been demonstrated (EMA, 2008). 
D2.2. Human data 
No studies were identified that have examined the chronic health effects of carfentanil. 
Fentanyl is used clinically for pain treatment. Rodriguez reviewed the use of different oral or nasal 
transmucosal fentanyl formulations. The proportion of fentanyl-treated patients presenting an adverse 
effect (AE) was high (about two out of three subjects receiving fentanyl). As expected, the most 
frequently reported AEs were those associated with opioid use (nausea, vomiting, dizziness, 
constipation, and drowsiness). The impact of those effects was, in general, mild and not leading to 
treatment discontinuation during treatment phase or even at long term. However, it is suspected that 
the safety may be overestimated, since most studies have been done in the short term and the 
methods have been focused mainly on assessing effectiveness (Rodríguez et al., 2015).  
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D3. Factors affecting public health risks 
D3.1. Availability and quality of the new psychoactive substance on the market  
Carfentanil is being sold by vendors on the surface web and dark web as a drug in its own right. It is 
sold in both wholesale and consumer quantities. In addition, carfentanil is being mixed with or sold as 
heroin and other opioids on the illicit opioid market in at least three countries in Europe. 
D3.2. Availability of the information, degree of knowledge and perceptions amongst users 
concerning the psychoactive substance and its effects 
Due to its relatively recent availability on the drug market, the availability of information, degree of 
knowledge and perceptions amongst users concerning carfentanil and its effects are limited. In 
addition, given that carfentanil has been mixed with or sold as heroin and other illicit opioids, many 
users will be unaware that they are using the drug. 
D3.3. Characteristics and behaviour of users  
No studies were identified that have examined the characteristics and behaviours of users of 
carfentanil. The available information on characteristics and behaviour of users is provided in Section 
D3.4. 
D3.4. Nature and extent of health consequences 
Acute health risks 
The available data suggests that the nature of the acute effects of carfentanil share some similarities 
with opioid analgesics such as morphine and fentanyl.  
The acute effects of these types of opioids include: euphoria, relaxation, analgesia, sedation, 
bradycardia, hypothermia, and respiratory depression. They also have an abuse liability and 
dependence potential (Cox, 2011; Dahan et al., 2001; Pattinson, 2008; Romberg et al., 2003). 
Similar to other opioid analgesics, the most serious acute risk arising from the use of carfentanil is 
likely to be from rapid and profound respiratory depression, which can lead to apnoea, respiratory 
arrest, and death (Cox, 2011; Dahan et al., 2001; Pattinson, 2008; White & Irvine, 1999).  
For fentanils in general, this risk may be exacerbated by:  
 the difficulty in diluting/using fentanils (as they are typically highly potent), which can lead to a 
toxic dose being accidentally used (de Boer et al., 2003; Sutter et al., 2017); 
 the apparent rapid onset of severe poisoning following use (Somerville et al., 2017); 
 using routes of administration that allow large amounts of the substance to rapidly reach the 
central nervous system (such as injecting, insufflation, and inhalation) (e.g. Macleod et al., 
2012);  
 availability of easy to use dosage forms (such as nasal sprays and e-liquids) (e.g. Macleod et 
al., 2012); 
 lack of awareness and experience of users with these new substances (effects and dosage); 
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 use of other central nervous system depressants (such as other opioids, benzodiazepines, 
and alcohol) (e.g. van der Schrier et al., 2017) 
 lack of tolerance to opioids in opioid-naïve persons (such as new or former users); 
 use in environments where it may be difficult to summon help in the event of poisoning (e.g. 
alone in a home environment) (Somerville et al., 2017); 
 limited availability of the antidote naloxone in community settings (EMCDDA, 2015; EMCDDA, 
2016; Somerville et al., 2017). 
In addition, and, often unknown to users, the fentanils are mixed with or sold as heroin and other illicit 
opioids. They are also used to make counterfeits of highly sought-after medicines, such as opioid 
analgesics and benzodiazepines. They have also been sold in or as drugs such as cocaine (Klar et 
al., 2016; SFDPH, 2015; Sutter et al., 2017; Tomassoni et al., 2017). Due to this, users may not be 
aware that they are using a fentanil; in some cases these individuals will have no tolerance to opioids 
nor access to community naloxone programmes. Overall, these factors may increase the risk of life-
threatening poisoning. 
Given the above risks, poisonings by fentanils may manifest as outbreaks which have the potential to 
overwhelm emergency responders and other local healthcare systems (Klar et al., 2016; SFDPH, 
2015; Sutter et al., 2017; Tomassoni et al., 2017). 
Accidental exposure to the fentanils may also pose a risk to non-users, including family and friends, 
law enforcement and emergency responders. Such risks may need to be assessed so that, where 
required, appropriate procedures, training and environmental and personal protective measures can 
be provided for handling materials suspected to contain these substances (IAB, 2017; Moss et al., 
2017; US CDC, 2016; US DEA, 2017). Any responses should continue to ensure the delivery of 
prompt and appropriate care to patients with suspected overdose (Cole & Nelson, 2017; Lynch, 
Suyama, & Guyette, 2017). 
Managing poisoning 
The antidote naloxone will reverse acute poisoning caused by carfentanil (Kim and Nelson, 2015; 
Ujváry et al., 2017).  
Carfentanil has been characterized as a quick-acting analgesic with a short duration of action 
(Jacobson, 1988; Janssen, 1982). Yet, renarcotisation has been observed in animals when these 
have not been reversed with a sufficiently high dose of a µ-opioid antagonist, or when an antagonist 
with a short duration of action is used (Miller et al., 1996; Portas, 2004). Redistribution from (fatty) 
tissues of carfentanil—due to its lipophilic nature—could be a possible factor contributing to this 
effect. 
Recent clinical and community experience in treating poisonings caused by carfentanil suggests that 
larger than normal doses and repeated doses of naloxone may be required to manage the poisoning 
in some cases; longer periods of observation may also be required (US CDC, 2013; Klar et al., 2016; 
Moss et al., 2017; Somerville et al., 2017; Sutter et al., 2017). This may reflect, among other factors, 
the high potency of the fentanils, their half-lives, the dose an individual is exposed to, and the 
relatively short half-life of naloxone. This may necessitate different strategies in treating opioid 
overdose patients, where fentanils, including carfentanil, could be involved. This may include 
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repeated or higher doses of antagonists and longer periods of observation (Cole & Nelson, 2017; Lust 
et al., 2011). 
Chronic health risks 
While there is limited data, the chronic health risks of carfentanil might share some similarities to 
opioids such as heroin and other fentanils. This may include dependence. 
D3.5. Long-term consequences of use 
While there is limited data, the chronic health risks of carfentanil might share some similarities to 
opioids such as heroin and other fentanils. This may include dependence. 
D3.6. Conditions under which the new psychoactive substance is obtained and used, including 
context-related effects and risks 
There is limited data on the conditions which carfentanil is obtained and used in Europe. Carfentanil 
has been sold on the surface web and darknet marketplaces, typically as powders. In addition, it has 
also been mixed with or sold as heroin and other opioids on the illicit opioid market. 
Section E. Social risks 
While there have been no studies on the social risks of carfentanil, it is likely that some of the risks 
are similar to those associated with illicit opioids, including fentanyl and heroin. 
E1. Individual social risks 
There is no information on the individual social risks that may be associated with the use of 
carfentanil. Given that carfentanil acts as an opioid analgesic, any such risks may have some 
similarities with those associated with illicit opioids. These may negatively impact on education or 
career, family or other personal and social relationships and may result in marginalisation. 
E2. Possible effects on direct social environment  
There is no information on the possible effects of carfentanil on the direct social environment. Given 
that carfentanil appears to act as an opioid analgesic, any such effects may have some similarities 
with those associated with the use of illicit opioids. 
E3. Possible effects on society as a whole 
There is no specific information on the possible effects of carfentanil on society as a whole.  
As discussed above, accidental exposure to the fentanils may pose a risk of poisoning to those who 
may come into contact with the substances. This includes the family and friends of users, law 
enforcement, emergency personnel, medical and forensic laboratory personnel as well as custodial 
settings and postal services. Where required, these risks should be assessed and appropriate 
procedures, training, and protective measures should be implemented. This may include training in 
managing poisoning (including in resuscitation and administration of naloxone to reverse poisoning). 
Any required responses should continue to ensure the delivery of prompt and appropriate care to 
patients with suspected overdose (Cole & Nelson, 2017; Lynch, Suyama, & Guyette, 2017). 
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E4. Economic costs 
There are no data on the health and social costs related to carfentanil. 
E5. Possible effects related to the cultural context, for example marginalisation 
There are no data on the possible effects of carfentanil related to the cultural context. 
E6. Possible appeal of the new psychoactive substance to specific population groups 
within the general population 
While no specific examples are available on the possible appeal of carfentanil to specific user groups 
(aside from psychonauts), it is reasonable to assume carfentanil may be sought by those looking for 
‘legal’ substitutes for illicit opioids, such as heroin and/or prescription opioids.  
Section F. Involvement of organised crime 
F1. Evidence that criminal groups are systematically involved in production, trafficking 
and distribution for financial gain 
There is limited information on the involvement of organised crime or established criminal groups in 
the manufacture, distribution and supply of carfentanil. 
In this respect, Estonia reported that almost all trafficking and distribution of fentanils, including 
carfentanil, is linked with organised crime groups in Estonia. In addition, they reported that these 
groups are keeping dealers under control through violence. 
The United Kingdom reported to Europol that some online vendors of carfentanil have been identified 
as being run by more than one person; however there is little intelligence to confirm links to organised 
crime groups. Information suggests that carfentanil mixed with heroin was sold through travelling 
communities and networks in the North East of England, with this carfentanil possibly being supplied 
by one of these via online platforms/vendors (44). 
In addition, the United Kingdom’s National Crime Agency (NCA) reported to Europol that they 
identified a supplier of carfentanil who was using the darknet to advertise and distribute carfentanil 
across the country and also internationally. A total of 19 customers in the United Kingdom are known 
to have purchased carfentanil from this site, placing a total of 37 orders. The size of orders varied 
from 50 milligrams (15 orders) to 1 gram (1 order). 
In the cases reported to Europol where the country of origin for the seizures was known, the countries 
were: China (specifically Hong Kong), the United Kingdom and Germany were also mentioned, but to 
a lesser extent (45).  
                                                          
(44) Canada reported that there is no evidence to date to indicate carfentanil production in the country. They also reported that 
they have not really seen any traditional organised crime group involvement or that the involvement is limited and that the 
darknet is often used to conduct transactions. 
(45) Carfentanil is sold as counterfeit oxycodone (CDN 80) or Xanax tablets and is also imported in powder form and then 
tableted in the country. Canada reported 6 carfentanil seizures in 2016 which occurred at the Vancouver and Montreal 
international mail centres. The country of origin was reported as China (5 seizures) and Hong Kong (1). In 2017, 5 seizures of 
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Germany reported a seizure of carfentanil by Canadian law enforcement in Vancouver, in June 2017. 
The carfentanil was detected in a package which was en-route from Hong Kong to Canada via 
Germany, using Deutsche Post DHL.  
Lithuania reported that there are indications that carfentanil may be imported from Russia and China. 
They also reported that carfentanil is often mixed with heroin and prepared for heroin users and most 
cases are related to heroin distribution in the local Roma community. 
Sweden indicated that carfentanil has been bought from internet vendors and delivered directly to the 
user from China, the United Kingdom and Germany. They reported that there are no indications of the 
domestic sale of carfentanil in Sweden.  
The United Kingdom reported that it was unclear how much, if any, carfentanil has been 
manufactured in the United Kingdom. Information indicates that it has been shipped from China/Hong 
Kong and the substance has been used as received, or mixed with other drugs, for example heroin, or 
cutting agents before being used or sold on. 
Latvia reported 6 seizures of carfentanil to the EMCDDA which occurred inside a prison or custodial 
setting. 
The seizure of an illicit laboratory in Europe in 2013 that was producing fentanils demonstrates the 
capability to manufacture fentanils exists within the European Union. 
F2. Impact on the production, trafficking and distribution of other substances, including 
existing psychoactive substances as well as new psychoactive substances 
No information was reported or identified concerning the impact of carfentanil on the production, 
trafficking and distribution of other substances, including existing psychoactive substances as well as 
new psychoactive substances. 
F3. Evidence of the same groups of people being involved in different types of crime 
No information was reported nor identified concerning evidence of the same groups of people being 
involved in different types of crime related to the availability of carfentanil. 
F4. Impact of violence from criminal groups on society as a whole or on social groups or 
local communities (public order and safety) 
No information was reported nor identified concerning incidents of violence related to the availability 
of carfentanil. 
F5. Evidence of money laundering practices, or impact of organised crime on other 
socioeconomic factors in society 
No information was reported nor identified concerning evidence of money laundering practices, or 
impact of organised crime on other socioeconomic factors in society related to the availability of 
carfentanil. 
                                                                                                                                                                                    
powders were seized at the border (Vancouver international mail centre and FedEx in Memphis). The country of origin was 
reported as China (3 seizures), Hong Kong (1) and the United States (1). 
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F6. Economic costs and consequences (evasion of taxes or duties, costs to the judicial 
system)  
No information was reported nor identified concerning the economic costs and consequences related 
to the availability of carfentanil. 
F7. Use of violence between or within criminal groups 
No information was reported nor identified concerning the use of violence between or within criminal 
groups related to the availability of carfentanil. 
F8. Evidence of strategies to prevent prosecution, for example through corruption or 
intimidation 
No information was reported nor identified concerning evidence of strategies to prevent prosecution 
related to the availability of carfentanil. 
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